gamma-aminobutyric acid has been researched along with Schizophrenia in 550 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
Schizophrenia: A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cognitive impairment causes morbidity in schizophrenia and could be due to abnormalities of cortical interneurons using the inhibitory neurotransmitter gamma-aminobutyric acid (GABA)." | 9.12 | Effects of gamma-aminobutyric acid-modulating drugs on working memory and brain function in patients with schizophrenia. ( Bullmore, E; Fletcher, P; Kamath, S; McKenna, P; Menzies, L; Ooi, C; Stephenson, C; Suckling, J, 2007) |
| "The authors investigate: (1) whether there is a lateral effect of hydrogen (1H) magnetic resonance (MR) spectroscopy observable metabolite ratios between the right and the left prefrontal lobe in chronic schizophrenia; (2) whether there is a change of proton metabolite ratios in chronic schizophrenia after neuroleptic treatment; (3) whether there is a relation between changes in 1H MR spectra and the clinical assessment of Brief Psychiatric Rating Scale (BPRS); and (4) to investigate a hypofrontality hypothesis in schizophrenia in terms of neurochemical aspects." | 9.08 | Observation of metabolic changes in chronic schizophrenia after neuroleptic treatment by in vivo hydrogen magnetic resonance spectroscopy. ( Choe, BY; Lee, C; Lee, CW; Paik, IH; Shinn, KS; Suh, TS, 1996) |
| "To substantiate a previously reported disturbance of gamma-aminobutyric acid (GABA) in chronic schizophrenia, plasma growth hormone (GH) response to a direct GABA agonist (baclofen, 10 mg) was assessed in 12 unmedicated chronic schizophrenic males and 10 sex- and age-matched healthy controls." | 9.06 | Baclofen-induced growth hormone secretion is blunted in chronic schizophrenics: neuroendocrine evidence for a GABA disturbance in schizophrenia. ( Forziati, D; Iovino, M; Maj, M; Monteleone, P; Steardo, L; Veltro, F, 1988) |
| "The observation that antagonists of the N-methyl-D-aspartate receptor (NMDAR), such as phencyclidine (PCP) and ketamine, transiently induce symptoms of acute schizophrenia had led to a paradigm shift from dopaminergic to glutamatergic dysfunction in pharmacological models of schizophrenia." | 8.90 | Reviewing the ketamine model for schizophrenia. ( Frohlich, J; Van Horn, JD, 2014) |
| "Less than half of patients with schizophrenia obtain full response to antipsychotic drugs and, while clozapine represents the treatment of choice for refractory psychosis, a significant number of individuals remain only partially responsive." | 8.89 | Topiramate in schizophrenia: a review of effects on psychopathology and metabolic parameters. ( Cohn, T; Hahn, MK; Remington, G; Teo, C, 2013) |
| "This study enrolled patients with TRS who did not respond to clozapine (ultra-resistant schizophrenia: URS) and who responded to clozapine (non-URS), patients with schizophrenia who responded to first-line antipsychotics (first-line responders: FLR), and healthy controls (HCs)." | 8.12 | Gamma-aminobutyric acid (GABA) levels in the midcingulate cortex and clozapine response in patients with treatment-resistant schizophrenia: A proton magnetic resonance spectroscopy ( ( De Luca, V; Edden, RAE; Gerretsen, P; Graff-Guerrero, A; Honda, S; Iwata, Y; Mar, W; Mikkelsen, M; Mimura, M; Nakajima, S; Noda, Y; Plitman, E; Remington, G; Sailasuta, N; Torres-Carmona, E; Truong, P; Tsugawa, S; Ueno, F, 2022) |
| "Our study is the first to report elevated GABA levels in the MCC in patients with schizophrenia resistant to clozapine treatment compared with those responsive to clozapine." | 8.12 | Gamma-aminobutyric acid (GABA) levels in the midcingulate cortex and clozapine response in patients with treatment-resistant schizophrenia: A proton magnetic resonance spectroscopy ( ( De Luca, V; Edden, RAE; Gerretsen, P; Graff-Guerrero, A; Honda, S; Iwata, Y; Mar, W; Mikkelsen, M; Mimura, M; Nakajima, S; Noda, Y; Plitman, E; Remington, G; Sailasuta, N; Torres-Carmona, E; Truong, P; Tsugawa, S; Ueno, F, 2022) |
| "Abnormal glutamate and GABA (gamma-aminobutyric acid) levels have been found in the early phase of schizophrenia and may underlie cognitive deficits." | 8.02 | Associations Between Cognitive Function and Levels of Glutamatergic Metabolites and Gamma-Aminobutyric Acid in Antipsychotic-Naïve Patients With Schizophrenia or Psychosis. ( Andersen, GS; Bojesen, KB; Broberg, BV; Edden, RAE; Fagerlund, B; Glenthøj, BY; Jessen, K; Larsson, HBW; Nielsen, MØ; Rostrup, E; Sigvard, A; Tangmose, K; Thomas, MB, 2021) |
| "In total, 56 antipsychotic-naïve patients with schizophrenia or psychotic disorder and 51 healthy control subjects underwent magnetic resonance spectroscopy to measure glutamate, glutamate+glutamine (Glx), and GABA levels in dorsal anterior cingulate cortex (ACC) and glutamate and Glx levels in left thalamus." | 8.02 | Associations Between Cognitive Function and Levels of Glutamatergic Metabolites and Gamma-Aminobutyric Acid in Antipsychotic-Naïve Patients With Schizophrenia or Psychosis. ( Andersen, GS; Bojesen, KB; Broberg, BV; Edden, RAE; Fagerlund, B; Glenthøj, BY; Jessen, K; Larsson, HBW; Nielsen, MØ; Rostrup, E; Sigvard, A; Tangmose, K; Thomas, MB, 2021) |
| "Whilst reduced signalling and gene expression related to gamma-aminobutyric acid (GABA) play a role in the presumed pathophysiology of schizophrenia, its origin is unclear." | 8.02 | In vivo gamma-aminobutyric acid-A/benzodiazepine receptor availability and genetic liability in asymptomatic individuals with high genetic loading of schizophrenia: A [11C]flumazenil positron emission tomography study. ( Cho, KIK; Jeong, JM; Kim, E; Kim, M; Kwon, JS; Lee, J; Lee, JS; Lee, TY; Seo, S; Yoon, YB, 2021) |
| "A total of 10 AIs with multiple relatives diagnosed as schizophrenia and 11 healthy controls underwent [11C]flumazenil positron emission tomography and neurocognitive function tests." | 8.02 | In vivo gamma-aminobutyric acid-A/benzodiazepine receptor availability and genetic liability in asymptomatic individuals with high genetic loading of schizophrenia: A [11C]flumazenil positron emission tomography study. ( Cho, KIK; Jeong, JM; Kim, E; Kim, M; Kwon, JS; Lee, J; Lee, JS; Lee, TY; Seo, S; Yoon, YB, 2021) |
| "Gamma-aminobutyric acid (GABA) dysfunction and its consequent imbalance are implicated in the pathophysiology of schizophrenia." | 7.88 | In vivo gamma-aminobutyric acid and glutamate levels in people with first-episode schizophrenia: A proton magnetic resonance spectroscopy study. ( Chan, Q; Chan, RCK; Cheung, EFC; Chiu, PW; Hung, KSY; Lui, SSY; Mak, HKF; Sham, PC, 2018) |
| "The N-methyl-D-aspartate receptor hypofunction model of schizophrenia predicts dysfunction in both glutamatergic and gamma-aminobutyric acidergic (GABAergic) transmission." | 7.85 | 7T Proton Magnetic Resonance Spectroscopy of Gamma-Aminobutyric Acid, Glutamate, and Glutamine Reveals Altered Concentrations in Patients With Schizophrenia and Healthy Siblings. ( Boer, VO; Cahn, W; Kahn, RS; Klomp, DW; Neggers, SF; Rösler, L; Thakkar, KN; Wijnen, JP, 2017) |
| "Previous research implicates altered metabolism of l-arginine, a versatile amino acid with a number of bioactive metabolites, in the pathogenesis of schizophrenia." | 7.83 | Altered brain arginine metabolism in schizophrenia. ( Bilkey, DK; Collie, ND; Dean, B; Jing, Y; Liu, P; Zhang, H, 2016) |
| "Pregabalin is an antiepileptic drug with anti-anxiety properties and is approved for treatment of generalized anxiety disorder." | 7.81 | Possible drug-drug interaction between pregabalin and clozapine in patients with schizophrenia: clinical perspectives. ( Damkier, P; Lykkegaard, S; Nielsen, J; Schjerning, O, 2015) |
| "Pregabalin was added to clozapine in 2 patients with schizophrenia, who both suffered from severe anxiety symptoms." | 7.81 | Possible drug-drug interaction between pregabalin and clozapine in patients with schizophrenia: clinical perspectives. ( Damkier, P; Lykkegaard, S; Nielsen, J; Schjerning, O, 2015) |
| "Environmental factors have been associated with psychiatric disorders and recent epidemiological studies suggest an association between prenatal lead (Pb(2+)) exposure and schizophrenia (SZ)." | 7.81 | Early-life lead exposure recapitulates the selective loss of parvalbumin-positive GABAergic interneurons and subcortical dopamine system hyperactivity present in schizophrenia. ( Guilarte, TR; Liu, X; McGlothan, JL; Ruby, KN; Soares, BD; Stansfield, KH, 2015) |
| ", cortical silent period (CSP) and short-interval cortical inhibition (SICI)) were measured over the motor cortex in 16 patients with schizophrenia before starting clozapine, then 6 weeks and 6 months after starting clozapine." | 7.81 | Clozapine potentiation of GABA mediated cortical inhibition in treatment resistant schizophrenia. ( Blumberger, DM; Daskalakis, ZJ; de Jesus, D; Farzan, F; Fitzgerald, PB; Kaster, TS; Radhu, N; Rajji, TK, 2015) |
| "Despite widely replicated abnormalities of gamma-aminobutyric acid (GABA) neurons in schizophrenia postmortem, few studies have measured tissue GABA levels in vivo." | 7.76 | Elevated gamma-aminobutyric acid levels in chronic schizophrenia. ( Cohen, BM; McCarthy, J; Ongür, D; Prescot, AP; Renshaw, PF, 2010) |
| "We found elevations in GABA/creatine in the schizophrenia group compared with control subjects [F(1,65) = 4." | 7.76 | Elevated gamma-aminobutyric acid levels in chronic schizophrenia. ( Cohen, BM; McCarthy, J; Ongür, D; Prescot, AP; Renshaw, PF, 2010) |
| "Postmortem samples from individuals with schizophrenia (n = 13) and control subjects (n = 10) were investigated for binding of [(3)H]tiagabine to GABA transporter-1 GAT-1." | 7.71 | Increased [(3)H]tiagabine binding to GAT-1 in the cingulate cortex in schizophrenia. ( Blennow, K; Dandenell, AK; Davidsson, P; Marcusson, J; Sundman-Eriksson, I, 2002) |
| "Markers of gamma-aminobutyric acid (GABA) neurotransmission seem to be altered in the prefrontal cortex (PFC) of subjects with schizophrenia." | 7.70 | Decreased glutamic acid decarboxylase67 messenger RNA expression in a subset of prefrontal cortical gamma-aminobutyric acid neurons in subjects with schizophrenia. ( Austin, MC; Lewis, DA; Pierri, JN; Sampson, AR; Volk, DW, 2000) |
| "In a previous paper, I have proposed that the deficiency of an endogenous caffeine-like substance is the underlying pathogenic mechanism in schizophrenia (1)." | 7.68 | Exploring the role of an endogenous caffeine-like substance in the pathogenesis of schizophrenia. ( Missak, SS, 1991) |
| " I report a patient who developed the syndrome during treatment for schizophrenia with the antipsychotic agent molindone hydrochloride." | 7.68 | Neuroleptic-induced "painful legs and moving toes" syndrome: successful treatment with clonazepam and baclofen. ( Sandyk, R, 1990) |
| "Baclofen and placebo were administered orally, in a double-blind design, and blood samples were collected before and 30, 60, 90, 120, 180, and 240 min after drug or placebo administration." | 6.66 | Baclofen-induced growth hormone secretion is blunted in chronic schizophrenics: neuroendocrine evidence for a GABA disturbance in schizophrenia. ( Forziati, D; Iovino, M; Maj, M; Monteleone, P; Steardo, L; Veltro, F, 1988) |
| " The animal model, using a sub-chronic dosing regimen (sc) with the non-competitive NMDA receptor antagonist PCP (phencyclidine), evolved from previous work in rats (for PCP) and primates (for cognition)." | 6.53 | Modelling the cognitive and neuropathological features of schizophrenia with phencyclidine. ( Neill, JC; Reynolds, GP, 2016) |
| "Schizophrenia is a devastating neuropsychiatric disorder of unknown etiology." | 6.48 | Is lead exposure in early life an environmental risk factor for Schizophrenia? Neurobiological connections and testable hypotheses. ( Guilarte, TR; Opler, M; Pletnikov, M, 2012) |
| "Schizophrenia is a common mental disorder affecting patients' thoughts, behavior, and cognition." | 5.72 | Role of the NRG1/ErbB4 and PI3K/AKT/mTOR signaling pathways in the anti-psychotic effects of aripiprazole and sertindole in ketamine-induced schizophrenia-like behaviors in rats. ( Nawwar, DA; Sayed, RH; Zaki, HF, 2022) |
| "Clozapine, the only approved drug for treatment-resistant schizophrenia (TRS), involves the GABAergic system as one of its targets." | 5.72 | Gamma-aminobutyric acid (GABA) levels in the midcingulate cortex and clozapine response in patients with treatment-resistant schizophrenia: A proton magnetic resonance spectroscopy ( ( De Luca, V; Edden, RAE; Gerretsen, P; Graff-Guerrero, A; Honda, S; Iwata, Y; Mar, W; Mikkelsen, M; Mimura, M; Nakajima, S; Noda, Y; Plitman, E; Remington, G; Sailasuta, N; Torres-Carmona, E; Truong, P; Tsugawa, S; Ueno, F, 2022) |
| "Ketamine is a noncompetitive antagonist of N-methyl-D-aspartate receptors (NMDARs)." | 5.72 | Comprehensive metabolomic characterization of the hippocampus in a ketamine mouse model of schizophrenia. ( Cheng, A; Fan, W; Fu, Y; Liao, L; Wang, X; Wei, Y; Wen, D; Xiao, L; Yang, H; Ye, Y, 2022) |
| "Both schizophrenia (SZ) and substance abuse (SA) exhibit significant heritability." | 5.51 | N-Methyl-d-aspartate receptor co-agonist availability affects behavioral and neurochemical responses to cocaine: insights into comorbid schizophrenia and substance abuse. ( Bergman, J; Carlezon, WA; Coyle, JT; Desai, RI; Donahue, RJ; Doyle, MR; Landino, SM; Presti, KT; Puhl, MD; Takagi, S, 2019) |
| "The mainstay treatment for schizophrenia is antipsychotic drugs (APDs), which are mostly effective against the positive symptoms (e." | 5.51 | Effect of cannabidiol on endocannabinoid, glutamatergic and GABAergic signalling markers in male offspring of a maternal immune activation (poly I:C) model relevant to schizophrenia. ( Babic, I; Huang, XF; Lum, JS; Newell, KA; Osborne, AL; Solowij, N; Weston-Green, K, 2019) |
| "Schizophrenia is accompanied by impaired cortical inhibition, as measured by several markers including the cortical silent period (CSP)." | 5.46 | Risperidone increases the cortical silent period in drug-naive patients with first-episode schizophrenia: A transcranial magnetic stimulation study. ( Ceskova, E; Hublova, V; Kasparek, T; Mayerova, M; Prikrylova Kucerova, H; Ustohal, L, 2017) |
| " Systemic nicotine given before the sample phase of the CMOR task reversed the ketamine-induced impairment, but this effect was blocked by co-administration of the GABAA receptor antagonist bicuculline at a dosage that itself did not cause impairment." | 5.42 | α₄β₂ Nicotinic receptor stimulation of the GABAergic system within the orbitofrontal cortex ameliorates the severe crossmodal object recognition impairment in ketamine-treated rats: implications for cognitive dysfunction in schizophrenia. ( Cloke, JM; Winters, BD, 2015) |
| "Schizophrenia is associated with atypical multisensory integration." | 5.42 | α₄β₂ Nicotinic receptor stimulation of the GABAergic system within the orbitofrontal cortex ameliorates the severe crossmodal object recognition impairment in ketamine-treated rats: implications for cognitive dysfunction in schizophrenia. ( Cloke, JM; Winters, BD, 2015) |
| " In neither patient, the increase in haloperidol dosage affected paranoid symptoms." | 5.26 | [Use of haloperidol in high doses in schizophrenia. Clinical, biochemical and pharmacokinetic study]. ( Bianchetti, G; Cuche, H; Loo, H; Morselli, PL; Scatton, B; Zarifian, E, 1982) |
| "gamma-Aminobutyric acid (Gaba) has been shown to influence dopamine activity in the brain." | 5.26 | gamma-Aminobutyric acid (Gaba) and the dopamine hypothesis of schizophrenia. ( Van Kammen, DP, 1977) |
| "Although numerous studies reported some changes of cortical silent period (CSP), an indicator of gamma-aminobutyric acid (GABA) function in central nervous system, in schizophrenia patients, it has been unknown how the disease stage and antipsychotic medication affect CSP values." | 5.22 | The cortical silent period in schizophrenia: A systematic review and meta-analysis focusing on disease stage and antipsychotic medication. ( Iyo, M; Kanahara, N; Kawasaki, Y; Komatsu, H; Masumo, Y; Miyazawa, A; Nakata, Y; Ozawa, Y; Shiko, Y, 2022) |
| " Our computational results mirror our empirical study of dopamine modulation in schizophrenia and healthy controls, which showed that amphetamine administration increased gamma power in patients but decreased it in controls." | 5.16 | Dopamine and gamma band synchrony in schizophrenia--insights from computational and empirical studies. ( Bard Ermentrout, G; Cho, RY; Kömek, K; Walker, CP, 2012) |
| "363 hospital-based psychiatric patients in India, Romania, and United States aged 18 to 65 years and meeting criteria for DSM-IV-TR diagnosis of chronic schizophrenia were randomized double-blind to receive BL-1020 10 mg/d, BL-1020 20-30 mg/d, placebo, or risperidone (2-8 mg/d) for 6 weeks." | 5.16 | Bl-1020, a new γ-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study. ( Anand, R; Davidson, M; Geffen, Y; Keefe, R; Rabinowitz, J, 2012) |
| "Cognitive impairment causes morbidity in schizophrenia and could be due to abnormalities of cortical interneurons using the inhibitory neurotransmitter gamma-aminobutyric acid (GABA)." | 5.12 | Effects of gamma-aminobutyric acid-modulating drugs on working memory and brain function in patients with schizophrenia. ( Bullmore, E; Fletcher, P; Kamath, S; McKenna, P; Menzies, L; Ooi, C; Stephenson, C; Suckling, J, 2007) |
| "The authors investigate: (1) whether there is a lateral effect of hydrogen (1H) magnetic resonance (MR) spectroscopy observable metabolite ratios between the right and the left prefrontal lobe in chronic schizophrenia; (2) whether there is a change of proton metabolite ratios in chronic schizophrenia after neuroleptic treatment; (3) whether there is a relation between changes in 1H MR spectra and the clinical assessment of Brief Psychiatric Rating Scale (BPRS); and (4) to investigate a hypofrontality hypothesis in schizophrenia in terms of neurochemical aspects." | 5.08 | Observation of metabolic changes in chronic schizophrenia after neuroleptic treatment by in vivo hydrogen magnetic resonance spectroscopy. ( Choe, BY; Lee, C; Lee, CW; Paik, IH; Shinn, KS; Suh, TS, 1996) |
| "To substantiate a previously reported disturbance of gamma-aminobutyric acid (GABA) in chronic schizophrenia, plasma growth hormone (GH) response to a direct GABA agonist (baclofen, 10 mg) was assessed in 12 unmedicated chronic schizophrenic males and 10 sex- and age-matched healthy controls." | 5.06 | Baclofen-induced growth hormone secretion is blunted in chronic schizophrenics: neuroendocrine evidence for a GABA disturbance in schizophrenia. ( Forziati, D; Iovino, M; Maj, M; Monteleone, P; Steardo, L; Veltro, F, 1988) |
| "The hypothesis of a gamma-aminobutyric acid (GABA) involvement in the pathophysiology of schizophrenia has been recently proposed but not confirmed." | 5.06 | Growth hormone response to sodium valproate in chronic schizophrenia. ( Iovino, M; Maj, M; Monteleone, P; Steardo, L, 1986) |
| " While the applications of MRS are numerous, this review has been confined to the use of single voxel spectroscopy in the assessment of five key metabolites and their roles in schizophrenia: N-acetylaspartate (NAA), glutamate (Glu) and glutamine (Gln), γ-aminobutyric acid (GABA) and glutathione (GSH)." | 4.98 | Current Practice and New Developments in the Use of In Vivo Magnetic Resonance Spectroscopy for the Assessment of Key Metabolites Implicated in the Pathophysiology of Schizophrenia. ( Dwyer, GE; Grüner, R; Hugdahl, K; Specht, K, 2018) |
| "We review our current understanding of abnormal γ band oscillations in schizophrenia, their association with symptoms and the underlying cortical circuit abnormality, with a particular focus on the role of fast-spiking parvalbumin gamma-aminobutyric acid (GABA) neurons in the disease state." | 4.93 | Gamma band oscillations: a key to understanding schizophrenia symptoms and neural circuit abnormalities. ( McCarley, RW; McNally, JM, 2016) |
| "The observation that antagonists of the N-methyl-D-aspartate receptor (NMDAR), such as phencyclidine (PCP) and ketamine, transiently induce symptoms of acute schizophrenia had led to a paradigm shift from dopaminergic to glutamatergic dysfunction in pharmacological models of schizophrenia." | 4.90 | Reviewing the ketamine model for schizophrenia. ( Frohlich, J; Van Horn, JD, 2014) |
| "Less than half of patients with schizophrenia obtain full response to antipsychotic drugs and, while clozapine represents the treatment of choice for refractory psychosis, a significant number of individuals remain only partially responsive." | 4.89 | Topiramate in schizophrenia: a review of effects on psychopathology and metabolic parameters. ( Cohn, T; Hahn, MK; Remington, G; Teo, C, 2013) |
| "The hypothesis that alterations of cortical inhibitory gamma-aminobutyric acid (GABA) neurons are a central element in the pathology of schizophrenia has emerged from a series of postmortem studies." | 4.86 | Alterations of cortical GABA neurons and network oscillations in schizophrenia. ( Gonzalez-Burgos, G; Hashimoto, T; Lewis, DA, 2010) |
| "A converging body of evidence implicates the gamma-aminobutyric acid (GABA) neurotransmitter system in the pathogenesis of schizophrenia." | 4.82 | GABA and schizophrenia: a review of basic science and clinical studies. ( Baker, J; Kochan, LD; Wassef, A, 2003) |
| "The atypical antipsychotics risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole have become first-line treatment for schizophrenia because they reduce the positive symptoms of psychosis but do not have a high incidence of extrapyramidal symptoms." | 4.82 | A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. ( Grady, MM; Stahl, SM, 2004) |
| "Deficits in a variety of different neurochemical species are consistent with a loss of cortical gamma-aminobutyric acid (GABA)ergic interneurons in schizophrenia." | 4.81 | Neurochemical correlates of cortical GABAergic deficits in schizophrenia: selective losses of calcium binding protein immunoreactivity. ( Beasley, CL; Reynolds, GP; Zhang, ZJ, 2001) |
| "A role for gamma-aminobutyric acid (GABA) in the pathophysiology of schizophrenia was first suggested by Eugene Roberts in 1972." | 4.76 | The interaction between GABA and dopamine: implications for schizophrenia. ( Garbutt, JC; van Kammen, DP, 1983) |
| "Cognitive deficits in schizophrenia are associated with altered GABA (gamma-aminobutyric acid) neurotransmission in the prefrontal cortex (PFC)." | 4.31 | Laminar-Specific Alterations in Calbindin-Positive Boutons in the Prefrontal Cortex of Subjects With Schizophrenia. ( Fish, KN; Lewis, DA; Rocco, BR; Wilson, JD, 2023) |
| "Observations from different fields of research coincide in indicating that a defective gamma-aminobutyric acid (GABA) interneuron system may be among the primary factors accounting for the varied clinical expression of schizophrenia." | 4.31 | Mapping alterations in the local synchrony of the cerebral cortex in schizophrenia. ( Blanco-Hinojo, L; Deus, J; Mané, A; Martínez-Vilavella, G; Pérez-Sola, V; Pujol, J; Pujol, N, 2023) |
| "This study enrolled patients with TRS who did not respond to clozapine (ultra-resistant schizophrenia: URS) and who responded to clozapine (non-URS), patients with schizophrenia who responded to first-line antipsychotics (first-line responders: FLR), and healthy controls (HCs)." | 4.12 | Gamma-aminobutyric acid (GABA) levels in the midcingulate cortex and clozapine response in patients with treatment-resistant schizophrenia: A proton magnetic resonance spectroscopy ( ( De Luca, V; Edden, RAE; Gerretsen, P; Graff-Guerrero, A; Honda, S; Iwata, Y; Mar, W; Mikkelsen, M; Mimura, M; Nakajima, S; Noda, Y; Plitman, E; Remington, G; Sailasuta, N; Torres-Carmona, E; Truong, P; Tsugawa, S; Ueno, F, 2022) |
| "Our study is the first to report elevated GABA levels in the MCC in patients with schizophrenia resistant to clozapine treatment compared with those responsive to clozapine." | 4.12 | Gamma-aminobutyric acid (GABA) levels in the midcingulate cortex and clozapine response in patients with treatment-resistant schizophrenia: A proton magnetic resonance spectroscopy ( ( De Luca, V; Edden, RAE; Gerretsen, P; Graff-Guerrero, A; Honda, S; Iwata, Y; Mar, W; Mikkelsen, M; Mimura, M; Nakajima, S; Noda, Y; Plitman, E; Remington, G; Sailasuta, N; Torres-Carmona, E; Truong, P; Tsugawa, S; Ueno, F, 2022) |
| "Compared with HC, schizophrenia patients had lower cognitive performance, higher methionine concentrations, decreased concentrations of glutamic acid, cysteine, aspartic acid, arginine, the ratio of glutamic acid to gamma-aminobutyric acid (Glu/GABA), and DAT availability in the left caudate nucleus (CN) and putamen." | 4.12 | Interactions between dopamine transporter and N-methyl-d-aspartate receptor-related amino acids on cognitive impairments in schizophrenia. ( Chen, YY; Chou, YH; Liu, MN; Yang, BH; Yang, KC, 2022) |
| "Recent studies suggest that altered gamma-aminobutyric acidergic (GABAergic) function may result in multisensory integration deficits in schizophrenia." | 4.12 | Striatal GABA level is associated with sensory integration ability in individuals with low levels of negative schizotypy. ( Cai, XL; Chan, RCK; Li, GY; Li, JQ; Lui, SSY; Wang, LL; Wang, Y; Yan, C; Zhao, WW, 2022) |
| "Abnormal glutamate and GABA (gamma-aminobutyric acid) levels have been found in the early phase of schizophrenia and may underlie cognitive deficits." | 4.02 | Associations Between Cognitive Function and Levels of Glutamatergic Metabolites and Gamma-Aminobutyric Acid in Antipsychotic-Naïve Patients With Schizophrenia or Psychosis. ( Andersen, GS; Bojesen, KB; Broberg, BV; Edden, RAE; Fagerlund, B; Glenthøj, BY; Jessen, K; Larsson, HBW; Nielsen, MØ; Rostrup, E; Sigvard, A; Tangmose, K; Thomas, MB, 2021) |
| "In total, 56 antipsychotic-naïve patients with schizophrenia or psychotic disorder and 51 healthy control subjects underwent magnetic resonance spectroscopy to measure glutamate, glutamate+glutamine (Glx), and GABA levels in dorsal anterior cingulate cortex (ACC) and glutamate and Glx levels in left thalamus." | 4.02 | Associations Between Cognitive Function and Levels of Glutamatergic Metabolites and Gamma-Aminobutyric Acid in Antipsychotic-Naïve Patients With Schizophrenia or Psychosis. ( Andersen, GS; Bojesen, KB; Broberg, BV; Edden, RAE; Fagerlund, B; Glenthøj, BY; Jessen, K; Larsson, HBW; Nielsen, MØ; Rostrup, E; Sigvard, A; Tangmose, K; Thomas, MB, 2021) |
| "Whilst reduced signalling and gene expression related to gamma-aminobutyric acid (GABA) play a role in the presumed pathophysiology of schizophrenia, its origin is unclear." | 4.02 | In vivo gamma-aminobutyric acid-A/benzodiazepine receptor availability and genetic liability in asymptomatic individuals with high genetic loading of schizophrenia: A [11C]flumazenil positron emission tomography study. ( Cho, KIK; Jeong, JM; Kim, E; Kim, M; Kwon, JS; Lee, J; Lee, JS; Lee, TY; Seo, S; Yoon, YB, 2021) |
| "A total of 10 AIs with multiple relatives diagnosed as schizophrenia and 11 healthy controls underwent [11C]flumazenil positron emission tomography and neurocognitive function tests." | 4.02 | In vivo gamma-aminobutyric acid-A/benzodiazepine receptor availability and genetic liability in asymptomatic individuals with high genetic loading of schizophrenia: A [11C]flumazenil positron emission tomography study. ( Cho, KIK; Jeong, JM; Kim, E; Kim, M; Kwon, JS; Lee, J; Lee, JS; Lee, TY; Seo, S; Yoon, YB, 2021) |
| "Abnormal functioning of the inhibitory gamma-aminobutyric acid (GABA) and excitatory (glutamate) systems is proposed to play a role in the development of schizophrenia spectrum disorder." | 4.02 | Reduced cortical GABA and glutamate in high schizotypy. ( Allen, P; Diaconescu, AO; Kozhuharova, P, 2021) |
| "Gamma-aminobutyric acid (GABA) dysfunction and its consequent imbalance are implicated in the pathophysiology of schizophrenia." | 3.88 | In vivo gamma-aminobutyric acid and glutamate levels in people with first-episode schizophrenia: A proton magnetic resonance spectroscopy study. ( Chan, Q; Chan, RCK; Cheung, EFC; Chiu, PW; Hung, KSY; Lui, SSY; Mak, HKF; Sham, PC, 2018) |
| " Here we discuss this disease concept in the context of our recent findings demonstrating that neural dysfunction arising from accumulation of the schizophrenia-associated metabolite l-proline is due to its structural mimicry of the neurotransmitter GABA that leads to alterations in GABA-ergic short-term synaptic plasticity." | 3.88 | Role of Endogenous Metabolite Alterations in Neuropsychiatric Disease. ( Crabtree, GW; Gogos, JA, 2018) |
| "The N-methyl-D-aspartate receptor hypofunction model of schizophrenia predicts dysfunction in both glutamatergic and gamma-aminobutyric acidergic (GABAergic) transmission." | 3.85 | 7T Proton Magnetic Resonance Spectroscopy of Gamma-Aminobutyric Acid, Glutamate, and Glutamine Reveals Altered Concentrations in Patients With Schizophrenia and Healthy Siblings. ( Boer, VO; Cahn, W; Kahn, RS; Klomp, DW; Neggers, SF; Rösler, L; Thakkar, KN; Wijnen, JP, 2017) |
| "Involvement of the gamma-aminobutyric acid (GABA)-ergic system in schizophrenia pathogenesis through disrupted neurodevelopment has been highlighted in numerous studies." | 3.85 | Comprehensive association analysis of 27 genes from the GABAergic system in Japanese individuals affected with schizophrenia. ( Balan, S; Hashimoto, T; Iwayama, Y; Kameno, Y; Kanahara, N; Kikuchi, M; Kurita, D; Maekawa, M; Shimamoto, C; Takagai, S; Toyota, T; Wakuda, T; Yamada, K; Yoshikawa, T, 2017) |
| "Convergent findings indicate that cortical gamma-aminobutyric acid (GABA)ergic circuitry is altered in schizophrenia." | 3.83 | Markedly Lower Glutamic Acid Decarboxylase 67 Protein Levels in a Subset of Boutons in Schizophrenia. ( Fish, KN; Lewis, DA; Rocco, BR, 2016) |
| " For the first time, the balance of GABA glutamate/glutamine concentrations was estimated quantitatively in the human brain of patients with ultra-high risk of schizophrenia." | 3.83 | (1)H-MRS and MEGA-PRESS pulse sequence in the study of balance of inhibitory and excitatory neurotransmitters in the human brain of ultra-high risk of schizophrenia patients. ( Akhadov, TA; Kaleda, VG; Keshishyan, RA; Lebedeva, IS; Menschikov, PE; Omelchenko, MA; Semenova, NA; Ublinskiy, MV; Varfolomeev, SD, 2016) |
| "Previous research implicates altered metabolism of l-arginine, a versatile amino acid with a number of bioactive metabolites, in the pathogenesis of schizophrenia." | 3.83 | Altered brain arginine metabolism in schizophrenia. ( Bilkey, DK; Collie, ND; Dean, B; Jing, Y; Liu, P; Zhang, H, 2016) |
| "Proline dehydrogenase (PRODH), which degrades L-proline, resides within the schizophrenia-linked 22q11." | 3.83 | Cytosolic Accumulation of L-Proline Disrupts GABA-Ergic Transmission through GAD Blockade. ( Crabtree, GW; Gogos, JA; Gordon, JA; Park, AJ, 2016) |
| "Pregabalin is an antiepileptic drug with anti-anxiety properties and is approved for treatment of generalized anxiety disorder." | 3.81 | Possible drug-drug interaction between pregabalin and clozapine in patients with schizophrenia: clinical perspectives. ( Damkier, P; Lykkegaard, S; Nielsen, J; Schjerning, O, 2015) |
| "Pregabalin was added to clozapine in 2 patients with schizophrenia, who both suffered from severe anxiety symptoms." | 3.81 | Possible drug-drug interaction between pregabalin and clozapine in patients with schizophrenia: clinical perspectives. ( Damkier, P; Lykkegaard, S; Nielsen, J; Schjerning, O, 2015) |
| "The down regulation of glutamic acid decarboxylase67 (GAD1), reelin (RELN), and BDNF expression in brain of schizophrenia (SZ) and bipolar (BP) disorder patients is associated with overexpression of DNA methyltransferase1 (DNMT1) and ten-eleven translocase methylcytosine dioxygenase1 (TET1)." | 3.81 | DNA-methyltransferase1 (DNMT1) binding to CpG rich GABAergic and BDNF promoters is increased in the brain of schizophrenia and bipolar disorder patients. ( Dong, E; Grayson, DR; Guidotti, A; Ruzicka, WB, 2015) |
| "Environmental factors have been associated with psychiatric disorders and recent epidemiological studies suggest an association between prenatal lead (Pb(2+)) exposure and schizophrenia (SZ)." | 3.81 | Early-life lead exposure recapitulates the selective loss of parvalbumin-positive GABAergic interneurons and subcortical dopamine system hyperactivity present in schizophrenia. ( Guilarte, TR; Liu, X; McGlothan, JL; Ruby, KN; Soares, BD; Stansfield, KH, 2015) |
| ", cortical silent period (CSP) and short-interval cortical inhibition (SICI)) were measured over the motor cortex in 16 patients with schizophrenia before starting clozapine, then 6 weeks and 6 months after starting clozapine." | 3.81 | Clozapine potentiation of GABA mediated cortical inhibition in treatment resistant schizophrenia. ( Blumberger, DM; Daskalakis, ZJ; de Jesus, D; Farzan, F; Fitzgerald, PB; Kaster, TS; Radhu, N; Rajji, TK, 2015) |
| "[(11)C]Flumazenil VT was significantly increased across all cortical brain regions in the healthy comparison group but not in the schizophrenia group." | 3.81 | In vivo measurement of GABA transmission in healthy subjects and schizophrenia patients. ( Cho, RY; Frankle, WG; Himes, ML; Lewis, DA; Mason, NS; Narendran, R; Paris, J; Prasad, KM; Walker, C, 2015) |
| "The involvement of the gamma-aminobutyric acid (GABA) system in schizophrenia is suggested by postmortem studies and the common use of GABA receptor-potentiating agents in treatment." | 3.81 | Abnormal GABAergic function and face processing in schizophrenia: A pharmacologic-fMRI study. ( Fang, Y; Phan, KL; Taylor, SF; Tso, IF; Welsh, RC, 2015) |
| "Altered transmission of gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter, may contribute to the development of schizophrenia." | 3.80 | Reduced binding potential of GABA-A/benzodiazepine receptors in individuals at ultra-high risk for psychosis: an [18F]-fluoroflumazenil positron emission tomography study. ( An, SK; Kang, JI; Kim, KR; Kim, SJ; Kwon, JS; Lee, E; Lee, JD; Lee, SY; Park, HJ, 2014) |
| "Inhibitory gamma-aminobutyric acid (GABA) transmission within the prefrontal cortex (PFC) regulates numerous functions, and perturbations in GABAergic transmission within this region have been proposed to contribute to some of the cognitive and behavioral abnormalities associated with disorders such as schizophrenia." | 3.80 | Prefrontal cortical GABA transmission modulates discrimination and latent inhibition of conditioned fear: relevance for schizophrenia. ( Floresco, SB; Piantadosi, PT, 2014) |
| "The major excitatory and inhibitory neurotransmitters, glutamate (Glu) and gamma-aminobutyric acid (GABA), respectively, are implicated in the pathophysiology of schizophrenia." | 3.79 | In vivo measurements of glutamate, GABA, and NAAG in schizophrenia. ( Barker, PB; Edden, RA; Holcomb, HH; Kontson, K; Rowland, LM; West, J; Wijtenburg, SA; Zhu, H, 2013) |
| "The aim of this study is to investigate the effects of pregabalin on the behavior of rats under the influence of ketamine, an NMDA receptor antagonist that mimics the symptoms of schizophrenia." | 3.78 | Effects of pregabalin on behavioral alterations induced by ketamine in rats. ( Baker, GB; Canever, L; Crippa, JA; Dursun, SM; Hallak, JE; Luca, RD; Nunes, EA; Oliveira, Ld; Peregrino, A; Quevedo, J; Zugno, A, 2012) |
| "Despite widely replicated abnormalities of gamma-aminobutyric acid (GABA) neurons in schizophrenia postmortem, few studies have measured tissue GABA levels in vivo." | 3.76 | Elevated gamma-aminobutyric acid levels in chronic schizophrenia. ( Cohen, BM; McCarthy, J; Ongür, D; Prescot, AP; Renshaw, PF, 2010) |
| "We found elevations in GABA/creatine in the schizophrenia group compared with control subjects [F(1,65) = 4." | 3.76 | Elevated gamma-aminobutyric acid levels in chronic schizophrenia. ( Cohen, BM; McCarthy, J; Ongür, D; Prescot, AP; Renshaw, PF, 2010) |
| "The advantages of BL-1020 for treatment of schizophrenia stem from its being a DA/5HT antagonist and a GABAergic agonist that releases cortical DA and antagonizes amphetamine-induced hyperactivity with reduced catalepsy and sedation." | 3.75 | BL-1020: a novel antipsychotic drug with GABAergic activity and low catalepsy, is efficacious in a rat model of schizophrenia. ( Geffen, Y; Gil-Ad, I; Huang, M; Klapper, L; Meltzer, HY; Nudelman, A; Rephaeli, A; Savitsky, K; Weizman, A; Winkler, I, 2009) |
| "Recent advances in schizophrenia (SZ) research indicate that the telencephalic gamma-aminobutyric acid (GABA)ergic neurotransmission deficit associated with this psychiatric disorder probably is mediated by the hypermethylation of the glutamic acid decarboxylase 67 (GAD(67)), reelin and other GABAergic promoters." | 3.75 | Characterization of the action of antipsychotic subtypes on valproate-induced chromatin remodeling. ( Costa, E; Dong, E; Grayson, DR; Guidotti, A; Kundakovic, M; Satta, R, 2009) |
| "Prefrontal deficits in gamma-aminobutyric acid (GABA)ergic gene expression, including neuropeptide Y (NPY), somatostatin (SST), and parvalbumin (PV) messenger RNAs (mRNAs), have been reported for multiple schizophrenia cohorts." | 3.75 | Molecular determinants of dysregulated GABAergic gene expression in the prefrontal cortex of subjects with schizophrenia. ( Akbarian, S; Baker, SP; Galdzicka, M; Ginns, E; Huang, HS; Mellios, N, 2009) |
| " In the present study, we examined the association between blood levels of 3-methoxy-4-hydroxyphenylglycol (MHPG), homovanillic acid (HVA), or brain-derived neurotrophic factor (BDNF) and scores on the Wisconsin Card Sorting Test (WCST) in patients with early-stage schizophrenia." | 3.75 | Associations between plasma levels of 3-methoxy-4-hydroxyphenylglycol (MHPG) and negative symptoms or cognitive impairments in early-stage schizophrenia. ( Goto, N; Hayashi, K; Hori, H; Ikenouchi-Sugita, A; Kakeda, S; Korogi, Y; Moriya, J; Nakamura, J; Ueda, N; Umene-Nakano, W; Yoshimura, R, 2009) |
| "Deficits in gamma-aminobutyric acid (GABA) signaling have been described in the prefrontal cortex, limbic system, and cerebellum in individuals with schizophrenia." | 3.74 | Altered expression of genes involved in GABAergic transmission and neuromodulation of granule cell activity in the cerebellum of schizophrenia patients. ( Bullock, WM; Bustillo, J; Cardon, K; Perrone-Bizzozero, NI; Roberts, RC, 2008) |
| "Acute administration of the psychotomimetic phencyclidine (PCP) can mimic some features of schizophrenia, while a repeated treatment regimen of PCP may provide a more effective way to model in animals the enduring cognitive dysfunction observed in many schizophrenic patients." | 3.74 | Sub-chronic psychotomimetic phencyclidine induces deficits in reversal learning and alterations in parvalbumin-immunoreactive expression in the rat. ( Abdul-Monim, Z; Neill, JC; Reynolds, GP, 2007) |
| "Neurodevelopmental deficits of parvalbumin-immunoreactive gamma-aminobutyric acid (GABA)ergic interneurons in prefrontal cortex have been reported in schizophrenia." | 3.74 | Prenatal exposure to an NMDA receptor antagonist, MK-801 reduces density of parvalbumin-immunoreactive GABAergic neurons in the medial prefrontal cortex and enhances phencyclidine-induced hyperlocomotion but not behavioral sensitization to methamphetamine ( Abekawa, T; Ito, K; Koyama, T; Nakagawa, S, 2007) |
| "There is an accumulation of evidence for abnormalities in schizophrenia of both the major neurotransmitter systems of the brain - those of GABA (gamma-aminobutyric acid) and glutamate." | 3.74 | The neuronal pathology of schizophrenia: molecules and mechanisms. ( Harte, MK; Reynolds, GP, 2007) |
| "Postmortem CNS studies have suggested an uncoupling of the gamma-aminobutyric acid (GABA) and benzodiazepine binding sites on the hippocampal GABA(A) receptor in schizophrenia." | 3.73 | Changes in hippocampal GABAA receptor subunit composition in bipolar 1 disorder. ( Dean, B; McLeod, M; Scarr, E, 2005) |
| "The neonatal ventral hippocampal lesion in the rat has been used as a model of schizophrenia, a human disorder associated with changes in markers of dopamine and gamma-aminobutyric acid (GABA) circuits in various regions of the brain." | 3.72 | The neonatal ventral hippocampal lesion model of schizophrenia: effects on dopamine and GABA mRNA markers in the rat midbrain. ( Khaing, ZZ; Lerman, DN; Lipska, BK; Weinberger, DR, 2003) |
| "A down-regulation of reelin and glutamic acid decarboxylase (GAD) 67 mRNAs was detected in gamma-aminobutyric acid (GABA)ergic cortical interneurons of schizophrenia (SZ) postmortem brains (10), suggesting that the availability of GABA and reelin may be decreased in SZ cortex." | 3.72 | DNA-methyltransferase 1 mRNA is selectively overexpressed in telencephalic GABAergic interneurons of schizophrenia brains. ( Caruncho, HJ; Costa, E; Davis, J; Grayson, DR; Guidotti, A; Liu, WS; Satta, R; Veldic, M, 2004) |
| "Disturbances of gamma-aminobutyric acid interneurons in the cerebral cortex contribute to the pathophysiology of schizophrenia and bipolar disorder." | 3.72 | Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-D-aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder. ( Benes, FM; Walsh, JP; Woo, TU, 2004) |
| "To test the hypothesis that glutamatergic inputs onto gamma-aminobutyric acid interneurons via the N-methyl-d-aspartate (NMDA) receptor are altered in the anterior cingulate cortex in schizophrenia and bipolar disorder." | 3.72 | Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-D-aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder. ( Benes, FM; Walsh, JP; Woo, TU, 2004) |
| "The density of gamma-aminobutyric acid interneurons that express the NMDA NR(2A)subunit appears to be decreased in schizophrenia and bipolar disorder." | 3.72 | Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-D-aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder. ( Benes, FM; Walsh, JP; Woo, TU, 2004) |
| "A number of investigations have provided a growing body of evidence of the involvement of the gamma-aminobutyric acid (GABA) transmitter system in the pathophysiology of schizophrenia and bipolar disorder." | 3.72 | Immunohistochemical and immunoblot study of GABA(A) alpha1 and beta2/3 subunits in the prefrontal cortex of subjects with schizophrenia and bipolar disorder. ( Asada, T; Hidaka, S; Ishikawa, M; Iwakiri, M; Mizukami, K, 2004) |
| "This study aimed to investigate the binding affinity of [3H]GABA and [3H]beta-alanine to GABA transporters GAT-1 and GAT-3 in the human dorsolateral prefrontal cortex (Brodmanns' area 9) in schizophrenia." | 3.72 | GABA transporters GAT-1 and GAT-3 in the human dorsolateral prefrontal cortex in schizophrenia. ( Dixon, G; Hinton, T; Johnston, GA; Schleimer, SB, 2004) |
| "Postmortem studies have provided evidence for abnormalities of the gamma-aminobutyric acid (GABA)-ergic system in schizophrenia, including deficits of GABA-containing interneurons." | 3.71 | Selective deficits in prefrontal cortical GABAergic neurons in schizophrenia defined by the presence of calcium-binding proteins. ( Beasley, CL; Patten, I; Reynolds, GP; Zhang, ZJ, 2002) |
| "Postmortem samples from individuals with schizophrenia (n = 13) and control subjects (n = 10) were investigated for binding of [(3)H]tiagabine to GABA transporter-1 GAT-1." | 3.71 | Increased [(3)H]tiagabine binding to GAT-1 in the cingulate cortex in schizophrenia. ( Blennow, K; Dandenell, AK; Davidsson, P; Marcusson, J; Sundman-Eriksson, I, 2002) |
| "Pharmacological, clinical, and postmortem studies suggest altered gamma-aminobutyric acid (GABA)-ergic and glutamatergic function in patients with schizophrenia." | 3.71 | Implications for altered glutamate and GABA metabolism in the dorsolateral prefrontal cortex of aged schizophrenic patients. ( Davis, KL; Gluck, MR; Haroutunian, V; Thomas, RG, 2002) |
| "Postmortem dorsolateral prefrontal cortex specimens from schizophrenia, Alzheimer's disease, and normal nonpsychiatric comparison subjects were assayed to determine activities of the principal glutamate and GABA-metabolizing enzymes glutamine synthetase, glutamate dehydrogenase, alpha-ketoglutarate dehydrogenase, phosphate-activated glutaminase, alanine aminotransferase, aspartate aminotransferase, glutamic acid decarboxylase, GABA-transaminase, and succinic semialdehyde dehydrogenase." | 3.71 | Implications for altered glutamate and GABA metabolism in the dorsolateral prefrontal cortex of aged schizophrenic patients. ( Davis, KL; Gluck, MR; Haroutunian, V; Thomas, RG, 2002) |
| "Greater phosphate-activated glutaminase and glutamic acid decarboxylase activities, specific to schizophrenia patients, provide additional biochemical evidence that dorsolateral prefrontal cortex glutamate and GABA metabolism is altered in schizophrenic subjects." | 3.71 | Implications for altered glutamate and GABA metabolism in the dorsolateral prefrontal cortex of aged schizophrenic patients. ( Davis, KL; Gluck, MR; Haroutunian, V; Thomas, RG, 2002) |
| "Some recent autopsy studies indicate that gamma-aminobutyric acid (GABA) function is decreased in brain areas that involve some of the well-described structural changes observed in schizophrenia." | 3.70 | GABA and brain abnormalities in schizophrenia. ( Barry, EJ; Gurklis, JA; Kelley, ME; Kramer, GL; Peters, JL; Petty, F; van Kammen, DP; Yao, JK, 1998) |
| "Markers of gamma-aminobutyric acid (GABA) neurotransmission seem to be altered in the prefrontal cortex (PFC) of subjects with schizophrenia." | 3.70 | Decreased glutamic acid decarboxylase67 messenger RNA expression in a subset of prefrontal cortical gamma-aminobutyric acid neurons in subjects with schizophrenia. ( Austin, MC; Lewis, DA; Pierri, JN; Sampson, AR; Volk, DW, 2000) |
| "The study describes changes over time in the adjunctive use of valproate and other mood stabilizers-lithium, carbamazepine, and gabapentin--among hospitalized psychiatric patients with a diagnosis of schizophrenia." | 3.70 | Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998. ( Allingham, B; Citrome, L; Levine, J, 2000) |
| " In the present study, we investigated the subunits gene expressions and ligand binding of the GABA(A) receptor following acute and chronic administration of phencyclidine (PCP), which induces schizophrenia-like symptoms, in rats using in situ hybridization and in vitro quantitative autoradiography." | 3.70 | Differential expression of GABA(A) receptor subunit mRNAs and ligand binding sites in rat brain following phencyclidine administration. ( Abe, S; Baba, A; Hori, T; Ito, T; Kurita, H; Shiraishi, H; Suzuki, T; Yamaguchi, M, 2000) |
| "Although there is evidence from postmortem studies suggestive of deficient inhibitory neurotransmission of gamma-aminobutyric acid (GABA) in schizophrenia, no direct in vivo evidence has been obtained to date." | 3.69 | Correlation between reduced in vivo benzodiazepine receptor binding and severity of psychotic symptoms in schizophrenia. ( Busatto, GF; Costa, DC; David, AS; Ell, PJ; Kerwin, RW; Lucey, JV; Pilowsky, LS, 1997) |
| "In a previous paper, I have proposed that the deficiency of an endogenous caffeine-like substance is the underlying pathogenic mechanism in schizophrenia (1)." | 3.68 | Exploring the role of an endogenous caffeine-like substance in the pathogenesis of schizophrenia. ( Missak, SS, 1991) |
| " I report a patient who developed the syndrome during treatment for schizophrenia with the antipsychotic agent molindone hydrochloride." | 3.68 | Neuroleptic-induced "painful legs and moving toes" syndrome: successful treatment with clonazepam and baclofen. ( Sandyk, R, 1990) |
| "We measured the contents of gamma-aminobutyric acid (GABA) and of other amino compounds in five regions of autopsied brain from 18 patients with schizophrenia and from a large group of adult control subjects dying without any neurological or psychiatric disorder." | 3.67 | Schizophrenia, tardive dyskinesia, and brain GABA. ( Hansen, S; Jones, K; Perry, TL, 1989) |
| "An experimental and clinico-pharmacological study of sodium valproate, a GABA-ergic drug, was conducted to elucidate the role of gamma-aminobutyric acid in the mechanisms responsible for affective disturbances, in particular for anxiety." | 3.67 | [Anxiolytic action of sodium valproate (possible role of gamma-aminobutyric acid in affective disorders)]. ( Aleksandrovskiĭ, IuA; Kharlamov, AN; Neznamov, GG; Poiurovskiĭ, MV; Raevskiĭ, KS, 1985) |
| "The authors measured gamma-aminobutyric acid (GABA) levels in the lumbar CSF of patients with depression, with psychosis, or undergoing evaluation for a neurologic disorder." | 3.66 | GABA levels in CSF of patients with psychiatric disorders. ( Bowers, MB; Gold, BI; Roth, RH; Sweeney, DW, 1980) |
| "The alteration in circulating levels of PRL, GH, TSH, and cortisol was studied after the oral administration of muscimol (3-hydroxy-5-aminomethylisoxazole) to human subjects with Huntington's disease (n = 4) and chronic schizophrenia (n = 5)." | 3.66 | Stimulation of prolactin and growth hormone secretion by muscimol, a gamma-aminobutyric acid agonist. ( Chase, TN; Frohman, LA; Neophytides, A; Tamminga, CA, 1978) |
| "A study of 246 patients (with schizophrenia, manic depressive psychoses and psychoorganic syndrome) treated by some drugs of a metabolic action (encephalotropic", "nootropic" drugs, piracetam, piriditol and pantogam) permitted one to determine the place of these preparations in a comprehensive treatment of mental disorders." | 3.66 | [Certain principles for differential utilization of metabolic treatment preparations in the complex therapy of mental disorders]. ( Avrutskiĭ, GIa; Laskova, NB, 1979) |
| "These results suggest that chronic administration of anxiolytics/hypnotics does not significantly affect MMN in schizophrenia." | 2.70 | Do high or low doses of anxiolytics and hypnotics affect mismatch negativity in schizophrenic subjects? An EEG and MEG study. ( Abe, O; Fukuda, M; Itoh, K; Iwanami, A; Kamio, S; Kasai, K; Kato, N; Koshida, I; Nakagome, K; Yamada, H; Yumoto, M, 2002) |
| "Baclofen and placebo were administered orally, in a double-blind design, and blood samples were collected before and 30, 60, 90, 120, 180, and 240 min after drug or placebo administration." | 2.66 | Baclofen-induced growth hormone secretion is blunted in chronic schizophrenics: neuroendocrine evidence for a GABA disturbance in schizophrenia. ( Forziati, D; Iovino, M; Maj, M; Monteleone, P; Steardo, L; Veltro, F, 1988) |
| "Depression and schizophrenia are burdensome, costly serious and disabling mental disorders." | 2.61 | Depression and schizophrenia viewed from the perspective of amino acidergic neurotransmission: Antipodes of psychiatric disorders. ( Pilc, A; Wierońska, JM, 2019) |
| "Schizophrenia is a complex disorder lacking an effective treatment option for the pervasive and debilitating cognitive impairments experienced by patients." | 2.58 | Mapping pathologic circuitry in schizophrenia. ( Glausier, JR; Lewis, DA, 2018) |
| "In DSM-5, catatonia syndrome may be diagnosed as a specifier to major mood disorders, psychotic disorders, general medical conditions, and as catatonia not otherwise specified." | 2.53 | Catatonia. ( Strik, W; Walther, S, 2016) |
| "Catatonia is potentially life threatening." | 2.53 | Catatonia. ( Strik, W; Walther, S, 2016) |
| " The animal model, using a sub-chronic dosing regimen (sc) with the non-competitive NMDA receptor antagonist PCP (phencyclidine), evolved from previous work in rats (for PCP) and primates (for cognition)." | 2.53 | Modelling the cognitive and neuropathological features of schizophrenia with phencyclidine. ( Neill, JC; Reynolds, GP, 2016) |
| "The origins of schizophrenia have eluded clinicians and researchers since Kraepelin and Bleuler began documenting their findings." | 2.52 | Neurodevelopment, GABA system dysfunction, and schizophrenia. ( Mirnics, K; Schmidt, MJ, 2015) |
| "Schizophrenia is associated with abnormalities of hippocampal structure and function." | 2.52 | GABAergic mechanisms of hippocampal hyperactivity in schizophrenia. ( Heckers, S; Konradi, C, 2015) |
| "Schizophrenia is considered a neurodevelopmental and neurodegenerative disorder." | 2.52 | New Pharmacotherapy Targeting Cognitive Dysfunction of Schizophrenia via Modulation of GABA Neuronal Function. ( Kurachi, M; Sumiyoshi, T; Uehara, T, 2015) |
| "Schizophrenia is a disorder of cognitive neurodevelopment." | 2.50 | Inhibitory neurons in human cortical circuits: substrate for cognitive dysfunction in schizophrenia. ( Lewis, DA, 2014) |
| "Schizophrenia is a disease affecting up to 1% of the population." | 2.50 | New approaches to the management of schizophrenia: focus on aberrant hippocampal drive of dopamine pathways. ( Lodge, DJ; Perez, SM, 2014) |
| "Schizophrenia is a devastating neuropsychiatric disorder of unknown etiology." | 2.48 | Is lead exposure in early life an environmental risk factor for Schizophrenia? Neurobiological connections and testable hypotheses. ( Guilarte, TR; Opler, M; Pletnikov, M, 2012) |
| "Schizophrenia is believed to result from problems during neural development that lead to improper function of synaptic transmission and plasticity, and in agreement, many of the susceptibility genes encode proteins critical for neural development." | 2.48 | Synaptic dysfunction in schizophrenia. ( Chen, YJ; Mei, L; Sathyamurthy, A; Xiong, WC; Yin, DM, 2012) |
| "Schizophrenia affects approximately 1% of the population and continues to be associated with poor outcome because of the limited efficacy of and noncompliance with existing antipsychotic medications." | 2.48 | Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications. ( Balu, D; Basu, A; Benneyworth, M; Coyle, JT; Konopaske, G, 2012) |
| "Schizophrenia has long been associated with an imbalance in dopamine (DA) neurotransmission, and brain imaging has played an important role in advancing our knowledge and providing evidence for the dopaminergic abnormalities." | 2.48 | The dopamine dysfunction in schizophrenia revisited: new insights into topography and course. ( Abi-Dargham, A; Kuepper, R; Skinbjerg, M, 2012) |
| "In animal experiments, seizures were found to increase NKCC1 expression, lower the KCC2 expression and accelerate neuronal differentiation." | 2.47 | Alterations in the expression of neuronal chloride transporters may contribute to schizophrenia. ( Kalkman, HO, 2011) |
| "Schizophrenia is a disorder of cognitive neurodevelopment with characteristic abnormalities in working memory attributed, at least in part, to alterations in the circuitry of the dorsolateral prefrontal cortex." | 2.47 | Postnatal developmental trajectories of neural circuits in the primate prefrontal cortex: identifying sensitive periods for vulnerability to schizophrenia. ( Hoftman, GD; Lewis, DA, 2011) |
| "Schizophrenia is a brain disorder associated with cognitive deficits that severely affect the patients' capacity for daily functioning." | 2.47 | GABA neuron alterations, cortical circuit dysfunction and cognitive deficits in schizophrenia. ( Fish, KN; Gonzalez-Burgos, G; Lewis, DA, 2011) |
| "Schizophrenia is a complex psychiatric disorder with a heterogeneous clinical phenotype." | 2.47 | Origins and perspectives of schizophrenia research. ( Dome, P; Faludi, G; Lazary, J, 2011) |
| "Schizophrenia is a disorder in which disturbances in the integration of emotion with cognition plays a central role and probably involves several different regions, including the dorsolateral prefrontal cortex, the rostral anterior cingulate cortex, the hippocampal formation, and basolateral amygdala (BLA)." | 2.46 | Amygdalocortical circuitry in schizophrenia: from circuits to molecules. ( Benes, FM, 2010) |
| "Brief postictal and alternating psychoses provide an opportunity to understand the complex relationships between epilepsy and schizophrenia-like brief psychotic episodes, and this understanding can assist in their management." | 2.44 | Alternating and postictal psychoses: review and a unifying hypothesis. ( Sachdev, PS, 2007) |
| "Schizophrenia is a devastating illness that is manifest through a variety of clinical signs and symptoms." | 2.44 | Deciphering the disease process of schizophrenia: the contribution of cortical GABA neurons. ( Hashimoto, T; Lewis, DA, 2007) |
| "Most models of schizophrenia are based on basal ganglia-thalamocortical (BGTC) neuronal circuits or brain structures that project to them." | 2.44 | Are anticorrelated networks in the brain relevant to schizophrenia? ( Williamson, P, 2007) |
| "Schizophrenia is a complex disorder, where family, twin and adoption studies have been demonstrating a high heritability of the disease and that this disease is not simply defined by several major genes but rather evolves from addition or potentiation of a specific cluster of genes, which subsequently determines the genetic vulnerability of an individual." | 2.44 | Molecular mechanisms of schizophrenia. ( Gallinat, J; Lang, UE; Muller, DJ; Puls, I; Strutz-Seebohm, N, 2007) |
| "Current treatments of schizophrenia are compromised by their inability to treat all symptoms of the disease and their side-effects." | 2.44 | Modelling prefrontal cortex deficits in schizophrenia: implications for treatment. ( Cochran, SM; Egerton, A; Morris, BJ; Pratt, JA; Winchester, C, 2008) |
| "Sleep-onset and maintenance insomnia is a characteristic feature of schizophrenic patients regardless of either their medication status (drug-naive or previously treated) or the phase of the clinical course (acute or chronic)." | 2.43 | Sleep disturbance in schizophrenia. ( Monti, D; Monti, JM, 2005) |
| "Insomnia is a common symptom in schizophrenia, although it is seldom the predominant complaint." | 2.43 | Sleep disturbance in schizophrenia. ( Monti, D; Monti, JM, 2005) |
| "Schizophrenia is a psychiatric disorder with a complicated pathophysiology, involving many biochemical abnormalities in the brain." | 2.43 | Neuroactive steroids in schizophrenia. ( Shulman, Y; Tibbo, PG, 2005) |
| "Schizophrenia is a chronic, disabling psychiatric disorder that genetic studies have shown to be highly heritable." | 2.42 | The GABA-glutamate connection in schizophrenia: which is the proximate cause? ( Coyle, JT, 2004) |
| "Thus, a possible avenue for the treatment of schizophrenia would be to address this GABAergic functional deficit using positive allosteric modulators of the action of GABA at GABAA receptors." | 2.42 | A GABAergic cortical deficit dominates schizophrenia pathophysiology. ( Costa, E; Davis, JM; Dong, E; Grayson, DR; Guidotti, A; Tremolizzo, L; Veldic, M, 2004) |
| "Namely, core schizophrenia is characterized by a left-temporal dysfunction associated with deficits in verbal processing." | 2.41 | The neurophysiological meaning of auditory P300 in subtypes of schizophrenia. ( Kalus, P; Müller, TJ; Strik, WK, 2001) |
| "Schizophrenia is one of the most common and perhaps the most disabling of mental disorders, for which effective forms of treatment have not yet been established definitively." | 2.40 | Schizophrenia, psychosis, and the basal ganglia. ( Busatto, GF; Kerwin, RW, 1997) |
| "Schizophrenia is the most prevalent form of psychosis, but this may also occur due to other medical conditions (e." | 2.40 | GABA-ergic neurons and the neurobiology of schizophrenia and other psychoses. ( Keverne, EB, 1999) |
| "Schizophrenia is associated with structural changes in the brain but it is not clear whether the changes are localized." | 2.39 | Neuropsychological implications of brain changes in schizophrenia: an overview. ( Deakin, JF, 1994) |
| "Schizophrenia and affective psychoses share the following: 1) several treatments are effective in both, 2) similar modes of inheritance, 3) congruent seasonal birth excesses, 4) enlarged cerebral ventricles and cerebellar vermian atrophy, 5) dexamethasone non-suppression." | 2.38 | A review of evidence for GABergic predominance/glutamatergic deficit as a common etiological factor in both schizophrenia and affective psychoses: more support for a continuum hypothesis of "functional" psychosis. ( Saederup, E; Squires, RF, 1991) |
| "Among psychiatric disorders the acute symptoms of schizophrenia are exacerbated by enhanced GABA-ergic function." | 2.36 | Pharmacology of GABA. ( Meldrum, B, 1982) |
| "gamma-Aminobutyric acid (GABA) is an important inhibitory neurotransmitter." | 2.36 | Biochemistry and the schizophrenia. Old concepts and new hypothesis. ( Berger, PA, 1981) |
| "The idea that schizophrenia is more than one illness is an old concept, but it finds increasing support in new studies of the clinical phenomenology, genetics, and biochemistry of schizophrenic patients." | 2.36 | Biochemistry and the schizophrenia. Old concepts and new hypothesis. ( Berger, PA, 1981) |
| "Schizophrenia is a common mental disorder affecting patients' thoughts, behavior, and cognition." | 1.72 | Role of the NRG1/ErbB4 and PI3K/AKT/mTOR signaling pathways in the anti-psychotic effects of aripiprazole and sertindole in ketamine-induced schizophrenia-like behaviors in rats. ( Nawwar, DA; Sayed, RH; Zaki, HF, 2022) |
| "Clozapine, the only approved drug for treatment-resistant schizophrenia (TRS), involves the GABAergic system as one of its targets." | 1.72 | Gamma-aminobutyric acid (GABA) levels in the midcingulate cortex and clozapine response in patients with treatment-resistant schizophrenia: A proton magnetic resonance spectroscopy ( ( De Luca, V; Edden, RAE; Gerretsen, P; Graff-Guerrero, A; Honda, S; Iwata, Y; Mar, W; Mikkelsen, M; Mimura, M; Nakajima, S; Noda, Y; Plitman, E; Remington, G; Sailasuta, N; Torres-Carmona, E; Truong, P; Tsugawa, S; Ueno, F, 2022) |
| "Ketamine is a noncompetitive antagonist of N-methyl-D-aspartate receptors (NMDARs)." | 1.72 | Comprehensive metabolomic characterization of the hippocampus in a ketamine mouse model of schizophrenia. ( Cheng, A; Fan, W; Fu, Y; Liao, L; Wang, X; Wei, Y; Wen, D; Xiao, L; Yang, H; Ye, Y, 2022) |
| "Schizophrenia is a neurodevelopmental disorder that NMDA receptor (NMDAR) hypofunction appears centrally involved." | 1.62 | Molecular Basis of GABA Hypofunction in Adolescent Schizophrenia-Like Animals. ( Chen, X; Cui, D; Hu, Y; Liu, W; Ma, Y; Wang, X; Xue, T, 2021) |
| "Schizophrenia is genetically highly heterogeneous, involving severe ultrarare mutations in genes that are critical to synaptic plasticity." | 1.56 | Genetics of schizophrenia in the South African Xhosa. ( Andrews, HF; Baldinger, A; Casadei, S; Fader, KM; Feng, M; Gibbs, RA; Gulsuner, S; Gur, RC; King, MC; Korchina, V; Majara, L; Malan, M; McClellan, JM; Mndini, MM; Mqulwana, SG; Muzny, D; Nagdee, M; Ngqengelele, LL; Ntola, OA; Pretorius, A; Ramesar, RS; Sibeko, G; Stein, DJ; Susser, ES; van der Merwe, C; Walsh, T; Willoughby, E; Zingela, Z, 2020) |
| "Both schizophrenia (SZ) and substance abuse (SA) exhibit significant heritability." | 1.51 | N-Methyl-d-aspartate receptor co-agonist availability affects behavioral and neurochemical responses to cocaine: insights into comorbid schizophrenia and substance abuse. ( Bergman, J; Carlezon, WA; Coyle, JT; Desai, RI; Donahue, RJ; Doyle, MR; Landino, SM; Presti, KT; Puhl, MD; Takagi, S, 2019) |
| "The mainstay treatment for schizophrenia is antipsychotic drugs (APDs), which are mostly effective against the positive symptoms (e." | 1.51 | Effect of cannabidiol on endocannabinoid, glutamatergic and GABAergic signalling markers in male offspring of a maternal immune activation (poly I:C) model relevant to schizophrenia. ( Babic, I; Huang, XF; Lum, JS; Newell, KA; Osborne, AL; Solowij, N; Weston-Green, K, 2019) |
| "Schizophrenia is characterized by a multiplicity of symptoms arising from almost all domains of mental function." | 1.48 | CSF GABA is reduced in first-episode psychosis and associates to symptom severity. ( Cervenka, S; Collste, K; Engberg, G; Erhardt, S; Fatouros-Bergman, H; Flyckt, L; Goiny, M; Malmqvist, A; Orhan, F; Piehl, F; Sellgren, CM; Victorsson, P, 2018) |
| "Schizophrenia is accompanied by impaired cortical inhibition, as measured by several markers including the cortical silent period (CSP)." | 1.46 | Risperidone increases the cortical silent period in drug-naive patients with first-episode schizophrenia: A transcranial magnetic stimulation study. ( Ceskova, E; Hublova, V; Kasparek, T; Mayerova, M; Prikrylova Kucerova, H; Ustohal, L, 2017) |
| " Results showed that chronic administration of ketamine can cause a variety of imbalances, and application of an antagonist of the D2 receptor in PFC can also induce imbalances but in a very different manner." | 1.43 | A heuristic model for working memory deficit in schizophrenia. ( Grace, AA; Pogarell, O; Qi, Z; Tretter, F; Voit, EO; Yu, GP, 2016) |
| "Ketamine-treated rats displayed a selective MSO task impairment with tactile-visual and olfactory-visual sensory combinations, whereas basic unisensory perception was unaffected." | 1.43 | A Novel Multisensory Integration Task Reveals Robust Deficits in Rodent Models of Schizophrenia: Converging Evidence for Remediation via Nicotinic Receptor Stimulation of Inhibitory Transmission in the Prefrontal Cortex. ( Bailey, CD; Chung, BY; Cloke, JM; De Lisio, S; Kim, JC; Nguyen, R; Wasserman, DI; Winters, BD, 2016) |
| "Schizophrenia is a neurodevelopmental disorder with altered expression of GABA-related genes in the prefrontal cortex (PFC)." | 1.42 | Altered cortical expression of GABA-related genes in schizophrenia: illness progression vs developmental disturbance. ( Bazmi, HH; Hoftman, GD; Lewis, DA; Li, S; Sampson, AR; Volk, DW, 2015) |
| " Systemic nicotine given before the sample phase of the CMOR task reversed the ketamine-induced impairment, but this effect was blocked by co-administration of the GABAA receptor antagonist bicuculline at a dosage that itself did not cause impairment." | 1.42 | α₄β₂ Nicotinic receptor stimulation of the GABAergic system within the orbitofrontal cortex ameliorates the severe crossmodal object recognition impairment in ketamine-treated rats: implications for cognitive dysfunction in schizophrenia. ( Cloke, JM; Winters, BD, 2015) |
| "Schizophrenia is associated with atypical multisensory integration." | 1.42 | α₄β₂ Nicotinic receptor stimulation of the GABAergic system within the orbitofrontal cortex ameliorates the severe crossmodal object recognition impairment in ketamine-treated rats: implications for cognitive dysfunction in schizophrenia. ( Cloke, JM; Winters, BD, 2015) |
| " We tested phenotypic homogeneity and gene dosage effects in the mouse null alleles muted (Bloc1s5(mu/mu)) and dysbindin (Bloc1s8(sdy/sdy))." | 1.40 | Mutations in the BLOC-1 subunits dysbindin and muted generate divergent and dosage-dependent phenotypes. ( Faundez, V; Gokhale, A; Larimore, J; Mullin, AP; Singleton, KS; Talbot, K; Tang, J; Tornieri, K; Zlatic, SA, 2014) |
| "Schizophrenia is characterized by loss of brain volume, which may represent an ongoing pathophysiological process." | 1.40 | GABA and glutamate in schizophrenia: a 7 T ¹H-MRS study. ( Andreychenko, A; Boer, VO; Bohlken, MM; Cahn, W; Hulshoff Pol, HE; Kahn, RS; Klomp, DW; Luijten, PR; Mandl, RC; Marsman, A, 2014) |
| "Schizophrenia is a severe, persistent, and fairly common mental illness." | 1.39 | Time-dependent effects of haloperidol on glutamine and GABA homeostasis and astrocyte activity in the rat brain. ( Basu, AC; Bolo, NR; Coyle, JT; Konopaske, GT; Renshaw, PF, 2013) |
| "Schizophrenia is characterized by anomalous perceptual experiences (e." | 1.39 | Perceptual and cognitive effects of antipsychotics in first-episode schizophrenia: the potential impact of GABA concentration in the visual cortex. ( Benedek, G; Kelemen, O; Kéri, S; Kiss, I, 2013) |
| "Thus schizophrenia is increasingly believed to involve multi-neurotransmitter deficits, all of which may contribute to altered dopaminergic tone in the mesolimbic, mesocortical and other areas of the brain." | 1.38 | Alpha7 nicotinic cholinergic neuromodulation may reconcile multiple neurotransmitter hypotheses of schizophrenia. ( Bencherif, M; Kucinski, AJ; Lippiello, PM; Stachowiak, MK, 2012) |
| "Schizophrenia is a debilitating neurodevelopmental disorder affecting approximately 1% of the population and imposing a significant burden on society." | 1.38 | Modeling interneuron dysfunction in schizophrenia. ( Mirnics, K; Schmidt, MJ, 2012) |
| "Schizophrenia is a heartbreaking, debilitating, youth-stealing, lifetime disorder for most individuals afflicted with it." | 1.38 | Biological perspectives: the role of glutamate in schizophrenia and its treatment. ( Grant, JS; Keltner, NL; Moore, RL; Steele, D; Swan, NA, 2012) |
| "Schizophrenia is a complex disorder that interferes with the function of several brain systems required for cognition and normal social behaviour." | 1.36 | Control of cortical GABA circuitry development by Nrg1 and ErbB4 signalling. ( Fazzari, P; Lerma, J; Lloyd, K; Luján, R; Marín, O; Paternain, AV; Pla, R; Rico, B; Valiente, M, 2010) |
| "Schizophrenia is characterized by impairments in working memory that are associated with reduced gamma-aminobutyric acid (GABA) neurotransmission in the dorsolateral prefrontal cortex." | 1.35 | Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia. ( Eggan, SM; Hashimoto, T; Lewis, DA, 2008) |
| "The advantages of BL-1020 for treatment of schizophrenia stem from its being a DA/5HT antagonist and a GABAergic agonist that releases cortical DA and antagonizes amphetamine-induced hyperactivity with reduced catalepsy and sedation." | 1.35 | BL-1020: a novel antipsychotic drug with GABAergic activity and low catalepsy, is efficacious in a rat model of schizophrenia. ( Geffen, Y; Gil-Ad, I; Huang, M; Klapper, L; Meltzer, HY; Nudelman, A; Rephaeli, A; Savitsky, K; Weizman, A; Winkler, I, 2009) |
| "The pathology of schizophrenia is characterized by increased hippocampal activity at baseline and during auditory hallucinations." | 1.33 | Regulation of synaptic plasticity in a schizophrenia model. ( Benes, FM; Bolshakov, VY; Gisabella, B, 2005) |
| " In the present study, we investigated the subunits gene expressions and ligand binding of the GABA(A) receptor following acute and chronic administration of phencyclidine (PCP), which induces schizophrenia-like symptoms, in rats using in situ hybridization and in vitro quantitative autoradiography." | 1.31 | Differential expression of GABA(A) receptor subunit mRNAs and ligand binding sites in rat brain following phencyclidine administration. ( Abe, S; Baba, A; Hori, T; Ito, T; Kurita, H; Shiraishi, H; Suzuki, T; Yamaguchi, M, 2000) |
| "Schizophrenia is in essence a developmental disorder, but an unusual one in that the onset of symptoms is markedly delayed." | 1.30 | Cellular and molecular neuropathology of schizophrenia: new directions from developmental neurobiology. ( Fedtsova, N; Jeste, DV; Turner, EE, 1997) |
| "Schizophrenia has been reported to be associated with alterations in GABAergic local circuit neurons of the prefrontal cortex." | 1.29 | Local circuit neurons of the prefrontal cortex in schizophrenia: selective increase in the density of calbindin-immunoreactive neurons. ( Daviss, SR; Lewis, DA, 1995) |
| "Patients with unipolar depression who received a dexamethasone suppression test had no correlation between nonsuppression of cortisol secretion and plasma levels of GABA." | 1.27 | Plasma GABA levels in psychiatric illness. ( Petty, F; Sherman, AD, 1984) |
| " In neither patient, the increase in haloperidol dosage affected paranoid symptoms." | 1.26 | [Use of haloperidol in high doses in schizophrenia. Clinical, biochemical and pharmacokinetic study]. ( Bianchetti, G; Cuche, H; Loo, H; Morselli, PL; Scatton, B; Zarifian, E, 1982) |
| "Muscimol, thought to be a agonist of gamma-aminobutyric acid (GABA), was administered to eight neuroleptic-free subjects with tardive dyskinesia." | 1.26 | Improvement in tardive dyskinesia after muscimol therapy. ( Chase, TN; Crayton, JW; Tamminga, CA, 1979) |
| "Gamma-aminobutyric acid (G." | 1.26 | Gamma-aminobutyric-acid deficiency in brain of schizophrenic patients. ( Buchanan, J; Hansen, S; Kish, SJ; Perry, TL, 1979) |
| "gamma-Aminobutyric acid (Gaba) has been shown to influence dopamine activity in the brain." | 1.26 | gamma-Aminobutyric acid (Gaba) and the dopamine hypothesis of schizophrenia. ( Van Kammen, DP, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 88 (16.00) | 18.7374 |
| 1990's | 50 (9.09) | 18.2507 |
| 2000's | 169 (30.73) | 29.6817 |
| 2010's | 194 (35.27) | 24.3611 |
| 2020's | 49 (8.91) | 2.80 |
| Authors | Studies |
|---|---|
| Nudelman, A | 2 |
| Gil-Ad, I | 2 |
| Shpaisman, N | 1 |
| Terasenko, I | 1 |
| Ron, H | 1 |
| Savitsky, K | 2 |
| Geffen, Y | 3 |
| Weizman, A | 3 |
| Rephaeli, A | 2 |
| Nakahara, T | 1 |
| Tsugawa, S | 2 |
| Noda, Y | 2 |
| Ueno, F | 2 |
| Honda, S | 2 |
| Kinjo, M | 1 |
| Segawa, H | 1 |
| Hondo, N | 1 |
| Mori, Y | 1 |
| Watanabe, H | 1 |
| Nakahara, K | 1 |
| Yoshida, K | 1 |
| Wada, M | 1 |
| Tarumi, R | 1 |
| Iwata, Y | 2 |
| Plitman, E | 2 |
| Moriguchi, S | 1 |
| de la Fuente-Sandoval, C | 3 |
| Uchida, H | 1 |
| Mimura, M | 2 |
| Graff-Guerrero, A | 4 |
| Nakajima, S | 2 |
| Atefimanash, P | 1 |
| Pourhamzeh, M | 1 |
| Susanabadi, A | 1 |
| Arabi, M | 1 |
| Jamali-Raeufy, N | 1 |
| Mehrabi, S | 1 |
| Kiemes, A | 1 |
| Gomes, FV | 2 |
| Cash, D | 1 |
| Uliana, DL | 1 |
| Simmons, C | 1 |
| Singh, N | 1 |
| Vernon, AC | 1 |
| Turkheimer, F | 1 |
| Davies, C | 1 |
| Stone, JM | 2 |
| Grace, AA | 6 |
| Modinos, G | 2 |
| Zhou, D | 1 |
| Xie, C | 1 |
| Li, X | 2 |
| Song, N | 1 |
| Kou, Z | 1 |
| Zhang, T | 2 |
| Yuan, TF | 1 |
| Nakao, K | 1 |
| Singh, M | 1 |
| Sapkota, K | 1 |
| Fitzgerald, A | 1 |
| Hablitz, JJ | 1 |
| Nakazawa, K | 3 |
| Miyazawa, A | 1 |
| Kanahara, N | 2 |
| Shiko, Y | 1 |
| Ozawa, Y | 1 |
| Kawasaki, Y | 1 |
| Komatsu, H | 1 |
| Masumo, Y | 1 |
| Nakata, Y | 1 |
| Iyo, M | 1 |
| Lee, MT | 1 |
| Mouri, A | 1 |
| Kubota, H | 1 |
| Lee, HJ | 1 |
| Chang, MH | 1 |
| Wu, CY | 1 |
| Knutson, DE | 1 |
| Mihovilovic, M | 1 |
| Cook, J | 1 |
| Sieghart, W | 1 |
| Nabeshima, T | 1 |
| Chiou, LC | 1 |
| Szabó, G | 1 |
| Éliás, O | 1 |
| Erdélyi, P | 1 |
| Potor, A | 1 |
| Túrós, GI | 1 |
| Károlyi, BI | 1 |
| Varró, G | 1 |
| Vaskó, ÁG | 1 |
| Bata, I | 1 |
| Kapus, GL | 1 |
| Dohányos, Z | 1 |
| Bobok, AÁ | 1 |
| Fodor, L | 1 |
| Thán, M | 1 |
| Vastag, M | 1 |
| Komlódi, Z | 1 |
| Soukupné Kedves, RÉ | 1 |
| Makó, É | 1 |
| Süveges, B | 1 |
| Greiner, I | 1 |
| Nawwar, DA | 1 |
| Zaki, HF | 1 |
| Sayed, RH | 1 |
| Soltani, E | 1 |
| Bateni, H | 1 |
| Shad, MU | 1 |
| Sonnenschein, SF | 3 |
| Mayeli, A | 3 |
| Yushmanov, VE | 3 |
| Blazer, A | 2 |
| Calabro, FJ | 2 |
| Perica, M | 2 |
| Foran, W | 2 |
| Luna, B | 2 |
| Hetherington, HP | 3 |
| Ferrarelli, F | 3 |
| Sarpal, DK | 2 |
| Torres-Carmona, E | 1 |
| Mar, W | 1 |
| Truong, P | 1 |
| Sailasuta, N | 1 |
| Mikkelsen, M | 1 |
| Edden, RAE | 2 |
| De Luca, V | 1 |
| Remington, G | 2 |
| Gerretsen, P | 1 |
| Yang, KC | 1 |
| Chen, YY | 1 |
| Liu, MN | 1 |
| Yang, BH | 1 |
| Chou, YH | 1 |
| Wei, Y | 1 |
| Xiao, L | 1 |
| Fan, W | 1 |
| Yang, H | 1 |
| Fu, Y | 1 |
| Ye, Y | 1 |
| Wang, X | 2 |
| Wen, D | 1 |
| Cheng, A | 1 |
| Liao, L | 1 |
| Zahid, U | 1 |
| Onwordi, EC | 1 |
| Hedges, EP | 1 |
| Wall, MB | 1 |
| Murray, RM | 1 |
| Egerton, A | 3 |
| Wilson, JD | 2 |
| Simmonite, M | 1 |
| Yao, B | 1 |
| Welsh, RC | 3 |
| Taylor, SF | 5 |
| Fish, KN | 4 |
| Rocco, BR | 2 |
| Lewis, DA | 51 |
| Dowling, KF | 1 |
| Dienel, SJ | 3 |
| Barile, Z | 1 |
| Bazmi, HH | 6 |
| de Bartolomeis, A | 1 |
| De Simone, G | 1 |
| De Prisco, M | 1 |
| Barone, A | 1 |
| Napoli, R | 1 |
| Beguinot, F | 1 |
| Billeci, M | 1 |
| Fornaro, M | 1 |
| Pujol, J | 1 |
| Pujol, N | 1 |
| Mané, A | 1 |
| Martínez-Vilavella, G | 1 |
| Deus, J | 1 |
| Pérez-Sola, V | 1 |
| Blanco-Hinojo, L | 1 |
| Vostrikov, VM | 1 |
| Hjelmervik, H | 1 |
| Craven, AR | 1 |
| Sinceviciute, I | 1 |
| Johnsen, E | 1 |
| Kompus, K | 1 |
| Bless, JJ | 1 |
| Kroken, RA | 1 |
| Løberg, EM | 1 |
| Ersland, L | 1 |
| Grüner, R | 2 |
| Hugdahl, K | 2 |
| Yoon, JH | 3 |
| Maddock, RJ | 4 |
| DongBo Cui, E | 1 |
| Minzenberg, MJ | 3 |
| Niendam, TA | 3 |
| Lesh, T | 1 |
| Solomon, M | 2 |
| Ragland, JD | 4 |
| Carter, C | 2 |
| Shiwaku, H | 1 |
| Nakano, Y | 1 |
| Kato, M | 1 |
| Takahashi, H | 1 |
| Hurtado, MY | 1 |
| Tanase, C | 1 |
| Lesh, TA | 2 |
| Carter, CS | 2 |
| Ranganath, C | 1 |
| Gulsuner, S | 1 |
| Stein, DJ | 1 |
| Susser, ES | 1 |
| Sibeko, G | 1 |
| Pretorius, A | 1 |
| Walsh, T | 1 |
| Majara, L | 1 |
| Mndini, MM | 1 |
| Mqulwana, SG | 1 |
| Ntola, OA | 1 |
| Casadei, S | 1 |
| Ngqengelele, LL | 1 |
| Korchina, V | 1 |
| van der Merwe, C | 1 |
| Malan, M | 1 |
| Fader, KM | 1 |
| Feng, M | 1 |
| Willoughby, E | 1 |
| Muzny, D | 1 |
| Baldinger, A | 1 |
| Andrews, HF | 1 |
| Gur, RC | 2 |
| Gibbs, RA | 1 |
| Zingela, Z | 1 |
| Nagdee, M | 1 |
| Ramesar, RS | 1 |
| King, MC | 1 |
| McClellan, JM | 1 |
| Kumar, V | 1 |
| Vajawat, B | 1 |
| Rao, NP | 1 |
| Reddy-Thootkur, M | 1 |
| Kraguljac, NV | 1 |
| Lahti, AC | 2 |
| Wang, YM | 1 |
| Xiao, YH | 1 |
| Xie, WL | 1 |
| Hoshino, O | 2 |
| Kameno, R | 1 |
| Kubo, J | 1 |
| Watanabe, K | 1 |
| Gouse, BM | 1 |
| Spears, WE | 1 |
| Nieves Archibald, A | 1 |
| Montalvo, C | 1 |
| Bojesen, KB | 1 |
| Broberg, BV | 1 |
| Fagerlund, B | 1 |
| Jessen, K | 1 |
| Thomas, MB | 1 |
| Sigvard, A | 1 |
| Tangmose, K | 1 |
| Nielsen, MØ | 1 |
| Andersen, GS | 1 |
| Larsson, HBW | 1 |
| Rostrup, E | 1 |
| Glenthøj, BY | 1 |
| Park, GH | 1 |
| Noh, H | 1 |
| Shao, Z | 1 |
| Ni, P | 1 |
| Qin, Y | 1 |
| Liu, D | 1 |
| Beaudreault, CP | 1 |
| Park, JS | 1 |
| Abani, CP | 1 |
| Park, JM | 1 |
| Le, DT | 1 |
| Gonzalez, SZ | 1 |
| Guan, Y | 1 |
| Cohen, BM | 2 |
| McPhie, DL | 1 |
| Coyle, JT | 8 |
| Lanz, TA | 1 |
| Xi, HS | 1 |
| Yin, C | 1 |
| Huang, W | 1 |
| Kim, HY | 1 |
| Chung, S | 1 |
| Grace, A | 1 |
| Lee, J | 2 |
| Yoon, YB | 1 |
| Cho, KIK | 1 |
| Seo, S | 1 |
| Lee, JS | 1 |
| Jeong, JM | 1 |
| Kim, E | 1 |
| Kim, M | 1 |
| Lee, TY | 1 |
| Kwon, JS | 2 |
| Dijkstra, AA | 1 |
| Gami-Patel, P | 1 |
| Rozemuller, AJM | 1 |
| Bugiani, M | 1 |
| Pijnenburg, YAL | 1 |
| Smit, GAB | 1 |
| Dols, A | 1 |
| Hoozemans, JJM | 1 |
| Quiñones, GM | 1 |
| Reid, MA | 2 |
| Van Derveer, AB | 1 |
| Bastos, G | 1 |
| Ferrell, AD | 1 |
| Gallimore, CG | 1 |
| Greene, ML | 1 |
| Holmes, JT | 1 |
| Kubricka, V | 1 |
| Ross, JM | 1 |
| Hamm, JP | 1 |
| Wang, YY | 1 |
| Zhao, B | 1 |
| Wu, MM | 1 |
| Zheng, XL | 1 |
| Lin, L | 1 |
| Yin, DM | 2 |
| Kim, HR | 1 |
| Rajagopal, L | 1 |
| Meltzer, HY | 4 |
| Martina, M | 1 |
| Ferdinand, JM | 1 |
| Peters, KZ | 1 |
| Yavas, E | 1 |
| Young, AMJ | 1 |
| Hu, Y | 2 |
| Liu, W | 1 |
| Ma, Y | 1 |
| Chen, X | 1 |
| Xue, T | 1 |
| Cui, D | 1 |
| Kozhuharova, P | 1 |
| Diaconescu, AO | 1 |
| Allen, P | 1 |
| Laufer, J | 1 |
| Cai, XL | 1 |
| Li, GY | 1 |
| Wang, LL | 1 |
| Zhao, WW | 1 |
| Wang, Y | 2 |
| Yan, C | 1 |
| Lui, SSY | 2 |
| Li, JQ | 1 |
| Chan, RCK | 2 |
| Devor, A | 1 |
| Andreassen, OA | 1 |
| Mäki-Marttunen, T | 1 |
| Smeland, OB | 1 |
| Fan, CC | 1 |
| Schork, AJ | 1 |
| Holland, D | 1 |
| Thompson, WK | 1 |
| Witoelar, A | 1 |
| Chen, CH | 1 |
| Desikan, RS | 1 |
| McEvoy, LK | 1 |
| Djurovic, S | 1 |
| Greengard, P | 1 |
| Svenningsson, P | 1 |
| Einevoll, GT | 1 |
| Dale, AM | 1 |
| Chiu, PW | 1 |
| Hung, KSY | 1 |
| Chan, Q | 1 |
| Sham, PC | 1 |
| Cheung, EFC | 1 |
| Mak, HKF | 1 |
| Giacopuzzi, E | 2 |
| Gennarelli, M | 2 |
| Minelli, A | 1 |
| Gardella, R | 1 |
| Valsecchi, P | 2 |
| Traversa, M | 1 |
| Bonvicini, C | 1 |
| Vita, A | 2 |
| Sacchetti, E | 1 |
| Magri, C | 2 |
| Renard, J | 1 |
| Szkudlarek, HJ | 1 |
| Kramar, CP | 1 |
| Jobson, CEL | 1 |
| Moura, K | 1 |
| Rushlow, WJ | 1 |
| Laviolette, SR | 2 |
| Włodarczyk, A | 1 |
| Szarmach, J | 1 |
| Cubała, WJ | 1 |
| Wiglusz, MS | 1 |
| Puhl, MD | 1 |
| Desai, RI | 1 |
| Takagi, S | 1 |
| Presti, KT | 1 |
| Doyle, MR | 1 |
| Donahue, RJ | 1 |
| Landino, SM | 1 |
| Bergman, J | 1 |
| Carlezon, WA | 1 |
| Hoftman, GD | 4 |
| Zhang, Y | 3 |
| Chen, K | 1 |
| Salibi, N | 1 |
| White, DM | 1 |
| Gawne, TJ | 1 |
| Denney, TS | 1 |
| So, RP | 1 |
| Kegeles, LS | 4 |
| Mao, X | 4 |
| Shungu, DC | 5 |
| Stanford, AD | 3 |
| Chen, CA | 1 |
| Glausier, JR | 3 |
| Paterson, C | 1 |
| Law, AJ | 2 |
| Yamazaki, M | 1 |
| Yamamoto, N | 1 |
| Yarimizu, J | 1 |
| Okabe, M | 1 |
| Moriyama, A | 1 |
| Furutani, M | 1 |
| Marcus, MM | 1 |
| Svensson, TH | 1 |
| Harada, K | 1 |
| Kehr, J | 1 |
| Yoshitake, T | 1 |
| Ichinose, F | 1 |
| Yoshitake, S | 1 |
| Kiss, B | 1 |
| Gyertyán, I | 1 |
| Adham, N | 1 |
| Jiang, DY | 1 |
| Wu, Z | 1 |
| Forsyth, CT | 1 |
| Yee, SP | 1 |
| Chen, G | 1 |
| Xia, M | 1 |
| Wang, J | 4 |
| Sheng, J | 1 |
| Tang, Y | 3 |
| Li, C | 3 |
| Lim, K | 1 |
| He, B | 1 |
| Xu, Y | 1 |
| Shukla, DK | 1 |
| Wijtenburg, SA | 4 |
| Chen, H | 1 |
| Chiappelli, JJ | 2 |
| Kochunov, P | 3 |
| Hong, LE | 4 |
| Rowland, LM | 5 |
| Crabtree, GW | 2 |
| Gogos, JA | 2 |
| Wierońska, JM | 1 |
| Pilc, A | 1 |
| Koshiyama, D | 1 |
| Kirihara, K | 1 |
| Tada, M | 1 |
| Nagai, T | 1 |
| Fujioka, M | 1 |
| Ichikawa, E | 1 |
| Ohta, K | 1 |
| Tani, M | 1 |
| Tsuchiya, M | 1 |
| Kanehara, A | 1 |
| Morita, K | 1 |
| Sawada, K | 1 |
| Matsuoka, J | 1 |
| Satomura, Y | 1 |
| Koike, S | 1 |
| Suga, M | 1 |
| Araki, T | 1 |
| Kasai, K | 2 |
| La Via, L | 1 |
| Bonini, D | 1 |
| Ravasio, V | 1 |
| Elhussiny, MEA | 1 |
| Orizio, F | 1 |
| Gangemi, F | 1 |
| Bresciani, R | 1 |
| Barbon, A | 1 |
| Tan, T | 1 |
| Wang, W | 1 |
| Williams, J | 1 |
| Ma, K | 1 |
| Cao, Q | 1 |
| Yan, Z | 1 |
| Dwyer, GE | 1 |
| Specht, K | 1 |
| Grove, TB | 1 |
| Ellingrod, VL | 1 |
| Tso, IF | 4 |
| Nakamura, JP | 1 |
| Schroeder, A | 1 |
| Hudson, M | 1 |
| Jones, N | 1 |
| Gillespie, B | 1 |
| Du, X | 2 |
| Notaras, M | 1 |
| Swaminathan, V | 1 |
| Reay, WR | 1 |
| Atkins, JR | 1 |
| Green, MJ | 1 |
| Carr, VJ | 1 |
| Cairns, MJ | 1 |
| Sundram, S | 1 |
| Hill, RA | 1 |
| Hui, J | 1 |
| Tremblay, S | 1 |
| Daskalakis, ZJ | 5 |
| Osborne, AL | 1 |
| Solowij, N | 1 |
| Babic, I | 1 |
| Lum, JS | 1 |
| Newell, KA | 1 |
| Huang, XF | 2 |
| Weston-Green, K | 1 |
| Shaw, AD | 1 |
| Knight, L | 1 |
| Freeman, TCA | 1 |
| Williams, GM | 1 |
| Moran, RJ | 1 |
| Friston, KJ | 1 |
| Walters, JTR | 1 |
| Singh, KD | 1 |
| Tillman, L | 1 |
| Zhang, J | 3 |
| Enwright, JF | 1 |
| Hayakawa, E | 1 |
| Ohgidani, M | 1 |
| Fujimura, Y | 1 |
| Kanba, S | 1 |
| Miura, D | 1 |
| Kato, TA | 1 |
| Nunes, EA | 1 |
| Canever, L | 1 |
| Oliveira, Ld | 1 |
| Luca, RD | 1 |
| Quevedo, J | 1 |
| Zugno, A | 1 |
| Peregrino, A | 1 |
| Crippa, JA | 1 |
| Dursun, SM | 1 |
| Baker, GB | 1 |
| Hallak, JE | 1 |
| Sotoyama, H | 1 |
| Namba, H | 1 |
| Chiken, S | 1 |
| Nambu, A | 1 |
| Nawa, H | 1 |
| Edden, RA | 3 |
| Kontson, K | 2 |
| Zhu, H | 2 |
| Barker, PB | 3 |
| Siekmeier, PJ | 1 |
| vanMaanen, DP | 1 |
| Kang, JI | 1 |
| Park, HJ | 1 |
| Kim, SJ | 1 |
| Kim, KR | 1 |
| Lee, SY | 1 |
| Lee, E | 1 |
| An, SK | 1 |
| Lee, JD | 1 |
| Konopaske, GT | 1 |
| Bolo, NR | 1 |
| Basu, AC | 2 |
| Renshaw, PF | 2 |
| Napolitano, A | 1 |
| Shah, K | 1 |
| Schubert, MI | 1 |
| Porkess, V | 1 |
| Fone, KC | 1 |
| Auer, DP | 1 |
| Kelemen, O | 1 |
| Kiss, I | 1 |
| Benedek, G | 1 |
| Kéri, S | 1 |
| Molina, V | 1 |
| Blanco, JA | 1 |
| Bernstein, HG | 1 |
| Tausch, A | 1 |
| Wagner, R | 1 |
| Steiner, J | 1 |
| Seeleke, P | 1 |
| Walter, M | 1 |
| Dobrowolny, H | 2 |
| Bogerts, B | 1 |
| Demeter, E | 1 |
| Phan, KL | 2 |
| Frohlich, J | 1 |
| Van Horn, JD | 1 |
| Volk, DW | 13 |
| Li, S | 1 |
| Sampson, AR | 7 |
| Larimore, J | 1 |
| Zlatic, SA | 1 |
| Gokhale, A | 1 |
| Tornieri, K | 1 |
| Singleton, KS | 1 |
| Mullin, AP | 1 |
| Tang, J | 1 |
| Talbot, K | 1 |
| Faundez, V | 1 |
| Chen, CM | 1 |
| Abi-Dargham, A | 5 |
| Lisanby, SH | 2 |
| Schroeder, CE | 1 |
| Schmidt, MJ | 2 |
| Mirnics, K | 4 |
| Piantadosi, PT | 2 |
| Floresco, SB | 3 |
| Kimoto, S | 4 |
| Perez, SM | 1 |
| Lodge, DJ | 2 |
| Ferraro, L | 1 |
| Beggiato, S | 1 |
| Borroto-Escuela, DO | 1 |
| Ravani, L | 1 |
| O'Connor, WT | 4 |
| Tomasini, MC | 1 |
| Borelli, AC | 1 |
| Agnati, LF | 1 |
| Antonelli, T | 1 |
| Tanganelli, S | 1 |
| Fuxe, K | 2 |
| Sohal, VS | 1 |
| Rideau Batista Novais, A | 1 |
| Crouzin, N | 1 |
| Cavalier, M | 1 |
| Boubal, M | 1 |
| Guiramand, J | 1 |
| Cohen-Solal, C | 1 |
| de Jesus Ferreira, MC | 1 |
| Cambonie, G | 1 |
| Vignes, M | 1 |
| Barbanel, G | 1 |
| Salavati, B | 1 |
| Rajji, TK | 2 |
| Price, R | 1 |
| Sun, Y | 1 |
| Pearlman, DM | 1 |
| Najjar, S | 1 |
| Schjerning, O | 1 |
| Lykkegaard, S | 1 |
| Damkier, P | 1 |
| Nielsen, J | 1 |
| Bitanihirwe, BK | 2 |
| Woo, TU | 6 |
| Marsman, A | 1 |
| Mandl, RC | 1 |
| Klomp, DW | 2 |
| Bohlken, MM | 1 |
| Boer, VO | 2 |
| Andreychenko, A | 1 |
| Cahn, W | 2 |
| Kahn, RS | 2 |
| Luijten, PR | 1 |
| Hulshoff Pol, HE | 1 |
| Tse, MT | 2 |
| Heckers, S | 3 |
| Konradi, C | 2 |
| Cloke, JM | 2 |
| Winters, BD | 2 |
| Chitrapu, A | 1 |
| Edelson, JR | 2 |
| Kalia, M | 1 |
| Costa E Silva, J | 1 |
| Dong, E | 8 |
| Ruzicka, WB | 4 |
| Grayson, DR | 14 |
| Guidotti, A | 17 |
| Jeevakumar, V | 1 |
| Kroener, S | 1 |
| O'Shea, SD | 1 |
| Berretta, S | 5 |
| Pantazopoulos, H | 1 |
| Markota, M | 1 |
| Brown, C | 1 |
| Batzianouli, ET | 1 |
| Harrison, PJ | 1 |
| Schubert, KO | 1 |
| Föcking, M | 1 |
| Cotter, DR | 1 |
| Subburaju, S | 5 |
| Benes, FM | 24 |
| Stansfield, KH | 1 |
| Ruby, KN | 1 |
| Soares, BD | 1 |
| McGlothan, JL | 1 |
| Liu, X | 1 |
| Guilarte, TR | 2 |
| Galderisi, S | 1 |
| Merlotti, E | 1 |
| Mucci, A | 1 |
| Krause, BW | 1 |
| McMahon, RP | 1 |
| Chiappelli, J | 1 |
| Nugent, KL | 1 |
| Nisonger, SJ | 1 |
| Korenic, SA | 1 |
| Kaster, TS | 1 |
| de Jesus, D | 1 |
| Radhu, N | 1 |
| Farzan, F | 1 |
| Blumberger, DM | 1 |
| Fitzgerald, PB | 3 |
| Powell, SB | 1 |
| Khan, A | 1 |
| Young, JW | 1 |
| Scott, CN | 1 |
| Buell, MR | 1 |
| Caldwell, S | 1 |
| Tsan, E | 1 |
| de Jong, LA | 1 |
| Acheson, DT | 1 |
| Lucero, J | 1 |
| Geyer, MA | 2 |
| Behrens, MM | 3 |
| Zaki, MM | 1 |
| Frankle, WG | 2 |
| Cho, RY | 2 |
| Prasad, KM | 1 |
| Mason, NS | 1 |
| Paris, J | 1 |
| Himes, ML | 1 |
| Walker, C | 1 |
| Narendran, R | 1 |
| Jadi, MP | 1 |
| Sejnowski, TJ | 1 |
| Strzelecki, D | 1 |
| Podgórski, M | 1 |
| Kałużyńska, O | 1 |
| Gawlik-Kotelnicka, O | 1 |
| Stefańczyk, L | 1 |
| Kotlicka-Antczak, M | 1 |
| Gmitrowicz, A | 1 |
| Grzelak, P | 1 |
| Medvedev, VE | 1 |
| Frolova, VI | 1 |
| Gushanskaya, EV | 1 |
| Ter-Israelyan, AU | 1 |
| Fang, Y | 1 |
| Reyes-Madrigal, F | 1 |
| León-Ortiz, P | 1 |
| Rodríguez-Mayoral, O | 1 |
| Solís-Vivanco, R | 1 |
| Favila, R | 1 |
| Uehara, T | 1 |
| Sumiyoshi, T | 1 |
| Kurachi, M | 1 |
| Summerfelt, A | 1 |
| Krishna, N | 1 |
| West, J | 2 |
| Muellerklein, F | 1 |
| McNally, JM | 1 |
| McCarley, RW | 1 |
| Brandt, AS | 1 |
| Unschuld, PG | 1 |
| Pradhan, S | 1 |
| Lim, IA | 1 |
| Churchill, G | 1 |
| Harris, AD | 1 |
| Hua, J | 1 |
| Ross, CA | 1 |
| van Zijl, PC | 1 |
| Margolis, RL | 1 |
| Georgiev, D | 2 |
| Yoshihara, T | 1 |
| Kawabata, R | 1 |
| Matsubara, T | 2 |
| Tsubomoto, M | 1 |
| Minabe, Y | 2 |
| Hashimoto, T | 16 |
| Qi, Z | 1 |
| Yu, GP | 1 |
| Tretter, F | 1 |
| Pogarell, O | 1 |
| Voit, EO | 1 |
| Ceretta, APC | 1 |
| Schaffer, LF | 1 |
| de Freitas, CM | 1 |
| Reinheimer, JB | 1 |
| Dotto, MM | 1 |
| Fachinetto, R | 1 |
| Walther, S | 1 |
| Strik, W | 1 |
| Thakkar, KN | 1 |
| Rösler, L | 1 |
| Wijnen, JP | 1 |
| Neggers, SF | 1 |
| Menschikov, PE | 1 |
| Semenova, NA | 1 |
| Ublinskiy, MV | 1 |
| Akhadov, TA | 1 |
| Keshishyan, RA | 1 |
| Lebedeva, IS | 1 |
| Omelchenko, MA | 1 |
| Kaleda, VG | 1 |
| Varfolomeev, SD | 1 |
| Wang, L | 1 |
| Jiang, W | 1 |
| Lin, Q | 1 |
| Zhao, C | 1 |
| Ustohal, L | 1 |
| Mayerova, M | 1 |
| Hublova, V | 1 |
| Prikrylova Kucerova, H | 1 |
| Ceskova, E | 1 |
| Kasparek, T | 1 |
| Liu, P | 1 |
| Jing, Y | 1 |
| Collie, ND | 1 |
| Dean, B | 3 |
| Bilkey, DK | 1 |
| Zhang, H | 1 |
| Schoonover, KE | 1 |
| McCollum, LA | 1 |
| Roberts, RC | 2 |
| Reynolds, GP | 14 |
| Neill, JC | 3 |
| Park, AJ | 1 |
| Gordon, JA | 1 |
| Lindberg, PG | 1 |
| Térémetz, M | 1 |
| Charron, S | 1 |
| Kebir, O | 1 |
| Saby, A | 1 |
| Bendjemaa, N | 1 |
| Lion, S | 1 |
| Crépon, B | 1 |
| Gaillard, R | 1 |
| Oppenheim, C | 1 |
| Krebs, MO | 1 |
| Amado, I | 1 |
| Gonzalez-Burgos, G | 6 |
| Atagün, Mİ | 1 |
| Şıkoğlu, EM | 1 |
| Soykan, Ç | 1 |
| Serdar Süleyman, C | 1 |
| Ulusoy-Kaymak, S | 1 |
| Çayköylü, A | 1 |
| Algın, O | 1 |
| Phillips, ML | 1 |
| Öngür, D | 2 |
| Moore, CM | 1 |
| Nguyen, R | 1 |
| Chung, BY | 1 |
| Wasserman, DI | 1 |
| De Lisio, S | 1 |
| Kim, JC | 1 |
| Bailey, CD | 1 |
| Cui, H | 1 |
| Xu, L | 1 |
| Zeng, B | 1 |
| Li, Y | 2 |
| Li, G | 1 |
| Liu, H | 1 |
| Lu, Z | 1 |
| Balan, S | 1 |
| Yamada, K | 2 |
| Iwayama, Y | 1 |
| Toyota, T | 1 |
| Shimamoto, C | 1 |
| Maekawa, M | 1 |
| Takagai, S | 1 |
| Wakuda, T | 1 |
| Kameno, Y | 1 |
| Kurita, D | 1 |
| Kikuchi, M | 2 |
| Yoshikawa, T | 1 |
| Ouhaz, Z | 1 |
| Ba-M'hamed, S | 1 |
| Bennis, M | 1 |
| Orhan, F | 1 |
| Fatouros-Bergman, H | 1 |
| Goiny, M | 1 |
| Malmqvist, A | 1 |
| Piehl, F | 1 |
| Cervenka, S | 1 |
| Collste, K | 1 |
| Victorsson, P | 1 |
| Sellgren, CM | 1 |
| Flyckt, L | 1 |
| Erhardt, S | 1 |
| Engberg, G | 1 |
| Bloomfield, C | 1 |
| French, SJ | 1 |
| Jones, DN | 1 |
| Reavill, C | 1 |
| Southam, E | 1 |
| Cilia, J | 1 |
| Totterdell, S | 1 |
| Eggan, SM | 2 |
| Wobrock, T | 1 |
| Schneider, M | 1 |
| Kadovic, D | 1 |
| Schneider-Axmann, T | 1 |
| Ecker, UK | 1 |
| Retz, W | 1 |
| Rösler, M | 1 |
| Falkai, P | 1 |
| Sakae, N | 1 |
| Yamasaki, N | 1 |
| Kitaichi, K | 1 |
| Fukuda, T | 1 |
| Yamada, M | 1 |
| Yoshikawa, H | 1 |
| Hiranita, T | 1 |
| Tatsumi, Y | 1 |
| Kira, J | 1 |
| Yamamoto, T | 1 |
| Miyakawa, T | 1 |
| Nakayama, KI | 1 |
| Winter, C | 1 |
| Djodari-Irani, A | 1 |
| Sohr, R | 1 |
| Morgenstern, R | 1 |
| Feldon, J | 4 |
| Juckel, G | 1 |
| Meyer, U | 5 |
| Huang, M | 1 |
| Klapper, L | 1 |
| Winkler, I | 1 |
| de Almeida, J | 2 |
| Mengod, G | 2 |
| Bullock, WM | 2 |
| Cardon, K | 1 |
| Bustillo, J | 2 |
| Perrone-Bizzozero, NI | 3 |
| Tseng, KY | 2 |
| Lewis, BL | 1 |
| Sesack, SR | 1 |
| Kloc, M | 1 |
| O'Donnell, P | 1 |
| Morris, HM | 1 |
| Ali, SS | 1 |
| Dugan, LL | 1 |
| Costa, E | 16 |
| Chen, Y | 2 |
| Kundakovic, M | 2 |
| Maloku, E | 2 |
| Ruzicka, W | 1 |
| Satta, R | 4 |
| Veldic, M | 9 |
| Zhubi, A | 3 |
| Lim, B | 3 |
| Matzilevich, D | 2 |
| Walsh, JP | 3 |
| Silver, H | 1 |
| Chertkow, Y | 1 |
| Weinreb, O | 1 |
| Danovich, L | 1 |
| Youdim, M | 1 |
| Mellios, N | 1 |
| Huang, HS | 3 |
| Baker, SP | 2 |
| Galdzicka, M | 1 |
| Ginns, E | 1 |
| Akbarian, S | 5 |
| Peedicayil, J | 1 |
| Puri, NV | 1 |
| Kadriu, B | 2 |
| Caruncho, H | 1 |
| Loza, I | 1 |
| Sershen, H | 1 |
| Lajtha, A | 1 |
| Smith, RC | 1 |
| Davis, JM | 5 |
| Schönfeldt-Lecuona, C | 1 |
| Wolf, RC | 1 |
| Osterfeld, ND | 1 |
| Vasic, N | 1 |
| Connemann, BJ | 1 |
| Schmid, M | 1 |
| Freudenmann, RW | 1 |
| Goto, N | 3 |
| Yoshimura, R | 3 |
| Moriya, J | 3 |
| Kakeda, S | 3 |
| Ueda, N | 2 |
| Ikenouchi-Sugita, A | 3 |
| Umene-Nakano, W | 2 |
| Hayashi, K | 3 |
| Oonari, N | 1 |
| Korogi, Y | 3 |
| Nakamura, J | 3 |
| Gisabella, B | 3 |
| Kantrowitz, J | 1 |
| Citrome, L | 2 |
| Javitt, D | 1 |
| George, TP | 1 |
| Bolognani, F | 1 |
| Botta, P | 1 |
| Valenzuela, CF | 1 |
| Gaspar, PA | 1 |
| Bustamante, ML | 1 |
| Silva, H | 1 |
| Aboitiz, F | 1 |
| Arrúe, A | 1 |
| Dávila, R | 1 |
| Zumárraga, M | 1 |
| Basterreche, N | 1 |
| González-Torres, MA | 1 |
| Goienetxea, B | 1 |
| Zamalloa, MI | 1 |
| Anguiano, JB | 1 |
| Guimón, J | 1 |
| Rutten, BP | 1 |
| Mill, J | 1 |
| Turner, CP | 1 |
| DeBenedetto, D | 1 |
| Ware, E | 1 |
| Stowe, R | 1 |
| Lee, A | 1 |
| Swanson, J | 1 |
| Walburg, C | 1 |
| Lambert, A | 1 |
| Lyle, M | 1 |
| Desai, P | 1 |
| Liu, C | 1 |
| Möhler, H | 2 |
| Belforte, JE | 1 |
| Zsiros, V | 1 |
| Sklar, ER | 1 |
| Jiang, Z | 1 |
| Yu, G | 1 |
| Quinlan, EM | 1 |
| Hori, H | 2 |
| Tayoshi, S | 1 |
| Nakataki, M | 1 |
| Sumitani, S | 1 |
| Taniguchi, K | 1 |
| Shibuya-Tayoshi, S | 1 |
| Numata, S | 1 |
| Iga, J | 1 |
| Ueno, S | 1 |
| Harada, M | 1 |
| Ohmori, T | 1 |
| Cherlyn, SY | 1 |
| Woon, PS | 1 |
| Liu, JJ | 1 |
| Ong, WY | 1 |
| Tsai, GC | 1 |
| Sim, K | 1 |
| O'Tuathaigh, CM | 1 |
| Harte, M | 1 |
| O'Leary, C | 1 |
| O'Sullivan, GJ | 1 |
| Blau, C | 1 |
| Lai, D | 1 |
| Harvey, RP | 1 |
| Tighe, O | 1 |
| Fagan, AJ | 1 |
| Kerskens, C | 1 |
| Waddington, JL | 1 |
| Tanaka, S | 2 |
| Li, Z | 1 |
| Liang, Y | 1 |
| Boules, M | 1 |
| Gordillo, A | 1 |
| Richelson, E | 1 |
| Rokem, A | 1 |
| Silver, MA | 1 |
| Fazzari, P | 1 |
| Paternain, AV | 1 |
| Valiente, M | 1 |
| Pla, R | 1 |
| Luján, R | 1 |
| Lloyd, K | 1 |
| Lerma, J | 1 |
| Marín, O | 1 |
| Rico, B | 1 |
| Englisch, S | 2 |
| Esser, A | 1 |
| Enning, F | 1 |
| Hohmann, S | 1 |
| Schanz, H | 1 |
| Zink, M | 2 |
| Prescot, AP | 1 |
| McCarthy, J | 1 |
| Cai, HL | 1 |
| Zhu, RH | 1 |
| Li, HD | 1 |
| Zhang, XH | 1 |
| Hu, L | 1 |
| Yang, W | 1 |
| Ye, HS | 1 |
| Agam, G | 1 |
| Ben-Shachar, D | 1 |
| Deutsch, SI | 1 |
| Rosse, RB | 1 |
| Schwartz, BL | 1 |
| Mastropaolo, J | 1 |
| Burket, JA | 1 |
| Nakano-Umene, W | 1 |
| Katsuki, A | 1 |
| Nishimura, J | 1 |
| Peleg-Raibstein, D | 1 |
| Mouttet, F | 1 |
| Beneyto, M | 1 |
| Rolls, ET | 1 |
| Deco, G | 1 |
| Dobbs, D | 1 |
| Auta, J | 2 |
| Gavin, DP | 1 |
| Matrisciano, F | 1 |
| Pinna, G | 1 |
| Sharma, RP | 1 |
| Tremolizzo, L | 3 |
| Tueting, P | 1 |
| Benneyworth, MA | 1 |
| Roseman, AS | 1 |
| Enomoto, T | 1 |
| Nullmeier, S | 1 |
| Panther, P | 1 |
| Frotscher, M | 1 |
| Zhao, S | 1 |
| Schwegler, H | 1 |
| Wolf, R | 1 |
| Kalkman, HO | 1 |
| Abekawa, T | 2 |
| Ito, K | 2 |
| Nakato, Y | 1 |
| Koyama, T | 2 |
| Wolf, DH | 1 |
| Satterthwaite, TD | 1 |
| Loughead, J | 1 |
| Pinkham, A | 1 |
| Overton, E | 1 |
| Elliott, MA | 1 |
| Dent, GW | 1 |
| Smith, MA | 1 |
| Gur, RE | 1 |
| Green, MF | 1 |
| Wynn, JK | 1 |
| Mathis, KI | 1 |
| Curley, AA | 2 |
| Arion, D | 1 |
| Asafu-Adjei, JK | 1 |
| Szulc, A | 1 |
| Galinska, B | 1 |
| Tarasow, E | 1 |
| Waszkiewicz, N | 1 |
| Konarzewska, B | 1 |
| Poplawska, R | 1 |
| Bibulowicz, D | 1 |
| Simonienko, K | 1 |
| Walecki, J | 1 |
| Hyde, TM | 1 |
| Lipska, BK | 3 |
| Ali, T | 1 |
| Mathew, SV | 1 |
| Metitiri, OE | 1 |
| Straub, RE | 1 |
| Ye, T | 1 |
| Colantuoni, C | 1 |
| Herman, MM | 1 |
| Bigelow, LB | 1 |
| Weinberger, DR | 5 |
| Kleinman, JE | 5 |
| Rossignol, E | 1 |
| Goldman, D | 1 |
| Liu, Y | 1 |
| Pu, W | 1 |
| Zhang, X | 2 |
| Zhao, J | 1 |
| Arinami, T | 1 |
| Inada, T | 2 |
| Port, JD | 1 |
| Agarwal, N | 1 |
| Opler, M | 1 |
| Pletnikov, M | 1 |
| Faludi, G | 1 |
| Dome, P | 1 |
| Lazary, J | 1 |
| Girgis, R | 1 |
| Ojeil, N | 1 |
| Xu, X | 1 |
| Gil, R | 1 |
| Slifstein, M | 1 |
| Alm, B | 1 |
| Meyer-Lindenberg, A | 1 |
| Stan, AD | 1 |
| Sheng, G | 1 |
| Demers, M | 1 |
| Bencherif, M | 1 |
| Stachowiak, MK | 1 |
| Kucinski, AJ | 1 |
| Lippiello, PM | 1 |
| Chen, YJ | 1 |
| Sathyamurthy, A | 1 |
| Xiong, WC | 1 |
| Mei, L | 1 |
| Kim, JY | 1 |
| Liu, CY | 1 |
| Zhang, F | 1 |
| Duan, X | 1 |
| Wen, Z | 1 |
| Song, J | 1 |
| Feighery, E | 1 |
| Lu, B | 1 |
| Rujescu, D | 2 |
| St Clair, D | 1 |
| Christian, K | 1 |
| Callicott, JH | 1 |
| Song, H | 1 |
| Ming, GL | 1 |
| Steele, D | 1 |
| Moore, RL | 1 |
| Swan, NA | 1 |
| Grant, JS | 1 |
| Keltner, NL | 1 |
| Lehmann, K | 1 |
| Steinecke, A | 1 |
| Bolz, J | 1 |
| Kömek, K | 1 |
| Bard Ermentrout, G | 1 |
| Walker, CP | 1 |
| Muraki, K | 1 |
| Toritsuka, M | 1 |
| Mugikura, S | 1 |
| Kajiwara, K | 1 |
| Kishimoto, T | 1 |
| Illingworth, E | 1 |
| Tanigaki, K | 1 |
| Pillai, A | 2 |
| Buckley, PF | 1 |
| Basu, A | 1 |
| Benneyworth, M | 1 |
| Balu, D | 1 |
| Konopaske, G | 1 |
| Keefe, R | 1 |
| Rabinowitz, J | 1 |
| Anand, R | 1 |
| Davidson, M | 1 |
| Holcomb, HH | 1 |
| Kuepper, R | 1 |
| Skinbjerg, M | 1 |
| Booij, J | 1 |
| van Amelsvoort, T | 1 |
| Inan, M | 1 |
| Petros, TJ | 1 |
| Anderson, SA | 1 |
| Palaniyappan, L | 1 |
| White, TP | 1 |
| Liddle, PF | 1 |
| Thomases, DR | 1 |
| Cass, DK | 1 |
| Hahn, MK | 1 |
| Cohn, T | 1 |
| Teo, C | 1 |
| Richetto, J | 1 |
| Calabrese, F | 1 |
| Riva, MA | 1 |
| Hasan, A | 1 |
| Mitchell, A | 1 |
| Schneider, A | 1 |
| Halene, T | 1 |
| Beasley, CL | 5 |
| Zhang, ZJ | 4 |
| Blum, BP | 1 |
| Mann, JJ | 2 |
| Eyles, DW | 1 |
| McGrath, JJ | 1 |
| Patten, I | 1 |
| Lara, DR | 1 |
| Jablonowski, K | 1 |
| Margolese, HC | 1 |
| Chouinard, G | 1 |
| Müller, TJ | 1 |
| Kalus, P | 2 |
| Strik, WK | 1 |
| Freedman, R | 2 |
| Olincy, A | 1 |
| Ross, RG | 1 |
| Waldo, MC | 1 |
| Stevens, KE | 1 |
| Adler, LE | 2 |
| Leonard, S | 1 |
| Moxon, KA | 1 |
| Gerhardt, GA | 1 |
| Gulinello, M | 1 |
| Schuckit, MA | 1 |
| Kelsoe, JR | 1 |
| Braff, DL | 1 |
| Wilhelmsen, KC | 1 |
| Hardoy, MC | 1 |
| Carta, MG | 1 |
| Carpiniello, B | 1 |
| Cianchetti, C | 1 |
| Congia, S | 1 |
| D'Errico, I | 1 |
| Emanuelli, G | 1 |
| Garonna, F | 1 |
| Hardoy, MJ | 1 |
| Nardini, M | 1 |
| Reeves, D | 1 |
| Mills, MJ | 1 |
| Billick, SB | 1 |
| Brodie, JD | 1 |
| Pierri, JN | 4 |
| Sun, Z | 2 |
| Lerman, DN | 2 |
| Khaing, ZZ | 2 |
| Weickert, CS | 2 |
| MORRONI, OB | 1 |
| Winterer, G | 2 |
| Wassef, A | 1 |
| Baker, J | 1 |
| Kochan, LD | 1 |
| Tsai, G | 1 |
| Goff, D | 1 |
| Caruncho, HJ | 2 |
| Liu, WS | 1 |
| Davis, J | 2 |
| Tooney, PA | 1 |
| Chahl, LA | 1 |
| Stahl, SM | 1 |
| Grady, MM | 1 |
| Mitchell, CP | 1 |
| Erritzoe, D | 1 |
| Talbot, P | 1 |
| Lopez, LM | 1 |
| Wassef, AA | 2 |
| Molloy, MS | 1 |
| Williams, NG | 1 |
| Abdul-Monim, Z | 2 |
| Cruz, D | 1 |
| Eggan, S | 1 |
| Erickson, S | 1 |
| Ishikawa, M | 1 |
| Mizukami, K | 1 |
| Iwakiri, M | 1 |
| Hidaka, S | 1 |
| Asada, T | 2 |
| Perlman, WR | 1 |
| Akil, M | 1 |
| Trudeau, LE | 1 |
| Schleimer, SB | 1 |
| Hinton, T | 1 |
| Dixon, G | 2 |
| Johnston, GA | 1 |
| Harper, CG | 1 |
| Tamminga, C | 1 |
| Clinton, SM | 1 |
| Meador-Woodruff, JH | 1 |
| Tisch, S | 1 |
| Silberstein, P | 1 |
| Limousin-Dowsey, P | 1 |
| Jahanshahi, M | 1 |
| Dopeso-Reyes, IG | 1 |
| Loza, MI | 1 |
| Rodríguez, MA | 1 |
| Bergen, SE | 1 |
| Nguyen, QL | 1 |
| Xu, B | 1 |
| Monteggia, LM | 1 |
| Crowell, AL | 1 |
| Gaughran, F | 1 |
| Howes, OD | 1 |
| Chrisman, L | 1 |
| Vincent, A | 1 |
| Petrie, KA | 1 |
| Schmidt, D | 1 |
| Bubser, M | 1 |
| Fadel, J | 1 |
| Carraway, RE | 1 |
| Deutch, AY | 1 |
| Ponten, H | 1 |
| Sönniksen, K | 1 |
| Abrahamsson, T | 1 |
| Waters, N | 2 |
| Gustafsson, B | 1 |
| Hanse, E | 1 |
| Groc, L | 1 |
| Ohnuma, T | 2 |
| Suzuki, T | 3 |
| Arai, H | 2 |
| Scarr, E | 1 |
| McLeod, M | 1 |
| Agis-Balboa, RC | 2 |
| Simonini, MV | 2 |
| Bolshakov, VY | 1 |
| Monti, JM | 1 |
| Monti, D | 1 |
| Levitt, P | 1 |
| Deng, C | 1 |
| Shulman, Y | 1 |
| Tibbo, PG | 1 |
| Toru, M | 1 |
| Zhang, L | 1 |
| Zhou, R | 1 |
| Xing, G | 1 |
| Cabungcal, JH | 1 |
| Nicolas, D | 1 |
| Kraftsik, R | 1 |
| Cuénod, M | 1 |
| Do, KQ | 1 |
| Hornung, JP | 1 |
| Van Den Bogaert, A | 1 |
| Del-Favero, J | 1 |
| Van Broeckhoven, C | 1 |
| Paz, RD | 1 |
| Andreasen, NC | 1 |
| Daoud, SZ | 1 |
| Conley, R | 1 |
| Roberts, R | 1 |
| Moghaddam, B | 1 |
| Roberts, E | 1 |
| Le-Niculescu, H | 1 |
| Balaraman, Y | 1 |
| Patel, S | 1 |
| Tan, J | 1 |
| Sidhu, K | 1 |
| Jerome, RE | 1 |
| Edenberg, HJ | 1 |
| Kuczenski, R | 1 |
| Nurnberger, JI | 1 |
| Faraone, SV | 1 |
| Tsuang, MT | 1 |
| Niculescu, AB | 1 |
| Menzies, L | 1 |
| Ooi, C | 1 |
| Kamath, S | 1 |
| Suckling, J | 1 |
| McKenna, P | 1 |
| Fletcher, P | 1 |
| Bullmore, E | 1 |
| Stephenson, C | 1 |
| Ikeda, M | 1 |
| Ozaki, N | 1 |
| Yamanouchi, Y | 1 |
| Kitajima, T | 1 |
| Kinoshita, Y | 1 |
| Iwata, N | 1 |
| Sachdev, PS | 2 |
| Nakagawa, S | 1 |
| López-Gil, X | 1 |
| Babot, Z | 1 |
| Amargós-Bosch, M | 1 |
| Suñol, C | 1 |
| Artigas, F | 1 |
| Adell, A | 1 |
| van der Stelt, O | 1 |
| Belger, A | 1 |
| Harte, MK | 1 |
| Endo, K | 1 |
| Hori, T | 2 |
| Abe, S | 2 |
| Zhao, X | 1 |
| Qin, S | 1 |
| Shi, Y | 1 |
| Zhang, A | 1 |
| Bian, L | 1 |
| Wan, C | 1 |
| Feng, G | 1 |
| Gu, N | 1 |
| Zhang, G | 1 |
| He, G | 1 |
| He, L | 1 |
| Mátyás, T | 1 |
| Buttner, N | 1 |
| Bhattacharyya, S | 1 |
| Walsh, J | 1 |
| Williamson, P | 1 |
| Minns, M | 1 |
| Di Cristo, G | 1 |
| Braun, I | 1 |
| Genius, J | 1 |
| Grunze, H | 1 |
| Bender, A | 1 |
| Möller, HJ | 1 |
| Trantham-Davidson, H | 1 |
| Kröner, S | 1 |
| Seamans, JK | 1 |
| Matevossian, A | 1 |
| Whittle, C | 1 |
| Kim, SY | 1 |
| Schumacher, A | 1 |
| Christensen, BK | 1 |
| Lang, UE | 1 |
| Puls, I | 1 |
| Muller, DJ | 1 |
| Strutz-Seebohm, N | 1 |
| Gallinat, J | 1 |
| Nyffeler, M | 1 |
| Yee, BK | 1 |
| Knuesel, I | 1 |
| Sakai, T | 1 |
| Oshima, A | 1 |
| Nozaki, Y | 1 |
| Ida, I | 1 |
| Haga, C | 1 |
| Akiyama, H | 1 |
| Nakazato, Y | 1 |
| Mikuni, M | 1 |
| Mahadik, SP | 1 |
| Demily, C | 1 |
| Franck, N | 1 |
| Talarovicova, A | 1 |
| Krskova, L | 1 |
| Kiss, A | 1 |
| Wu, Q | 1 |
| Vierling-Claassen, D | 1 |
| Siekmeier, P | 1 |
| Stufflebeam, S | 1 |
| Kopell, N | 1 |
| Pratt, JA | 1 |
| Winchester, C | 1 |
| Cochran, SM | 1 |
| Morris, BJ | 1 |
| Lisman, JE | 1 |
| Green, RW | 1 |
| Javitt, DC | 2 |
| Berger, PA | 3 |
| Rexroth, K | 1 |
| Nestoros, JN | 1 |
| Owen, F | 3 |
| Cross, AJ | 3 |
| Crow, TJ | 3 |
| Lofthouse, R | 1 |
| Poulter, M | 2 |
| Lloyd, KG | 1 |
| Worms, P | 1 |
| Kim, JS | 3 |
| Kornhuber, HH | 3 |
| Brand, U | 1 |
| Menge, HG | 1 |
| Gale, K | 1 |
| Casu, M | 1 |
| Shen, QJ | 1 |
| Snyder, SH | 2 |
| Loo, H | 2 |
| Cuche, H | 2 |
| Sechter, D | 1 |
| Wunderlich, H | 1 |
| Wunderlich, HP | 1 |
| Stoudemire, A | 1 |
| Nelson, A | 1 |
| Houpt, JL | 1 |
| Garbutt, JC | 1 |
| van Kammen, DP | 8 |
| Kausen, J | 1 |
| Zimmermann, P | 1 |
| Fünfgeld, EW | 1 |
| Klenke, D | 1 |
| Henkel, H | 1 |
| Hadjiconstantinou, M | 1 |
| Neff, NH | 1 |
| Rossor, M | 1 |
| Kornhuber, J | 2 |
| Kornhuber, ME | 2 |
| Gerner, RH | 2 |
| Fairbanks, L | 1 |
| Anderson, GM | 1 |
| Young, JG | 1 |
| Scheinin, M | 1 |
| Linnoila, M | 1 |
| Hare, TA | 4 |
| Shaywitz, BA | 1 |
| Cohen, DJ | 1 |
| Meldrum, B | 2 |
| Petty, F | 3 |
| Sherman, AD | 4 |
| Zimmer, R | 2 |
| Teelken, AW | 2 |
| Cramer, H | 1 |
| Ackenheil, M | 3 |
| Zander, KJ | 2 |
| Fischer, H | 1 |
| DeFeudis, FV | 2 |
| Rodnight, R | 1 |
| Bracha, HS | 2 |
| Emrich, HM | 1 |
| Altmann, H | 1 |
| Dose, M | 1 |
| von Zerssen, D | 1 |
| Arora, RC | 1 |
| Metz, J | 1 |
| Spokes, EG | 2 |
| Garrett, NJ | 1 |
| Rossor, MN | 1 |
| Iversen, LL | 1 |
| Schlesser, MA | 1 |
| Lautin, A | 1 |
| Angrist, B | 1 |
| Stanley, M | 1 |
| Gershon, S | 1 |
| Heckl, K | 1 |
| Karobath, M | 1 |
| Reichelt, KL | 1 |
| Hole, K | 1 |
| Hamberger, A | 1 |
| Saelid, G | 1 |
| Edminson, PD | 1 |
| Braestrup, CB | 1 |
| Lingjaerde, O | 1 |
| Ledaal, P | 1 |
| Orbeck, H | 1 |
| Charras, C | 1 |
| Sternberg, DE | 1 |
| Waters, RN | 1 |
| Bunney, WE | 3 |
| Gillman, MA | 1 |
| Lichtigfeld, FJ | 1 |
| Scatton, B | 1 |
| Zarifian, E | 1 |
| Bianchetti, G | 1 |
| Morselli, PL | 1 |
| Meier, KD | 1 |
| McCarthy, BW | 1 |
| Gomes, UR | 1 |
| Neethling, AC | 1 |
| Shanley, BC | 1 |
| Taljaard, JJ | 1 |
| Potgieter, L | 1 |
| Roux, JT | 1 |
| Gold, BI | 1 |
| Bowers, MB | 1 |
| Roth, RH | 1 |
| Sweeney, DW | 1 |
| Jørgensen, A | 1 |
| Magelund, CG | 1 |
| Kim, JJ | 1 |
| Potkin, SG | 1 |
| Hagman, JO | 1 |
| Tafazzoli, A | 1 |
| Jones, EG | 1 |
| Deakin, JF | 3 |
| Ferré, S | 1 |
| Snaprud, P | 1 |
| Ungerstedt, U | 1 |
| Maeda, H | 1 |
| Stroud, D | 1 |
| Kelley, ME | 2 |
| Gurklis, J | 1 |
| Guarneri, P | 1 |
| Gilbertson, MW | 1 |
| Yao, JK | 2 |
| Peters, J | 1 |
| Devor, EJ | 1 |
| Waziri, R | 4 |
| Smith, RS | 1 |
| Maes, M | 1 |
| Wikinski, SI | 1 |
| Acosta, GB | 1 |
| Young, KA | 1 |
| Randall, PK | 1 |
| Wilcox, RE | 1 |
| Choe, BY | 1 |
| Suh, TS | 1 |
| Shinn, KS | 1 |
| Lee, CW | 1 |
| Lee, C | 1 |
| Paik, IH | 1 |
| Daviss, SR | 1 |
| Busatto, GF | 2 |
| Pilowsky, LS | 1 |
| Costa, DC | 1 |
| Ell, PJ | 1 |
| David, AS | 1 |
| Lucey, JV | 1 |
| Kerwin, RW | 2 |
| Maitre, M | 1 |
| Frusciante, M | 1 |
| Miller, JL | 1 |
| Omori, M | 1 |
| Pearce, J | 1 |
| Komoroski, RA | 1 |
| Griffin, WS | 1 |
| Mrak, RE | 1 |
| Husain, MM | 1 |
| Karson, CN | 1 |
| Senitz, D | 1 |
| Beckmann, H | 1 |
| Verhoeff, NP | 1 |
| Goldman-Rakic, PS | 1 |
| Selemon, LD | 2 |
| Turner, EE | 1 |
| Fedtsova, N | 1 |
| Jeste, DV | 1 |
| Whitehead, RE | 1 |
| Melchitzky, DS | 2 |
| Kramer, GL | 1 |
| Barry, EJ | 1 |
| Gurklis, JA | 1 |
| Peters, JL | 1 |
| Dott, SG | 1 |
| Harris, A | 1 |
| Brown, A | 1 |
| O'Boyle, M | 1 |
| Meyer, WJ | 1 |
| Rose, RM | 1 |
| Keverne, EB | 1 |
| Stevens, JR | 2 |
| Augood, SJ | 1 |
| McKenna, PJ | 1 |
| Emson, PC | 1 |
| Lee, DE | 1 |
| Tobin, AJ | 1 |
| Trojanowski, JQ | 1 |
| Arnold, SE | 1 |
| Usiskin, SI | 1 |
| Nicolson, R | 1 |
| Lenane, M | 1 |
| Rapoport, JL | 1 |
| Austin, MC | 1 |
| Tomitaka, S | 1 |
| Tomitaka, M | 1 |
| Tolliver, BK | 1 |
| Sharp, FR | 1 |
| Levine, J | 1 |
| Allingham, B | 1 |
| Anjilvel, S | 1 |
| Chan, S | 1 |
| Ellis, SP | 1 |
| Xanthopoulos, E | 1 |
| Malaspina, D | 1 |
| Gorman, JM | 1 |
| Laruelle, M | 1 |
| Kaufmann, CA | 1 |
| Ito, T | 1 |
| Baba, A | 1 |
| Kurita, H | 1 |
| Yamaguchi, M | 1 |
| Shiraishi, H | 1 |
| Albuquerque, EX | 1 |
| Pereira, EF | 1 |
| Mike, A | 1 |
| Eisenberg, HM | 1 |
| Maelicke, A | 1 |
| Alkondon, M | 1 |
| Pearce, BD | 1 |
| Valadi, NM | 1 |
| Po, CL | 1 |
| Miller, AH | 1 |
| Volk, D | 1 |
| Austin, M | 1 |
| Pierri, J | 1 |
| Sampson, A | 1 |
| Lewis, D | 1 |
| Munno, DW | 1 |
| Todtenkopf, MS | 2 |
| Logiotatos, P | 1 |
| Williams, M | 1 |
| Carlsson, A | 1 |
| Holm-Waters, S | 1 |
| Tedroff, J | 1 |
| Nilsson, M | 1 |
| Carlsson, ML | 1 |
| Pappas, GD | 1 |
| Pesold, C | 1 |
| Hussain, T | 1 |
| Penn, AA | 1 |
| Jones, LB | 1 |
| Kostoulakos, P | 1 |
| Yamada, H | 1 |
| Kamio, S | 1 |
| Nakagome, K | 1 |
| Iwanami, A | 1 |
| Fukuda, M | 1 |
| Yumoto, M | 1 |
| Itoh, K | 1 |
| Koshida, I | 1 |
| Abe, O | 1 |
| Kato, N | 1 |
| Sundman-Eriksson, I | 1 |
| Blennow, K | 1 |
| Davidsson, P | 1 |
| Dandenell, AK | 1 |
| Marcusson, J | 1 |
| Cotter, D | 1 |
| Landau, S | 1 |
| Beasley, C | 1 |
| Stevenson, R | 1 |
| Chana, G | 1 |
| MacMillan, L | 1 |
| Everall, I | 1 |
| Shim, SS | 1 |
| Gluck, MR | 1 |
| Thomas, RG | 1 |
| Davis, KL | 1 |
| Haroutunian, V | 1 |
| Carlsson, VA | 1 |
| Keith, SJ | 1 |
| Gunderson, JG | 1 |
| Reifman, A | 1 |
| Buchsbaum, S | 1 |
| Mosher, LR | 1 |
| Hippius, H | 1 |
| Matussek, N | 1 |
| Tamminga, CA | 6 |
| Crayton, JW | 2 |
| Chase, TN | 3 |
| Bennett, JP | 1 |
| Enna, SJ | 1 |
| Bylund, DB | 1 |
| Gillin, JC | 1 |
| Wyatt, RJ | 2 |
| Woelk, H | 1 |
| Frederiksen, PK | 2 |
| Koran, LM | 1 |
| van den Berg, CJ | 1 |
| Perry, TL | 2 |
| Kish, SJ | 1 |
| Buchanan, J | 1 |
| Hansen, S | 2 |
| Gulmann, NC | 1 |
| Faull, KF | 1 |
| DoAmaral, JR | 1 |
| Barchas, JD | 1 |
| Pericić, D | 1 |
| Neophytides, A | 1 |
| Frohman, LA | 1 |
| Langer, DH | 1 |
| Brown, GL | 1 |
| Sedvall, G | 1 |
| Vinar, O | 1 |
| Avrutskiĭ, GIa | 1 |
| Laskova, NB | 1 |
| Kryzhanovskiĭ, GN | 1 |
| Aliev, MN | 1 |
| Lichtshtein, D | 1 |
| Dobkin, J | 1 |
| Ebstein, RP | 1 |
| Biederman, J | 1 |
| Rimon, R | 1 |
| Belmaker, RH | 1 |
| Plantey, F | 1 |
| Smythies, JR | 1 |
| Bradley, RJ | 1 |
| Linton, PH | 1 |
| Seeman, P | 1 |
| Lee, T | 1 |
| Luchins, D | 1 |
| Simpson, MD | 2 |
| Slater, P | 2 |
| Royston, MC | 2 |
| Cassady, SL | 1 |
| Thaker, GK | 3 |
| Moran, M | 1 |
| Birt, A | 1 |
| Strömberg, I | 1 |
| Seiger, A | 1 |
| Olson, L | 1 |
| Nordström, AL | 1 |
| Wiesel, FA | 1 |
| Bygdeman, M | 1 |
| Wetmore, C | 1 |
| Palmer, MR | 1 |
| Hoffer, BJ | 1 |
| Davidson, AT | 1 |
| Baruah, S | 3 |
| Hegwood, TS | 3 |
| Wolkowitz, OM | 1 |
| Pickar, D | 2 |
| Squires, RF | 1 |
| Saederup, E | 1 |
| Missak, SS | 1 |
| Sandyk, R | 1 |
| Czudek, C | 1 |
| Andrews, HB | 1 |
| Ciu, Z | 1 |
| Gao, BL | 1 |
| Jones, K | 1 |
| Nguyen, JA | 1 |
| Skan, WJ | 1 |
| Monteleone, P | 3 |
| Maj, M | 2 |
| Iovino, M | 2 |
| Forziati, D | 1 |
| Veltro, F | 1 |
| Steardo, L | 3 |
| Ferrier, IN | 1 |
| Johnson, JA | 1 |
| Johnstone, EC | 1 |
| Owens, DG | 1 |
| Raevskiĭ, KS | 1 |
| Aleksandrovskiĭ, IuA | 1 |
| Poiurovskiĭ, MV | 1 |
| Kharlamov, AN | 1 |
| Neznamov, GG | 1 |
| Korpi, ER | 1 |
| Goodman, SI | 1 |
| Zontini, G | 1 |
| Barbaccia, ML | 1 |
| Ferrero, P | 1 |
| Roy, A | 1 |
| Sunderland, T | 1 |
| Paul, SM | 1 |
| Goodwin, FK | 1 |
| Alphs, LD | 1 |
| Lafferman, J | 1 |
| Ferraro, TN | 1 |
| Gelernter, J | 1 |
| Kazarian, BA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pan European Collaboration on Antipsychotic Naïve Schizophrenia II[NCT02339844] | Phase 4 | 130 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| Effect of Sarcosine on Symptomatology, Quality of Life, Cognitive and Sexual Functioning, Blood Levels of Sarcosine, Glycine, BDNF and MMP-9, Oculomotor, Brain Metabolism and Oxidative Stress Parameters in Schizophrenia.[NCT01503359] | Phase 2 | 70 participants (Anticipated) | Interventional | 2012-01-31 | Completed | ||
| Evaluation of Schemes of Administration of Intravenous Ketamine in Treatment-resistant Depression: Clinical-neuroimaging Correlation[NCT03742557] | Phase 3 | 30 participants (Anticipated) | Interventional | 2018-10-01 | Recruiting | ||
| A Randomised Double Blind Placebo Controlled 12 Week Trial of Methotrexate Added to Treatment As Usual in Early Schizophrenia[NCT02074319] | Phase 1 | 92 participants (Actual) | Interventional | 2013-12-31 | Completed | ||
| A Randomized Controlled Trial of Adjunctive Siltuximab in Schizophrenia[NCT02796859] | Phase 1/Phase 2 | 30 participants (Anticipated) | Interventional | 2016-05-31 | Recruiting | ||
| An Open-Label Trial of Tocilizumab in Schizophrenia[NCT01696929] | Phase 1 | 8 participants (Actual) | Interventional | 2012-09-30 | Completed | ||
| A Six-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center, Phase II Study to Determine the Efficacy, Tolerability and Safety of Low and High Non-overlapping Dose Ranges of BL-1020 Compared to Placebo and Risperidone[NCT00567710] | Phase 2 | 360 participants (Anticipated) | Interventional | 2008-07-31 | Completed | ||
| MK-0777 for the Treatment of Cognitive Impairments in Patients With Schizophrenia[NCT00505076] | Phase 2 | 63 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| Treatment of Cognitive Disability in Schizophrenia With a GABA-A Alpha2/3 Receptor Agonist[NCT00129441] | Phase 2 | 16 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| Addition of Tiagabine to Second-Generation Antipsychotics in the Treatment of Recent-Onset Schizophrenia by Modification of Developmental Reorganization of the Prefrontal Cortex[NCT00179465] | Phase 3 | 36 participants (Anticipated) | Interventional | 2003-11-30 | Active, not recruiting | ||
| Phase IV Study of Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia[NCT00595504] | Phase 4 | 25 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| Prolonged-release Melatonin Versus Placebo for Benzodiazepine Discontinuation in Patients With Schizophrenia: a Randomized Clinical Trial[NCT01431092] | Phase 4 | 86 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| The Emergence of Abstract Structure Knowledge Across Learning and Sleep[NCT05746299] | 250 participants (Anticipated) | Interventional | 2023-03-29 | Recruiting | |||
| A Post Marketing Study to Evaluate the Safety and Efficacy of Endourage Complete Spectrum Oral Mucosal Drops (OMD) in Adults Desiring a Reduction in Ethanol Use[NCT04659278] | 0 participants (Actual) | Interventional | 2021-09-30 | Withdrawn (stopped due to Study has been placed on hold) | |||
| Imaging Framework for Testing GABAergic/Glutamatergic Drugs in Bipolar Alcoholics[NCT03220776] | Phase 2 | 54 participants (Actual) | Interventional | 2017-08-07 | Completed | ||
| Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia[NCT03323437] | Phase 4 | 47 participants (Actual) | Interventional | 2017-09-15 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Brief Assessment of Cognition in Schizophrenia (BACS) is the metric used to characterize cognition in this study. The BACS consists of 6 subscales: Verbal Memory (range 0-75), Working Memory (range 0-28), Motor Speed (range 0-100), Verbal Fluency (measure is total number of words generated in two 60 second trials), Attention and Processing speed (range 0-110), and Executive Function (range 0-22). For each subscale, higher scores reflect better cognition. For each subscale, a Standard Deviation Score was calculated based on normative data (Keefe et al. Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS). Schizophrenia Research 102 (2008) 108-115). The BACS composite score is calculated as the average Standard Deviation Score of the 6 subscale scores. The change in BACS composite score was calculated as the BACS composite score at 8 weeks minus the BACS composite score at baseline. (NCT01696929)
Timeframe: Change in BACS composite score from baseline to 8 weeks
| Intervention | Change in BACS Composite Score (Mean) |
|---|---|
| Tocilizumab | 0.7 |
The Positive and Negative Symptoms Scale (PANSS) is the metric used to characterize psychotic symptoms in this study. The PANSS consists of 30 items, each scored 1-7. The range for the PANSS total score is 30-210. There are 3 subscales - PANSS positive score (range 7-49), PANSS negative score (range 7-49), and PANSS general score (range 16-112). PANSS total score is the summation of these 3 subscales. Higher values for the total and subscale scores reflect more severe psychopathology. A positive change in PANSS total score reflects an increase in psychopathology. A negative change in PANSS total score reflects a decrease in psychopathology. (NCT01696929)
Timeframe: Change in PANSS total score from baseline to 8 weeks
| Intervention | Change in PANSS Total Score (Mean) |
|---|---|
| Tocilizumab | -2.6 |
The primary outcome measure is the composite score on the Matrics Consensus Cognitive Battery (MCCB). The MCCB composite score is a standardized mean of the seven domain scores. T-scores are standardized to normative data, and have an estimated mean of 50 and SD of 10 in the general healthy population. Data reduction for analysis of neurocognitive testing used the following steps: i) individual neurocognitive test scores at baseline and follow-up were converted to t-scores; ii) t-scores within the pre-specified cognitive domains measured by more than one test were averaged to obtain a domain-specific t-score; and iii) domain-specific t-scores were averaged to create the MCCB composite score. (NCT00505076)
Timeframe: 4 weeks
| Intervention | composite score (Mean) |
|---|---|
| MK-077 8 mg BID | 27.9 |
| MK-0777 3 mg BID | 31.3 |
| Placebo BID | 32.5 |
The Schizophrenia Cognition Rating Scale (SCoRS) assessed functional capacity. The SCoRS Interviewer Global Rating of function has a range 1 to 10. Higher ratings indicate greater impairment. (NCT00505076)
Timeframe: 4 Weeks (Baseline to End of Treatment)
| Intervention | SCoRS Score (Mean) | |
|---|---|---|
| Baseline | End of Treatment | |
| MK-077 8 mg BID | 4.1 | 4.0 |
| MK-0777 3 mg BID | 4.8 | 4.6 |
| Placebo BID | 3.8 | 3.6 |
The UCSD Performance-Based Skills Assessment assessed functional capacity. The UPSA Summary Score has a range from 0 to 120. A higher score indicates less impairment. (NCT00505076)
Timeframe: Baseline and end of treatment, a total of four weeks.
| Intervention | UPSA Summary Score (Mean) | |
|---|---|---|
| Baseline | End of Treatment | |
| MK-077 8 mg BID | 91.7 | 90.4 |
| MK-0777 3 mg BID | 85.0 | 86.3 |
| Placebo BID | 95.0 | 96.5 |
For the AX Continuous Performance Test, subjects are required to maintain an attentional set across a delay interval in order to overcome a prepotent response tendency (target responses are required when an X is presented but only in the context of a preceding A; non-target conditions are AY, BX and BY). The dependent measure was d-prime at the long delay (calculated as AX hits minus BX false alarms, which is particularly sensitive to context processing impairments in individuals with schizophrenia. (NCT00129441)
Timeframe: Week 4
| Intervention | d-prime (Mean) |
|---|---|
| L-830982 | 1.9 |
| Placebo | 0.7 |
The Brief Psychiatric Rating Scale-anchored (BPRS; Overall and Gorham, 1962; Woerner, Mannuzza, Kane, 1988) is an 18-item scale that is among the most widely used measure of psychopathology. Scores range from 1-7, with higher scores reflecting greater pathology. A total score is derived from the sum of all 18 items (possible scores range from 18-126). It relies on clinical judgment in the assessment of key areas of psychopathology (depression, anxiety, psychosis). (NCT00129441)
Timeframe: Week 4
| Intervention | Scores on a scale (Mean) |
|---|---|
| L-830982 | 26.3 |
| Placebo | 27.0 |
The N-back task is a sequential-letter memory task for which working memory load is varied, as the respondent must indicate when the current stimulus matches the one from 'n' steps earlier in the sequence. The dependent measure for the N-back task was performance in the 2-back condition, which provides the best index of performance and dorsolateral prefrontal cortex disturbances in subjects with schizophrenia. (NCT00129441)
Timeframe: Week 4
| Intervention | proportion of errors (Mean) |
|---|---|
| L-830982 | 0.239 |
| Placebo | 0.297 |
The N-back task is a sequential-letter memory task for which working memory load is varied, as the respondent must indicate when the current stimulus matches the one from 'n' steps earlier in the sequence. The dependent measure for the N-back task was performance in the 2-back condition, which provides the best index of performance and dorsolateral prefrontal cortex disturbances in subjects with schizophrenia. (NCT00129441)
Timeframe: Week 4
| Intervention | msec (Mean) |
|---|---|
| L-830982 | 786 |
| Placebo | 684 |
The POP task is a cued stimulus-response reversal paradigm that, similar to the AX Continuous Performance Test, requires increases in cognitive control through the maintenance and use of context information to overcome prepotent response tendencies. (NCT00129441)
Timeframe: Week 4
| Intervention | msec (Mean) |
|---|---|
| L-830982 | 57 |
| Placebo | 66 |
The POP task is a cued stimulus-response reversal paradigm that, similar to the AX Continuous Performance Test, requires increases in cognitive control through the maintenance and use of context information to overcome prepotent response tendencies. (NCT00129441)
Timeframe: Week 4
| Intervention | proportion of errors (Mean) |
|---|---|
| L-830982 | 0.042 |
| Placebo | 0.031 |
"The Delayed Memory Index consists of verbal and nonverbal recall tasks (words, drawings) that the subject views early in the evaluation and without warning, is asked to recall ~1/2 hr later. Scores are expressed as standardized scores normalized to a population mean of 100, with a standard deviation of 15 (possible scores between 40-135). Higher scores reflect better performance. Subjects received the A form at baseline and wk-4 visit and the B form at the wk-2 visit (A/B forms are equivalent alternate forms, which allow for retesting patients without the confound of practice effects)." (NCT00129441)
Timeframe: Week 4
| Intervention | Standard Score (Mean) |
|---|---|
| L-830982 | 85.3 |
| Placebo | 63.8 |
"Five index scores are computed from the RBANS (immediate memory, language, visuospatial, attention, delayed memory) that are combined to provide the Total Score. The Total Score is expressed as a standardized score normalized to a population mean of 100, with a standard deviation of 15 (possible scores 40-135). Higher scores reflect better performance. All subjects received the A form at baseline and the wk-4 visit and the B form at the wk-2 visit (the A/B forms are equivalent alternate forms, which allow for retesting patients without the confound of practice effects)." (NCT00129441)
Timeframe: Week 4
| Intervention | Standard Score (Mean) |
|---|---|
| L-830982 | 76.7 |
| Placebo | 70.8 |
A comparison between the ramelteon group and the placebo group of change in abdominal fat measured by a DEXA scan, assessed at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | g (Mean) |
|---|---|
| Ramelteon | 3934.86 |
| Placebo (Sugar Pill) | 5120.92 |
A comparison between the ramelteon group and the placebo group of change in insulin resistance measured by the homeostatic model assessment of insulin resistance (HOMA-IR), assessed at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | HOMA score (Mean) |
|---|---|
| Ramelteon | 2.4 |
| Placebo (Sugar Pill) | 2.36 |
A comparison between the ramelteon group and the placebo group in change in waist circumference (measured in cm) measured at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | cm (Mean) |
|---|---|
| Ramelteon | 106.09 |
| Placebo (Sugar Pill) | 108.37 |
Concentrations of GABA+, referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy (i.e., MEGA-PRESS). (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 3.90 |
| Gabapentin | 3.93 |
| Placebo Oral Tablet | 3.73 |
Concentrations of Glx (i.e., glutamate + glutamine), referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy. (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 21.59 |
| Gabapentin | 21.69 |
| Placebo Oral Tablet | 22.25 |
180 reviews available for gamma-aminobutyric acid and Schizophrenia
| Article | Year |
|---|---|
Glutamatergic and GABAergic metabolite levels in schizophrenia-spectrum disorders: a meta-analysis of
Topics: gamma-Aminobutyric Acid; Glutamic Acid; Glutamine; Humans; Magnetic Resonance Spectroscopy; Proton M | 2022 |
The cortical silent period in schizophrenia: A systematic review and meta-analysis focusing on disease stage and antipsychotic medication.
Topics: Antipsychotic Agents; Clozapine; gamma-Aminobutyric Acid; Humans; Neural Inhibition; Olanzapine; Que | 2022 |
Neurofunctional correlates of glutamate and GABA imbalance in psychosis: A systematic review.
Topics: gamma-Aminobutyric Acid; Glutamic Acid; Humans; Magnetic Resonance Imaging; Psychotic Disorders; Sch | 2023 |
Insulin effects on core neurotransmitter pathways involved in schizophrenia neurobiology: a meta-analysis of preclinical studies. Implications for the treatment.
Topics: Animals; Disks Large Homolog 4 Protein; gamma-Aminobutyric Acid; Humans; Insulin; Neurobiology; Neur | 2023 |
Frontal GABA in schizophrenia: A meta-analysis of
Topics: gamma-Aminobutyric Acid; Humans; Magnetic Resonance Imaging; Prefrontal Cortex; Proton Magnetic Reso | 2021 |
The role of glutamate and GABA in cognitive dysfunction in schizophrenia and mood disorders - A systematic review of magnetic resonance spectroscopy studies.
Topics: Brain; Cognitive Dysfunction; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Magnetic Resonance Spe | 2022 |
Metabolite abnormalities in psychosis risk: A meta-analysis of proton magnetic resonance spectroscopy studies.
Topics: gamma-Aminobutyric Acid; Glutamic Acid; Humans; Proton Magnetic Resonance Spectroscopy; Psychotic Di | 2020 |
Emerging therapeutic targets for schizophrenia: a framework for novel treatment strategies for psychosis.
Topics: Animals; Antipsychotic Agents; Dopamine; Drug Design; gamma-Aminobutyric Acid; Glutamates; Hippocamp | 2021 |
A Role for Somatostatin-Positive Interneurons in Neuro-Oscillatory and Information Processing Deficits in Schizophrenia.
Topics: Animals; Brain Waves; gamma-Aminobutyric Acid; Humans; Interneurons; Neocortex; Parvalbumins; Schizo | 2021 |
Beyond Dopamine Receptor Antagonism: New Targets for Schizophrenia Treatment and Prevention.
Topics: Animals; Antipsychotic Agents; D-Amino-Acid Oxidase; Dopamine Antagonists; gamma-Aminobutyric Acid; | 2021 |
Genetic evidence for role of integration of fast and slow neurotransmission in schizophrenia.
Topics: Brain; Dopamine; Dopamine and cAMP-Regulated Phosphoprotein 32; gamma-Aminobutyric Acid; Genetic Pre | 2017 |
Mapping pathologic circuitry in schizophrenia.
Topics: Brain Mapping; gamma-Aminobutyric Acid; Humans; Interneurons; Nerve Net; Parvalbumins; Prefrontal Co | 2018 |
Depression and schizophrenia viewed from the perspective of amino acidergic neurotransmission: Antipodes of psychiatric disorders.
Topics: Animals; Antipsychotic Agents; Depression; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Receptors | 2019 |
Current Practice and New Developments in the Use of In Vivo Magnetic Resonance Spectroscopy for the Assessment of Key Metabolites Implicated in the Pathophysiology of Schizophrenia.
Topics: Aspartic Acid; gamma-Aminobutyric Acid; Glutamic Acid; Glutamine; Glutathione; Humans; Magnetic Reso | 2018 |
The Fragile Brain: Stress Vulnerability, Negative Affect and GABAergic Neurocircuits in Psychosis.
Topics: Affect; Amygdala; Animals; Brain; Disease Models, Animal; gamma-Aminobutyric Acid; Hippocampus; Huma | 2019 |
The Current and Future Potential of Transcranial Magnetic Stimulation With Electroencephalography in Psychiatry.
Topics: Biomarkers; Bipolar Disorder; Depressive Disorder, Major; Electroencephalography; Frontal Lobe; gamm | 2019 |
Crossing the Chloride Channel: The Current and Potential Therapeutic Value of the Neuronal K
Topics: Central Nervous System; Chloride Channels; Chlorides; Epilepsy; gamma-Aminobutyric Acid; Gene Target | 2019 |
A proposal for reframing schizophrenia research.
Topics: Antipsychotic Agents; Brain; Displacement, Psychological; DNA Copy Number Variations; DNA Mutational | 2013 |
Disruption of glutamate-glutamine-GABA cycle significantly impacts on suicidal behaviour: survey of the literature and own findings on glutamine synthetase.
Topics: Brain; Case-Control Studies; Cell Count; Female; gamma-Aminobutyric Acid; Glutamate-Ammonia Ligase; | 2013 |
Reviewing the ketamine model for schizophrenia.
Topics: Age of Onset; Animals; Dopamine; gamma-Aminobutyric Acid; Humans; Ketamine; Phencyclidine; Receptors | 2014 |
Inhibitory neurons in human cortical circuits: substrate for cognitive dysfunction in schizophrenia.
Topics: Cerebral Cortex; Cognition Disorders; gamma-Aminobutyric Acid; Humans; Nerve Net; Neural Inhibition; | 2014 |
Neurodevelopment, GABA system dysfunction, and schizophrenia.
Topics: Animals; Brain; gamma-Aminobutyric Acid; Humans; Receptors, GABA; Risk Factors; Schizophrenia | 2015 |
New approaches to the management of schizophrenia: focus on aberrant hippocampal drive of dopamine pathways.
Topics: Allosteric Regulation; Animals; Antipsychotic Agents; Cell- and Tissue-Based Therapy; Deep Brain Sti | 2014 |
Neurotensin NTS1-dopamine D2 receptor-receptor interactions in putative receptor heteromers: relevance for Parkinson's disease and schizophrenia.
Topics: Animals; Brain; Dopamine; gamma-Aminobutyric Acid; Humans; Neurotensin; Parkinson Disease; Receptors | 2014 |
Imaging-based neurochemistry in schizophrenia: a systematic review and implications for dysfunctional long-term potentiation.
Topics: Brain; Cognition Disorders; Dopamine; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Long-Term Pote | 2015 |
Prefrontal cortical gamma-aminobutyric acid transmission and cognitive function: drawing links to schizophrenia from preclinical research.
Topics: Animals; Cognition Disorders; gamma-Aminobutyric Acid; Humans; Prefrontal Cortex; Schizophrenia; Sig | 2015 |
GABAergic mechanisms of hippocampal hyperactivity in schizophrenia.
Topics: Animals; gamma-Aminobutyric Acid; Hippocampus; Humans; Neurons; Schizophrenia | 2015 |
GABA abnormalities in schizophrenia: a methodological review of in vivo studies.
Topics: Animals; Brain; GABA Agents; gamma-Aminobutyric Acid; Humans; Interneurons; Magnetic Resonance Spect | 2015 |
Biomarkers of psychiatric diseases: current status and future prospects.
Topics: Acetyltransferases; Alzheimer Disease; Biomarkers; Bipolar Disorder; Brain; Brain-Derived Neurotroph | 2015 |
Clozapine and GABA transmission in schizophrenia disease models: establishing principles to guide treatments.
Topics: Animals; Antipsychotic Agents; Brain; Clozapine; Disease Models, Animal; gamma-Aminobutyric Acid; Sc | 2015 |
Losing the sugar coating: potential impact of perineuronal net abnormalities on interneurons in schizophrenia.
Topics: Animals; Brain; Extracellular Matrix; gamma-Aminobutyric Acid; Humans; Interneurons; Schizophrenia | 2015 |
Building models for postmortem abnormalities in hippocampus of schizophrenics.
Topics: Action Potentials; Animals; Disease Models, Animal; gamma-Aminobutyric Acid; Hippocampus; Humans; In | 2015 |
Neurobiological background of negative symptoms.
Topics: Acetylcholine; Brain; Dopamine; Functional Neuroimaging; gamma-Aminobutyric Acid; Glutamic Acid; Hum | 2015 |
The Role of Endocannabinoid Signaling in Cortical Inhibitory Neuron Dysfunction in Schizophrenia.
Topics: Arachidonic Acids; Cognition; Endocannabinoids; gamma-Aminobutyric Acid; Glycerides; Humans; Interne | 2016 |
Abnormal Gamma Oscillations in N-Methyl-D-Aspartate Receptor Hypofunction Models of Schizophrenia.
Topics: Action Potentials; Animals; Cerebral Cortex; Electroencephalography; GABAergic Neurons; Gamma Rhythm | 2016 |
New Pharmacotherapy Targeting Cognitive Dysfunction of Schizophrenia via Modulation of GABA Neuronal Function.
Topics: Animals; Cognition Disorders; gamma-Aminobutyric Acid; Humans; Psychotropic Drugs; Receptor, Seroton | 2015 |
Gamma band oscillations: a key to understanding schizophrenia symptoms and neural circuit abnormalities.
Topics: Animals; Cognition Disorders; gamma-Aminobutyric Acid; Humans; Neurons; Parvalbumins; Psychotic Diso | 2016 |
Catatonia.
Topics: Benzodiazepines; Catatonia; Diagnostic and Statistical Manual of Mental Disorders; Electroconvulsive | 2016 |
Modelling the cognitive and neuropathological features of schizophrenia with phencyclidine.
Topics: Animals; Antipsychotic Agents; Cognition; gamma-Aminobutyric Acid; Humans; Interneurons; Parvalbumin | 2016 |
GABA neurons and the mechanisms of network oscillations: implications for understanding cortical dysfunction in schizophrenia.
Topics: Cerebral Cortex; Cyclic AMP; gamma-Aminobutyric Acid; Humans; N-Methylaspartate; Nerve Net; Neurons; | 2008 |
Cell and receptor type-specific alterations in markers of GABA neurotransmission in the prefrontal cortex of subjects with schizophrenia.
Topics: Animals; Biomarkers; gamma-Aminobutyric Acid; Gene Expression; Humans; Memory; Neural Pathways; Neur | 2008 |
GABAergic promoter hypermethylation as a model to study the neurochemistry of schizophrenia vulnerability.
Topics: Animals; Antipsychotic Agents; Brain; Cell Adhesion Molecules, Neuronal; DNA Methylation; Epigenesis | 2009 |
Multifunctional pharmacotherapy: what can we learn from study of selective serotonin reuptake inhibitor augmentation of antipsychotics in negative-symptom schizophrenia?
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Biogenic Monoamines; Drug Synergism; Drug Ther | 2009 |
GABA(B) receptors, schizophrenia and sleep dysfunction: a review of the relationship and its potential clinical and therapeutic implications.
Topics: Animals; Antipsychotic Agents; Benzhydryl Compounds; Central Nervous System Depressants; Central Ner | 2009 |
Clozapine, GABA(B), and the treatment of resistant schizophrenia.
Topics: Antipsychotic Agents; Baclofen; Clozapine; Drug Resistance; GABA Agonists; GABA Antagonists; gamma-A | 2009 |
Molecular mechanisms underlying glutamatergic dysfunction in schizophrenia: therapeutic implications.
Topics: Animals; Disease Models, Animal; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Interneurons; Model | 2009 |
Amygdalocortical circuitry in schizophrenia: from circuits to molecules.
Topics: Amygdala; Animals; Cerebral Cortex; gamma-Aminobutyric Acid; Hippocampus; Humans; Models, Neurologic | 2010 |
Epigenetic mediation of environmental influences in major psychotic disorders.
Topics: Alleles; Bipolar Disorder; Child; Child Abuse; Diseases in Twins; DNA Methylation; Epigenesis, Genet | 2009 |
BL-1020, an oral antipsychotic agent that reduces dopamine activity and enhances GABAA activity, for the treatment of schizophrenia.
Topics: Animals; Antipsychotic Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic | 2010 |
Genetic association studies of glutamate, GABA and related genes in schizophrenia and bipolar disorder: a decade of advance.
Topics: Animals; Bipolar Disorder; gamma-Aminobutyric Acid; Genetic Association Studies; Glutamic Acid; Huma | 2010 |
Alterations of cortical GABA neurons and network oscillations in schizophrenia.
Topics: Biological Clocks; Cerebral Cortex; gamma-Aminobutyric Acid; Humans; Nerve Net; Neurons; Schizophren | 2010 |
[Schizophrenia and cortical GABA neurotransmission].
Topics: Cerebral Cortex; gamma-Aminobutyric Acid; Humans; Schizophrenia; Synaptic Transmission | 2010 |
Developmental pathology, dopamine, stress and schizophrenia.
Topics: Animals; Dopamine; gamma-Aminobutyric Acid; Hippocampus; Humans; Neurons; Schizophrenia; Stress, Psy | 2011 |
Insights into the neurodevelopmental origin of schizophrenia from postmortem studies of prefrontal cortical circuitry.
Topics: Autopsy; Biomarkers; gamma-Aminobutyric Acid; Humans; Nerve Net; Prefrontal Cortex; Protein Subunits | 2011 |
A computational neuroscience approach to schizophrenia and its onset.
Topics: Adolescent; Adolescent Development; Cerebral Cortex; Computational Biology; Critical Period, Psychol | 2011 |
Epigenetic GABAergic targets in schizophrenia and bipolar disorder.
Topics: Animals; Antipsychotic Agents; Bipolar Disorder; Epigenesis, Genetic; Excitatory Amino Acid Agents; | 2011 |
The chandelier neuron in schizophrenia.
Topics: Animals; gamma-Aminobutyric Acid; Humans; Interneurons; Prefrontal Cortex; Schizophrenia | 2011 |
Alterations in the expression of neuronal chloride transporters may contribute to schizophrenia.
Topics: Age Factors; Animals; Chlorides; Epilepsy; gamma-Aminobutyric Acid; Humans; Mice; Neural Stem Cells; | 2011 |
Postnatal developmental trajectories of neural circuits in the primate prefrontal cortex: identifying sensitive periods for vulnerability to schizophrenia.
Topics: Adolescent; Adolescent Development; Age of Onset; Animals; Disease Models, Animal; gamma-Aminobutyri | 2011 |
Visual masking in schizophrenia: overview and theoretical implications.
Topics: Antipsychotic Agents; Brain; Electroencephalography; gamma-Aminobutyric Acid; Humans; Interneurons; | 2011 |
Genetics and function of neocortical GABAergic interneurons in neurodevelopmental disorders.
Topics: Autistic Disorder; Epilepsy; gamma-Aminobutyric Acid; Humans; Interneurons; Neocortex; Schizophrenia | 2011 |
GABA neuron alterations, cortical circuit dysfunction and cognitive deficits in schizophrenia.
Topics: Animals; Biological Clocks; Cerebral Cortex; Cognition Disorders; Cortical Synchronization; Disease | 2011 |
[Genome-wide association analyses for neuroleptic-induced tardive dyskinesia].
Topics: Acetylcholine; Animals; Antipsychotic Agents; gamma-Aminobutyric Acid; Genetic Predisposition to Dis | 2011 |
MR spectroscopy in schizophrenia.
Topics: Aspartic Acid; gamma-Aminobutyric Acid; Glutamates; Magnetic Resonance Spectroscopy; Neurotransmitte | 2011 |
Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia.
Topics: Cognition Disorders; GABAergic Neurons; gamma-Aminobutyric Acid; Humans; Interneurons; Parvalbumins; | 2012 |
Is lead exposure in early life an environmental risk factor for Schizophrenia? Neurobiological connections and testable hypotheses.
Topics: Age Factors; Animals; Apoptosis; Dopamine; Environmental Exposure; Environmental Pollutants; gamma-A | 2012 |
Origins and perspectives of schizophrenia research.
Topics: Biomedical Research; Dopamine; Fetal Development; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Sc | 2011 |
The glutamate hypothesis of schizophrenia: neuroimaging and drug development.
Topics: Animals; Diagnostic Imaging; Drug Design; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Psychotic | 2012 |
Altered cortical GABA neurotransmission in schizophrenia: insights into novel therapeutic strategies.
Topics: Animals; Antipsychotic Agents; Cognition Disorders; gamma-Aminobutyric Acid; Humans; Prefrontal Cort | 2012 |
Synaptic dysfunction in schizophrenia.
Topics: Acetylcholine; Animals; Brain; Dopamine; gamma-Aminobutyric Acid; Gene Expression Regulation, Develo | 2012 |
GABA through the ages: regulation of cortical function and plasticity by inhibitory interneurons.
Topics: Aging; Animals; Cell Movement; Cerebral Cortex; gamma-Aminobutyric Acid; Humans; Interneurons; Mice; | 2012 |
Reliable biomarkers and predictors of schizophrenia and its treatment.
Topics: Biomarkers; Brain-Derived Neurotrophic Factor; Carrier Proteins; Dopamine; Dysbindin; Dystrophin-Ass | 2012 |
Nicotinic receptors and functional regulation of GABA cell microcircuitry in bipolar disorder and schizophrenia.
Topics: Bipolar Disorder; gamma-Aminobutyric Acid; Glutamate Decarboxylase; Hippocampus; Humans; Interneuron | 2012 |
Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications.
Topics: Animals; Cognition; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Ketamine; Receptors, N-Methyl-D- | 2012 |
The dopamine dysfunction in schizophrenia revisited: new insights into topography and course.
Topics: Animals; Cognition; Dopamine; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Receptors, Dopamine D2 | 2012 |
Imaging as tool to investigate psychoses and antipsychotics.
Topics: Antipsychotic Agents; Diagnostic Imaging; Dihydroxyphenylalanine; Dopamine; Dopamine Plasma Membrane | 2012 |
Losing your inhibition: linking cortical GABAergic interneurons to schizophrenia.
Topics: Animals; Cerebral Cortex; GABAergic Neurons; gamma-Aminobutyric Acid; Humans; Interneurons; Neural I | 2013 |
The concept of salience network dysfunction in schizophrenia: from neuroimaging observations to therapeutic opportunities.
Topics: Cerebral Cortex; Dopamine; gamma-Aminobutyric Acid; Glutamic Acid; Gyrus Cinguli; Humans; Magnetic R | 2012 |
Topiramate in schizophrenia: a review of effects on psychopathology and metabolic parameters.
Topics: Anticonvulsants; Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Fructose; gamma-Aminobu | 2013 |
Epigenetic dysregulation in schizophrenia: molecular and clinical aspects of histone deacetylase inhibitors.
Topics: Antipsychotic Agents; Clozapine; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, | 2013 |
Hippocampal neurons in schizophrenia.
Topics: gamma-Aminobutyric Acid; Glutamic Acid; Hippocampus; Humans; Nerve Tissue Proteins; Neurons; Schizop | 2002 |
The GABAergic system in schizophrenia.
Topics: 4-Aminobutyrate Transaminase; Calcium-Binding Proteins; Cell Count; gamma-Aminobutyric Acid; Glutama | 2002 |
Neuronal calcium-binding proteins and schizophrenia.
Topics: Biomarkers; Calcium-Binding Proteins; gamma-Aminobutyric Acid; Gyrus Cinguli; Hippocampus; Humans; I | 2002 |
Inhibitory deficit in schizophrenia is not necessarily a GABAergic deficit.
Topics: Adenosine; Animals; Brain; Dopamine; GABA Agonists; gamma-Aminobutyric Acid; Humans; Neural Inhibiti | 2002 |
Impaired prefrontal inhibition in schizophrenia: relevance for cognitive dysfunction.
Topics: Cognition Disorders; gamma-Aminobutyric Acid; Gene Expression Regulation; Humans; Nerve Net; Prefron | 2002 |
The neurophysiological meaning of auditory P300 in subtypes of schizophrenia.
Topics: Arousal; Choline; Dopamine; Event-Related Potentials, P300; Evoked Potentials, Auditory; Functional | 2001 |
The genetics of sensory gating deficits in schizophrenia.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Brain; gamma-Aminobutyric Acid; Humans; Neural Inhibition; | 2003 |
GABA and schizophrenia: a review of basic science and clinical studies.
Topics: Animals; Clinical Trials as Topic; GABA Agents; gamma-Aminobutyric Acid; Humans; Receptors, GABA-A; | 2003 |
Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia.
Topics: Antipsychotic Agents; Clinical Trials as Topic; gamma-Aminobutyric Acid; Humans; Receptors, Glutamat | 2003 |
A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation.
Topics: Acetates; Amines; Anticonvulsants; Antipsychotic Agents; Clinical Trials as Topic; Clozapine; Cycloh | 2004 |
GABAergic cortical neuron chromatin as a putative target to treat schizophrenia vulnerability.
Topics: Animals; Cell Adhesion Molecules, Neuronal; Chromatin Assembly and Disassembly; DNA (Cytosine-5-)-Me | 2003 |
Epigenetic downregulation of GABAergic function in schizophrenia: potential for pharmacological intervention?
Topics: Animals; Brain; Cell Adhesion Molecules, Neuronal; Epigenesis, Genetic; Extracellular Matrix Protein | 2003 |
Positron emission tomography and single photon emission CT molecular imaging in schizophrenia.
Topics: Antipsychotic Agents; Brain; Dopamine; gamma-Aminobutyric Acid; Humans; Schizophrenia; Serotonin; To | 2003 |
Calcium binding protein markers of GABA deficits in schizophrenia--postmortem studies and animal models.
Topics: Animals; Biomarkers; Calcium-Binding Proteins; Disease Models, Animal; gamma-Aminobutyric Acid; Huma | 2004 |
Selective alterations in prefrontal cortical GABA neurotransmission in schizophrenia: a novel target for the treatment of working memory dysfunction.
Topics: Animals; GABA Agents; GABA Plasma Membrane Transport Proteins; gamma-Aminobutyric Acid; Glutamate De | 2004 |
Postnatal development of prefrontal inhibitory circuits and the pathophysiology of cognitive dysfunction in schizophrenia.
Topics: Adolescent; Animals; Cognition Disorders; gamma-Aminobutyric Acid; Humans; Neural Inhibition; Neural | 2004 |
Postmortem investigations of the pathophysiology of schizophrenia: the role of susceptibility genes.
Topics: Catechol O-Methyltransferase; Corpus Striatum; Dopamine; gamma-Aminobutyric Acid; Genetic Predisposi | 2004 |
Glutamate co-transmission as an emerging concept in monoamine neuron function.
Topics: Biogenic Monoamines; Brain; Dopamine; Excitatory Postsynaptic Potentials; Fluorescent Antibody Techn | 2004 |
The GABA-glutamate connection in schizophrenia: which is the proximate cause?
Topics: Animals; gamma-Aminobutyric Acid; Glutamates; Hippocampus; Humans; Prefrontal Cortex; Receptors, N-M | 2004 |
Thalamic dysfunction in schizophrenia: neurochemical, neuropathological, and in vivo imaging abnormalities.
Topics: Animals; Brain Chemistry; Cell Count; Diagnostic Imaging; Dopamine; gamma-Aminobutyric Acid; Glutami | 2004 |
The basal ganglia: anatomy, physiology, and pharmacology.
Topics: Acetylcholine; Basal Ganglia; Cognition Disorders; Corpus Striatum; Frontal Lobe; gamma-Aminobutyric | 2004 |
A GABAergic cortical deficit dominates schizophrenia pathophysiology.
Topics: Animals; Antipsychotic Agents; Cerebral Cortex; Dendrites; Excitatory Amino Acid Antagonists; gamma- | 2004 |
A GABA, reelin, and the neurodevelopmental hypothesis of schizophrenia.
Topics: Animals; Brain Chemistry; Cell Adhesion Molecules, Neuronal; Extracellular Matrix Proteins; gamma-Am | 2004 |
Targeting synapses and myelin in the prevention of schizophrenia.
Topics: gamma-Aminobutyric Acid; Humans; Myelin Sheath; Nerve Net; Prefrontal Cortex; Schizophrenia; Synapse | 2005 |
GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon.
Topics: Animals; Benzodiazepines; Bipolar Disorder; Cell Adhesion Molecules, Neuronal; Cerebral Cortex; Chlo | 2005 |
Hypothesis: minimal changes in neural transmission in schizophrenia: decreased glutamatergic and GABAergic functions in the prefrontal cortex.
Topics: Animals; Brain Chemistry; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Models, Neurological; Pref | 2005 |
Sleep disturbance in schizophrenia.
Topics: Brain; Dopamine; gamma-Aminobutyric Acid; Humans; Schizophrenia; Sleep Initiation and Maintenance Di | 2005 |
Sleep disturbance in schizophrenia.
Topics: Brain; Dopamine; gamma-Aminobutyric Acid; Humans; Schizophrenia; Sleep Initiation and Maintenance Di | 2005 |
Sleep disturbance in schizophrenia.
Topics: Brain; Dopamine; gamma-Aminobutyric Acid; Humans; Schizophrenia; Sleep Initiation and Maintenance Di | 2005 |
Sleep disturbance in schizophrenia.
Topics: Brain; Dopamine; gamma-Aminobutyric Acid; Humans; Schizophrenia; Sleep Initiation and Maintenance Di | 2005 |
Sleep disturbance in schizophrenia.
Topics: Brain; Dopamine; gamma-Aminobutyric Acid; Humans; Schizophrenia; Sleep Initiation and Maintenance Di | 2005 |
Sleep disturbance in schizophrenia.
Topics: Brain; Dopamine; gamma-Aminobutyric Acid; Humans; Schizophrenia; Sleep Initiation and Maintenance Di | 2005 |
Sleep disturbance in schizophrenia.
Topics: Brain; Dopamine; gamma-Aminobutyric Acid; Humans; Schizophrenia; Sleep Initiation and Maintenance Di | 2005 |
Sleep disturbance in schizophrenia.
Topics: Brain; Dopamine; gamma-Aminobutyric Acid; Humans; Schizophrenia; Sleep Initiation and Maintenance Di | 2005 |
Sleep disturbance in schizophrenia.
Topics: Brain; Dopamine; gamma-Aminobutyric Acid; Humans; Schizophrenia; Sleep Initiation and Maintenance Di | 2005 |
Neuroactive steroids in schizophrenia.
Topics: Antipsychotic Agents; Binding, Competitive; Brain Chemistry; gamma-Aminobutyric Acid; Humans; N-Meth | 2005 |
[Brain of patients with chronic schizophrenia and neurotransmitters].
Topics: Animals; Brain Chemistry; Chromatography, High Pressure Liquid; Chronic Disease; gamma-Aminobutyric | 2005 |
The roles of cannabinoid and dopamine receptor systems in neural emotional learning circuits: implications for schizophrenia and addiction.
Topics: Amygdala; Animals; Appetitive Behavior; Arachidonic Acids; Association Learning; Cannabinoids; Centr | 2006 |
Molecular and cellular mechanisms of altered GAD1/GAD67 expression in schizophrenia and related disorders.
Topics: Animals; Brain; Down-Regulation; gamma-Aminobutyric Acid; Gene Expression Regulation, Enzymologic; G | 2006 |
Major affective disorders and schizophrenia: a common molecular signature?
Topics: Dopamine; gamma-Aminobutyric Acid; Genetic Predisposition to Disease; Glutamic Acid; Humans; Mood Di | 2006 |
GABA(A) receptor diversity and pharmacology.
Topics: Animals; Anxiety Disorders; gamma-Aminobutyric Acid; Humans; Interneurons; Memory; Neural Inhibition | 2006 |
Pathophysiologically based treatment interventions in schizophrenia.
Topics: Dopamine; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Memory Disorders; Models, Neurological; Pr | 2006 |
Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations.
Topics: Animals; Cognition Disorders; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Neural Inhibition; Pre | 2006 |
Rat modeling for GABA defects in schizophrenia.
Topics: Animals; Brain; Disease Models, Animal; gamma-Aminobutyric Acid; Humans; Long-Term Potentiation; Pro | 2006 |
Epigenetic targets in GABAergic neurons to treat schizophrenia.
Topics: Animals; Cerebral Cortex; Epigenesis, Genetic; GABA Agents; gamma-Aminobutyric Acid; Humans; Molecul | 2006 |
GABAergic malfunction in the limbic system resulting from an aboriginal genetic defect in voltage-gated Na+-channel SCN5A is proposed to give rise to susceptibility to schizophrenia.
Topics: gamma-Aminobutyric Acid; Gene Deletion; Genetic Predisposition to Disease; Humans; Limbic System; Mo | 2006 |
Alternating and postictal psychoses: review and a unifying hypothesis.
Topics: Brain; Electroencephalography; Epilepsy; gamma-Aminobutyric Acid; Humans; N-Methylaspartate; Psychot | 2007 |
Deciphering the disease process of schizophrenia: the contribution of cortical GABA neurons.
Topics: Animals; Cortical Synchronization; gamma-Aminobutyric Acid; Humans; Interneurons; Memory, Short-Term | 2007 |
Application of electroencephalography to the study of cognitive and brain functions in schizophrenia.
Topics: Catechol O-Methyltransferase; Cognition Disorders; Electroencephalography; Event-Related Potentials, | 2007 |
[Gene polymorphism and gene expression in schizophrenia].
Topics: Carrier Proteins; Catechol O-Methyltransferase; Dopamine; Dysbindin; Dystrophin-Associated Proteins; | 2006 |
Are anticorrelated networks in the brain relevant to schizophrenia?
Topics: Affect; Basal Ganglia; Cerebrovascular Circulation; gamma-Aminobutyric Acid; Hallucinations; Humans; | 2007 |
Searching for unique endophenotypes for schizophrenia and bipolar disorder within neural circuits and their molecular regulatory mechanisms.
Topics: Amygdala; Antioxidants; Bipolar Disorder; Calcium Channels, L-Type; Down-Regulation; gamma-Aminobuty | 2007 |
Development of cortical GABAergic circuits and its implications for neurodevelopmental disorders.
Topics: Autistic Disorder; Brain Diseases; Cerebral Cortex; gamma-Aminobutyric Acid; Humans; Interneurons; N | 2007 |
The role of cortical inhibition in the pathophysiology and treatment of schizophrenia.
Topics: Animals; Cerebral Cortex; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Interneurons; Schizophreni | 2007 |
Molecular mechanisms of schizophrenia.
Topics: Dopamine; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Models, Neurological; Phosphatidylinositol | 2007 |
Some assessments of the amygdala role in suprahypothalamic neuroendocrine regulation: a minireview.
Topics: Alzheimer Disease; Amygdala; Anxiety Disorders; Autistic Disorder; Corticotropin-Releasing Hormone; | 2007 |
Modelling prefrontal cortex deficits in schizophrenia: implications for treatment.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Excitatory Amino Acid Antagonists; gamma-Amin | 2008 |
Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia.
Topics: Animals; Cognition; Dopamine; gamma-Aminobutyric Acid; Gene Expression; Hippocampus; Homeostasis; Hu | 2008 |
Neuropharmacological actions of GABA agonists: predictability for their clinical usefulness.
Topics: Antipsychotic Agents; Brain Chemistry; Dyskinesia, Drug-Induced; Epilepsy; gamma-Aminobutyric Acid; | 1981 |
Dynamic utilization of GABA in substantia nigra: regulation by dopamine and GABA in the striatum, and its clinical and behavioral implications.
Topics: 4-Aminobutyrate Transaminase; Afferent Pathways; Aminocaproates; Animals; Basal Ganglia; Behavior, A | 1981 |
[Biochemistry of schizophrenia and mechanism of action of neuroleptics].
Topics: Antipsychotic Agents; Corpus Striatum; Dopamine; Dopamine beta-Hydroxylase; gamma-Aminobutyric Acid; | 1982 |
Interictal schizophrenia-like psychoses in temporal lobe epilepsy.
Topics: Anticonvulsants; Brain; Carbamazepine; Electroencephalography; Epilepsy, Temporal Lobe; Functional L | 1983 |
The interaction between GABA and dopamine: implications for schizophrenia.
Topics: Animals; Antipsychotic Agents; Baclofen; Brain Chemistry; Catalepsy; Dopamine; gamma-Aminobutyric Ac | 1983 |
Catecholamine systems of retina: a model for studying synaptic mechanisms.
Topics: Adenylyl Cyclases; Adrenergic alpha-Agonists; Animals; Antipsychotic Agents; Darkness; Dopamine; Ele | 1984 |
Biological markers in mental disorders: post-mortem studies.
Topics: Age Factors; Alzheimer Disease; Basal Ganglia; Brain Chemistry; Choline O-Acetyltransferase; Circadi | 1984 |
Pharmacology of GABA.
Topics: 4-Aminobutyrate Transaminase; Anxiety Disorders; Autonomic Nervous System; Barbiturates; Benzodiazep | 1982 |
GABA and acute psychoses.
Topics: Acute Disease; Animals; Brain; Cats; gamma-Aminobutyric Acid; Glutamate Decarboxylase; Humans; Limbi | 1982 |
GABA binding processes and behavior.
Topics: Aging; Animals; Basal Ganglia Diseases; Behavior; Behavior, Animal; Epilepsy; Extrapyramidal Tracts; | 1983 |
Schizophrenia: some current neurochemical approaches.
Topics: Biogenic Amines; Brain; Dopamine; gamma-Aminobutyric Acid; Humans; Monoamine Oxidase; Norepinephrine | 1983 |
Postmortem studies in psychiatry.
Topics: Alcoholism; Alzheimer Disease; Brain Chemistry; Cholecystokinin; Depressive Disorder; Dopamine; Endo | 1984 |
Biochemistry and the schizophrenia. Old concepts and new hypothesis.
Topics: Acetylcholine; Amphetamine; Animals; Brain; Cocaine; Dopamine; Endorphins; gamma-Aminobutyric Acid; | 1981 |
Biologically active peptide-containing fractions in schizophrenia and childhood autism.
Topics: Autistic Disorder; Central Nervous System; Dopamine; gamma-Aminobutyric Acid; Humans; Norepinephrine | 1981 |
A theory of schizophrenia: role of environment.
Topics: Aggression; Animals; Brain Chemistry; Disease Models, Animal; Environment; gamma-Aminobutyric Acid; | 1982 |
Neuropsychological implications of brain changes in schizophrenia: an overview.
Topics: Awareness; Brain; Brain Damage, Chronic; Dominance, Cerebral; gamma-Aminobutyric Acid; Glutamic Acid | 1994 |
A theoretical and neurophysiological consideration on the pathogenesis of positive symptoms of schizophrenia: implications of dopaminergic function in the emotional circuit.
Topics: Brain; Brain Mapping; Delusions; Dopamine; Emotions; gamma-Aminobutyric Acid; Hallucinations; Humans | 1994 |
Neurotransmitter systems in schizophrenia.
Topics: Acetylcholine; Animals; Dopamine; gamma-Aminobutyric Acid; Neurotransmitter Agents; Schizophrenia; S | 1995 |
[Role of excitatory amino acids in neuropathology].
Topics: Animals; Epilepsy; Excitatory Amino Acids; gamma-Aminobutyric Acid; Glutamic Acid; In Vitro Techniqu | 1995 |
The gamma-hydroxybutyrate signalling system in brain: organization and functional implications.
Topics: Animals; Brain; gamma-Aminobutyric Acid; Humans; Mammals; Models, Neurological; Rats; Receptors, GAB | 1997 |
The biological basis of schizophrenia: new directions.
Topics: Animals; Aspartic Acid; Brain; Cholecystokinin; Disease Models, Animal; Dopamine; Entorhinal Cortex; | 1997 |
Functional and anatomical aspects of prefrontal pathology in schizophrenia.
Topics: Attention; Brain Mapping; Dopamine; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Interneurons; Me | 1997 |
Schizophrenia, psychosis, and the basal ganglia.
Topics: Antipsychotic Agents; Basal Ganglia; Behavioral Symptoms; gamma-Aminobutyric Acid; Humans; Neuropsyc | 1997 |
Critical review of GABA-ergic drugs in the treatment of schizophrenia.
Topics: Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Dopamine; GABA | 1999 |
GABA-ergic neurons and the neurobiology of schizophrenia and other psychoses.
Topics: Animals; Cerebral Cortex; gamma-Aminobutyric Acid; Humans; Interneurons; Psychoses, Substance-Induce | 1999 |
Epilepsy, schizophrenia, and the extended amygdala.
Topics: Amygdala; Biogenic Monoamines; Epilepsy; gamma-Aminobutyric Acid; Humans; Nerve Net; Neurons; Nucleu | 1999 |
Altered GABA neurotransmission and prefrontal cortical dysfunction in schizophrenia.
Topics: Adolescent; Animals; Axons; Child; Child, Preschool; gamma-Aminobutyric Acid; Humans; Infant; Memory | 1999 |
Reduced inhibitory capacity in prefrontal cortex of schizophrenics.
Topics: Dopamine; gamma-Aminobutyric Acid; Humans; Neural Inhibition; Neurons; Prefrontal Cortex; Schizophre | 1995 |
Neural circuitry of the prefrontal cortex in schizophrenia.
Topics: Cell Count; gamma-Aminobutyric Acid; Glutamate Decarboxylase; Humans; Neurons; Prefrontal Cortex; RN | 1995 |
In pursuit of the molecular neuropathology of schizophrenia.
Topics: gamma-Aminobutyric Acid; Gene Expression; Glutamate Decarboxylase; Humans; Prefrontal Cortex; RNA, M | 1995 |
The current status of tardive dyskinesia.
Topics: Age Factors; Antipsychotic Agents; Cholinergic Antagonists; Dyskinesia, Drug-Induced; Free Radicals; | 2000 |
Amygdalo-entorhinal inputs to the hippocampal formation in relation to schizophrenia.
Topics: Afferent Pathways; Amygdala; Animals; Entorhinal Cortex; gamma-Aminobutyric Acid; Glutamic Acid; Hip | 2000 |
Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence.
Topics: Animals; Antipsychotic Agents; Biogenic Monoamines; Brain Chemistry; Dopamine; gamma-Aminobutyric Ac | 2001 |
GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder.
Topics: Animals; Bipolar Disorder; Cerebral Cortex; gamma-Aminobutyric Acid; Humans; Interneurons; Limbic Sy | 2001 |
Neurochemical correlates of cortical GABAergic deficits in schizophrenia: selective losses of calcium binding protein immunoreactivity.
Topics: Biomarkers; Calcium-Binding Proteins; Cerebral Cortex; gamma-Aminobutyric Acid; Humans; Immunohistoc | 2001 |
Dendritic spine hypoplasticity and downregulation of reelin and GABAergic tone in schizophrenia vulnerability.
Topics: Adolescent; Adult; Age of Onset; Animals; Antigens, CD; Bipolar Disorder; Brain; Cell Adhesion Molec | 2001 |
Early brain wiring: activity-dependent processes.
Topics: Axons; Brain; Cyclic AMP; gamma-Aminobutyric Acid; Geniculate Bodies; Humans; N-Methylaspartate; Ner | 2001 |
Regionally diverse cortical pathology in schizophrenia: clues to the etiology of the disease.
Topics: Brain; Carrier Proteins; Cell Count; gamma-Aminobutyric Acid; Humans; Immunohistochemistry; Nerve Fi | 2001 |
Recent cytoarchitechtonic changes in the prefrontal cortex of schizophrenics.
Topics: gamma-Aminobutyric Acid; Humans; Prefrontal Cortex; Pyramidal Cells; Schizophrenia | 2001 |
Special report: schizophrenia 1976.
Topics: Aftercare; Ambulatory Care; Attention; Cross-Cultural Comparison; gamma-Aminobutyric Acid; Hospitali | 1976 |
[The role of GABA neurons in some neurological and psychiatric disorders (author's transl)].
Topics: Brain; Epilepsy; gamma-Aminobutyric Acid; Humans; Huntington Disease; Neurons; Parkinson Disease; Sc | 1979 |
[The significance of endorphins and gamma-aminobutyric acid in clinical psychopharmacology (author's transl)].
Topics: Anxiety; Bipolar Disorder; Deficiency Diseases; Depression; Endorphins; gamma-Aminobutyric Acid; Hum | 1978 |
Biochemical studies in schizophrenia.
Topics: Aminobutyrates; Brain; Creatine Kinase; Dopamine; gamma-Aminobutyric Acid; Humans; Longitudinal Stud | 1976 |
Building a bridge between neurobiology and mental illness.
Topics: Bipolar Disorder; Brain; Brain Mapping; gamma-Aminobutyric Acid; Humans; Mental Disorders; Receptors | 1992 |
Benzodiazepines in the treatment of schizophrenia: a review and reappraisal.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, | 1991 |
A review of evidence for GABergic predominance/glutamatergic deficit as a common etiological factor in both schizophrenia and affective psychoses: more support for a continuum hypothesis of "functional" psychosis.
Topics: Affective Disorders, Psychotic; Antipsychotic Agents; Brain; gamma-Aminobutyric Acid; Glutamates; Hu | 1991 |
[Significance of GABA-energic system in the central nervous system in clinical psychologic medicine].
Topics: Animals; Brain Chemistry; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Hepatic Encephalopathy; | 1990 |
Postmortem neurochemistry in schizophrenia.
Topics: Acetylcholine; Brain; Brain Chemistry; Cholecystokinin; Dopamine; Endorphins; gamma-Aminobutyric Aci | 1986 |
Schizophrenia: instability in norepinephrine, serotonin, and gamma-aminobutyric acid systems.
Topics: Brain; gamma-Aminobutyric Acid; Humans; Norepinephrine; Schizophrenia; Serotonin | 1988 |
[Role of gamma-aminobutyric acid in metabolic processes in the brain and peripheral organs].
Topics: Adrenal Glands; Amino Acids; Aminobutyrates; Animals; Blood Glucose; Brain; Carbohydrate Metabolism; | 1972 |
20 trials available for gamma-aminobutyric acid and Schizophrenia
| Article | Year |
|---|---|
Abnormal GABAergic function and negative affect in schizophrenia.
Topics: Adult; Cerebral Cortex; Cross-Over Studies; Female; GABA Modulators; gamma-Aminobutyric Acid; Humans | 2014 |
Supplementation of antipsychotic treatment with sarcosine – GlyT1 inhibitor – causes changes of glutamatergic (1)NMR spectroscopy parameters in the left hippocampus in patients with stable schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Aspartic Acid; Choline; Creatine; Double-Blind Method; Fema | 2015 |
Elevated plasma γ-aminobutyrate/glutamate ratio and responses to risperidone antipsychotic treatment in schizophrenia.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Chromatography, Liquid; Female; gamma-Aminobutyri | 2010 |
Amygdala abnormalities in first-degree relatives of individuals with schizophrenia unmasked by benzodiazepine challenge.
Topics: Adult; Alprazolam; Amygdala; Anti-Anxiety Agents; Case-Control Studies; Cross-Over Studies; Double-B | 2011 |
Proton magnetic resonance spectroscopy study of brain metabolite changes after antipsychotic treatment.
Topics: Adult; Antipsychotic Agents; Aspartic Acid; Brain; Brain Chemistry; Diagnostic and Statistical Manua | 2011 |
Dopamine and gamma band synchrony in schizophrenia--insights from computational and empirical studies.
Topics: Adolescent; Adult; Amphetamine; Brain Waves; Computer Simulation; Cortical Synchronization; Dopamine | 2012 |
Bl-1020, a new γ-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Cognition Disorders; Dopamine Antagonists; Double-Bli | 2012 |
Gabapentin in antipsychotic-induced tardive dyskinesia: results of 1-year follow-up.
Topics: Acetates; Adult; Amines; Anticonvulsants; Antipsychotic Agents; Cyclohexanecarboxylic Acids; Dyskine | 2003 |
Effects of gamma-aminobutyric acid-modulating drugs on working memory and brain function in patients with schizophrenia.
Topics: Adult; Brain; Cerebral Cortex; Cognition Disorders; Double-Blind Method; Flumazenil; GABA Modulators | 2007 |
Benzodiazepines in schizophrenia: a need for reassessment.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Dopamine; Dose-Response Relationshi | 1980 |
Therapeutic effects of GABA-ergic drugs in affective disorders. A preliminary report.
Topics: Adolescent; Adult; Analgesics; Anticonvulsants; Bipolar Disorder; Carbamazepine; Clinical Trials as | 1983 |
Sodium valproate in schizophrenia: some biochemical correlates.
Topics: Adult; Clinical Trials as Topic; gamma-Aminobutyric Acid; Homovanillic Acid; Humans; Male; Methoxyhy | 1980 |
CSF diazepam binding inhibitor and schizophrenia: clinical and biochemical relationships.
Topics: Adult; Arousal; Brain; Carrier Proteins; Diazepam Binding Inhibitor; Dopamine; gamma-Aminobutyric Ac | 1993 |
Observation of metabolic changes in chronic schizophrenia after neuroleptic treatment by in vivo hydrogen magnetic resonance spectroscopy.
Topics: Adolescent; Adult; Antipsychotic Agents; Chronic Disease; Creatine; Female; Follow-Up Studies; Front | 1996 |
Do high or low doses of anxiolytics and hypnotics affect mismatch negativity in schizophrenic subjects? An EEG and MEG study.
Topics: Acoustic Stimulation; Adult; Anti-Anxiety Agents; Attention; Benzodiazepines; Dose-Response Relation | 2002 |
Muscimol: GABA agonist therapy in schizophrenia.
Topics: Aminobutyrates; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Evaluation; gamma-A | 1978 |
GABA agonist-induced changes in motor, oculomotor, and attention measures correlate in schizophrenics with tardive dyskinesia.
Topics: Adult; Antipsychotic Agents; Attention; Chronic Disease; Double-Blind Method; Dyskinesia, Drug-Induc | 1992 |
Baclofen-induced growth hormone secretion is blunted in chronic schizophrenics: neuroendocrine evidence for a GABA disturbance in schizophrenia.
Topics: Adult; Aged; Baclofen; Brain; Chronic Disease; gamma-Aminobutyric Acid; Growth Hormone; Humans; Male | 1988 |
Brain gamma-aminobutyric acid abnormality in tardive dyskinesia. Reduction in cerebrospinal fluid GABA levels and therapeutic response to GABA agonist treatment.
Topics: Adult; Aminocaproates; Brain; Clinical Trials as Topic; Double-Blind Method; Dyskinesia, Drug-Induce | 1987 |
Growth hormone response to sodium valproate in chronic schizophrenia.
Topics: Adult; Brain; Chronic Disease; Double-Blind Method; gamma-Aminobutyric Acid; Growth Hormone; Humans; | 1986 |
350 other studies available for gamma-aminobutyric acid and Schizophrenia
| Article | Year |
|---|---|
A mutual prodrug ester of GABA and perphenazine exhibits antischizophrenic efficacy with diminished extrapyramidal effects.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Biological Availability; Catalepsy; Dextroamphe | 2008 |
Hippocampal chloride transporter KCC2 contributes to excitatory GABA dysregulation in the developmental rat model of schizophrenia.
Topics: Animals; Bumetanide; Diuretics; gamma-Aminobutyric Acid; Hippocampus; K Cl- Cotransporters; Male; Pr | 2021 |
GABA
Topics: Animals; Disease Models, Animal; gamma-Aminobutyric Acid; Hippocampus; Methylazoxymethanol Acetate; | 2022 |
Rare presence of autoantibodies targeting to NMDA and GABA
Topics: Autoantibodies; gamma-Aminobutyric Acid; Humans; Receptors, GABA-A; Receptors, N-Methyl-D-Aspartate; | 2022 |
5-HT2A receptor dysregulation in a schizophrenia relevant mouse model of NMDA receptor hypofunction.
Topics: Animals; Disease Models, Animal; gamma-Aminobutyric Acid; Mice; Pyramidal Cells; Receptor, Serotonin | 2022 |
Targeting α6GABA
Topics: Animals; Disease Models, Animal; gamma-Aminobutyric Acid; Humans; Methamphetamine; Mice; Phencyclidi | 2022 |
Multiparameter Optimization of Naphthyridine Derivatives as Selective α5-GABA
Topics: Allosteric Regulation; Animals; gamma-Aminobutyric Acid; Naphthyridines; Receptors, GABA-A; Schizoph | 2022 |
Role of the NRG1/ErbB4 and PI3K/AKT/mTOR signaling pathways in the anti-psychotic effects of aripiprazole and sertindole in ketamine-induced schizophrenia-like behaviors in rats.
Topics: Animals; Antipsychotic Agents; Aripiprazole; gamma-Aminobutyric Acid; Glutamate Decarboxylase; Gluta | 2022 |
Different Modalities of Transcranial Magnetic Stimulation to Manage Schizophrenia.
Topics: gamma-Aminobutyric Acid; Humans; Motor Cortex; Neural Inhibition; Schizophrenia; Transcranial Magnet | 2022 |
A longitudinal investigation of GABA, glutamate, and glutamine across the insula during antipsychotic treatment of first-episode schizophrenia.
Topics: Antipsychotic Agents; Creatine; gamma-Aminobutyric Acid; Glutamic Acid; Glutamine; Humans; Magnetic | 2022 |
Gamma-aminobutyric acid (GABA) levels in the midcingulate cortex and clozapine response in patients with treatment-resistant schizophrenia: A proton magnetic resonance spectroscopy (
Topics: Clozapine; gamma-Aminobutyric Acid; Humans; Proton Magnetic Resonance Spectroscopy; Schizophrenia; S | 2022 |
Interactions between dopamine transporter and N-methyl-d-aspartate receptor-related amino acids on cognitive impairments in schizophrenia.
Topics: Amino Acids; Arginine; Aspartic Acid; Cognitive Dysfunction; Corpus Striatum; Cysteine; Dopamine; Do | 2022 |
Comprehensive metabolomic characterization of the hippocampus in a ketamine mouse model of schizophrenia.
Topics: Amino Acids; Animals; Antipsychotic Agents; Biomarkers; Disease Models, Animal; gamma-Aminobutyric A | 2022 |
Dorsolateral Prefrontal Cortex Glutamate/Gamma-Aminobutyric Acid (GABA) Alterations in Clinical High Risk and First-Episode Schizophrenia: A Preliminary 7-T Magnetic Resonance Spectroscopy Imaging Study.
Topics: Dorsolateral Prefrontal Cortex; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Magnetic Resonance I | 2022 |
Increased rostral medial frontal GABA+ in early psychosis is obscured by levels of negative affect.
Topics: Affect; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Psychotic Disorders; Schizophrenia | 2023 |
Laminar-Specific Alterations in Calbindin-Positive Boutons in the Prefrontal Cortex of Subjects With Schizophrenia.
Topics: Calbindins; GABAergic Neurons; gamma-Aminobutyric Acid; Glutamate Decarboxylase; Humans; Prefrontal | 2023 |
Localization and Diagnostic Specificity of Glutamic Acid Decarboxylase Transcript Alterations in the Dorsolateral Prefrontal Cortex in Schizophrenia.
Topics: Dorsolateral Prefrontal Cortex; gamma-Aminobutyric Acid; Glutamate Decarboxylase; Humans; Prefrontal | 2023 |
Mapping alterations in the local synchrony of the cerebral cortex in schizophrenia.
Topics: Cerebral Cortex; gamma-Aminobutyric Acid; Gyrus Cinguli; Humans; Magnetic Resonance Imaging; Prefron | 2023 |
[Neuromorphological aspect of the GABAergic hypothesis of the pathogenesis of schizophrenia].
Topics: Animals; Brain; gamma-Aminobutyric Acid; Humans; Interneurons; Schizophrenia | 2019 |
Intra-Regional Glu-GABA vs Inter-Regional Glu-Glu Imbalance: A 1H-MRS Study of the Neurochemistry of Auditory Verbal Hallucinations in Schizophrenia.
Topics: Adult; gamma-Aminobutyric Acid; Glutamic Acid; Glutamine; Gyrus Cinguli; Hallucinations; Humans; Pre | 2020 |
Reduced in vivo visual cortex GABA in schizophrenia, a replication in a recent onset sample.
Topics: Adolescent; Adult; Female; gamma-Aminobutyric Acid; Humans; Male; Proton Magnetic Resonance Spectros | 2020 |
Detection of autoantibodies against GABA
Topics: Autoantibodies; Encephalitis; gamma-Aminobutyric Acid; Humans; Receptors, N-Methyl-D-Aspartate; Schi | 2020 |
Disrupted GABAergic facilitation of working memory performance in people with schizophrenia.
Topics: Adult; Brain; Female; gamma-Aminobutyric Acid; Humans; Magnetic Resonance Spectroscopy; Male; Memory | 2020 |
Genetics of schizophrenia in the South African Xhosa.
Topics: Age Factors; Autistic Disorder; Bipolar Disorder; Dopamine; Female; gamma-Aminobutyric Acid; Genetic | 2020 |
Spatiotemporal regulation of GABA concentration in extracellular space by gliotransmission crucial for extrasynaptic receptor-mediated improvement of sensory tuning performance in schizophrenia.
Topics: GABA Plasma Membrane Transport Proteins; gamma-Aminobutyric Acid; Humans; Models, Neurological; Neur | 2020 |
Catatonia in a hospitalized patient with COVID-19 and proposed immune-mediated mechanism.
Topics: Aged; Atrial Fibrillation; Basal Ganglia; Betacoronavirus; C-Reactive Protein; Catatonia; Coronaviru | 2020 |
Associations Between Cognitive Function and Levels of Glutamatergic Metabolites and Gamma-Aminobutyric Acid in Antipsychotic-Naïve Patients With Schizophrenia or Psychosis.
Topics: Antipsychotic Agents; Cognition; gamma-Aminobutyric Acid; Glutamic Acid; Glutamine; Gyrus Cinguli; H | 2021 |
Activated microglia cause metabolic disruptions in developmental cortical interneurons that persist in interneurons from individuals with schizophrenia.
Topics: Adult; Cerebral Cortex; Coculture Techniques; Encephalitis; gamma-Aminobutyric Acid; Gene Expression | 2020 |
In vivo gamma-aminobutyric acid-A/benzodiazepine receptor availability and genetic liability in asymptomatic individuals with high genetic loading of schizophrenia: A [11C]flumazenil positron emission tomography study.
Topics: Brain; Carbon Radioisotopes; Flumazenil; gamma-Aminobutyric Acid; Humans; Positron-Emission Tomograp | 2021 |
Reduction of GABA subunit theta-containing cortical neurons in schizophrenia.
Topics: Cerebral Cortex; gamma-Aminobutyric Acid; Gyrus Cinguli; Humans; Neurons; Schizophrenia | 2021 |
Reduced GABA/glutamate in the thalamus of individuals at clinical high risk for psychosis.
Topics: Adolescent; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Magnetic Resonance Imaging; Psychotic Di | 2021 |
Glutamate and Gamma-Aminobutyric Acid Abnormalities in Antipsychotic-Naïve Patients With Schizophrenia: Evidence From Empirical and Meta-analytic Studies Using Magnetic Resonance Spectroscopy.
Topics: Antipsychotic Agents; Cognition; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Magnetic Resonance | 2021 |
Overexpression of neuregulin 1 in GABAergic interneurons results in reversible cortical disinhibition.
Topics: Action Potentials; Animals; Behavior, Animal; Dependovirus; gamma-Aminobutyric Acid; Genotype; Inter | 2021 |
Depolarizing GABA
Topics: Animals; Bumetanide; Cognitive Dysfunction; Disease Models, Animal; gamma-Aminobutyric Acid; Mice; P | 2021 |
Modulation of stimulated dopamine release in rat nucleus accumbens shell by GABA in vitro: Effect of sub-chronic phencyclidine pretreatment.
Topics: Animals; Dopamine; Excitatory Amino Acid Antagonists; Female; GABA Agonists; gamma-Aminobutyric Acid | 2021 |
Molecular Basis of GABA Hypofunction in Adolescent Schizophrenia-Like Animals.
Topics: Animals; Astrocytes; Cell Communication; Dizocilpine Maleate; Excitatory Amino Acid Antagonists; GAB | 2021 |
Reduced cortical GABA and glutamate in high schizotypy.
Topics: Female; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Magnetic Resonance Imaging; Male; Schizophre | 2021 |
Absence of altered in vivo concentration of dorsolateral prefrontal cortex GABA in recent onset schizophrenia.
Topics: Dorsolateral Prefrontal Cortex; gamma-Aminobutyric Acid; Humans; Prefrontal Cortex; Schizophrenia | 2022 |
Striatal GABA level is associated with sensory integration ability in individuals with low levels of negative schizotypy.
Topics: Corpus Striatum; gamma-Aminobutyric Acid; Humans; Schizophrenia; Schizotypal Personality Disorder | 2022 |
In vivo gamma-aminobutyric acid and glutamate levels in people with first-episode schizophrenia: A proton magnetic resonance spectroscopy study.
Topics: Adolescent; Adult; Female; gamma-Aminobutyric Acid; Glutamine; Gyrus Cinguli; Humans; Image Processi | 2018 |
Exome sequencing in schizophrenic patients with high levels of homozygosity identifies novel and extremely rare mutations in the GABA/glutamatergic pathways.
Topics: Adolescent; Adult; Aged; DNA Mutational Analysis; Exome; Female; gamma-Aminobutyric Acid; Genetic Pr | 2017 |
Adolescent THC Exposure Causes Enduring Prefrontal Cortical Disruption of GABAergic Inhibition and Dysregulation of Sub-Cortical Dopamine Function.
Topics: Animals; Biomarkers; Brain Waves; Cognition; Dopamine; Dronabinol; gamma-Aminobutyric Acid; Glutamat | 2017 |
Benzodiazepines in combination with antipsychotic drugs for schizophrenia: GABA-ergic targeted therapy.
Topics: Antipsychotic Agents; Benzodiazepines; gamma-Aminobutyric Acid; Humans; Psychotic Disorders; Schizop | 2017 |
N-Methyl-d-aspartate receptor co-agonist availability affects behavioral and neurochemical responses to cocaine: insights into comorbid schizophrenia and substance abuse.
Topics: Animals; Cocaine; Comorbidity; Dopamine; Dopamine Uptake Inhibitors; gamma-Aminobutyric Acid; Glutam | 2019 |
Altered Gradients of Glutamate and Gamma-Aminobutyric Acid Transcripts in the Cortical Visuospatial Working Memory Network in Schizophrenia.
Topics: Adult; Cerebral Cortex; Female; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Male; Memory, Short- | 2018 |
7T Proton Magnetic Resonance Spectroscopy of the Anterior Cingulate Cortex in First-Episode Schizophrenia.
Topics: Adult; Aspartic Acid; Cognitive Dysfunction; Female; gamma-Aminobutyric Acid; Glutamic Acid; Gyrus C | 2019 |
Long-range gamma phase synchronization as a compensatory strategy during working memory in high-performing patients with schizophrenia.
Topics: Adolescent; Adult; Electroencephalography; Electroencephalography Phase Synchronization; Female; Fro | 2018 |
Toward Better Strategies for Understanding Disrupted Cortical Excitatory/Inhibitory Balance in Schizophrenia.
Topics: gamma-Aminobutyric Acid; Glutamic Acid; Humans; Memory, Short-Term; Schizophrenia | 2018 |
Functional mechanism of ASP5736, a selective serotonin 5-HT
Topics: Action Potentials; Animals; Cognitive Dysfunction; Discrimination, Psychological; Dopamine; Dopamine | 2018 |
Effects of cariprazine on extracellular levels of glutamate, GABA, dopamine, noradrenaline and serotonin in the medial prefrontal cortex in the rat phencyclidine model of schizophrenia studied by microdialysis and simultaneous recordings of locomotor acti
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; E | 2018 |
GABAergic deficits and schizophrenia-like behaviors in a mouse model carrying patient-derived neuroligin-2 R215H mutation.
Topics: Animals; Behavior, Animal; Cell Adhesion Molecules, Neuronal; Disease Models, Animal; gamma-Aminobut | 2018 |
Effect of Electroconvulsive Therapy on Medial Prefrontal γ-Aminobutyric Acid Among Schizophrenia Patients: A Proton Magnetic Resonance Spectroscopy Study.
Topics: Adolescent; Adult; Antipsychotic Agents; Electroconvulsive Therapy; Female; gamma-Aminobutyric Acid; | 2018 |
Anterior Cingulate Glutamate and GABA Associations on Functional Connectivity in Schizophrenia.
Topics: Adult; Connectome; Female; gamma-Aminobutyric Acid; Glutamic Acid; Gyrus Cinguli; Humans; Magnetic R | 2019 |
Role of Endogenous Metabolite Alterations in Neuropsychiatric Disease.
Topics: DiGeorge Syndrome; gamma-Aminobutyric Acid; Humans; Metabolism, Inborn Errors; Metabolomics; Molecul | 2018 |
Electrophysiological evidence for abnormal glutamate-GABA association following psychosis onset.
Topics: Acoustic Stimulation; Adult; Brain; Electroencephalography; Evoked Potentials, Auditory; Female; Gam | 2018 |
A novel homozygous mutation in GAD1 gene described in a schizophrenic patient impairs activity and dimerization of GAD67 enzyme.
Topics: Adult; gamma-Aminobutyric Acid; Glutamate Decarboxylase; Glutamic Acid; Homozygote; Humans; Male; Mu | 2018 |
Stress Exposure in Dopamine D4 Receptor Knockout Mice Induces Schizophrenia-Like Behaviors via Disruption of GABAergic Transmission.
Topics: Animals; Behavior, Animal; Cognitive Dysfunction; Diazepam; Exploratory Behavior; Female; GABA Modul | 2019 |
The maternal immune activation model uncovers a role for the Arx gene in GABAergic dysfunction in schizophrenia.
Topics: Adult; Animals; Brain; Disease Models, Animal; Female; GABA Agents; Gamma Rhythm; gamma-Aminobutyric | 2019 |
Effect of cannabidiol on endocannabinoid, glutamatergic and GABAergic signalling markers in male offspring of a maternal immune activation (poly I:C) model relevant to schizophrenia.
Topics: Animals; Cannabidiol; Disease Models, Animal; Endocannabinoids; Female; gamma-Aminobutyric Acid; Glu | 2019 |
Oscillatory, Computational, and Behavioral Evidence for Impaired GABAergic Inhibition in Schizophrenia.
Topics: Adult; Cerebral Cortex; Discrimination, Psychological; Female; Gamma Rhythm; gamma-Aminobutyric Acid | 2020 |
Markers of glutamate and GABA neurotransmission in the prefrontal cortex of schizophrenia subjects: Disease effects differ across anatomical levels of resolution.
Topics: gamma-Aminobutyric Acid; Glutamic Acid; Humans; Prefrontal Cortex; Schizophrenia; Synaptic Transmiss | 2020 |
Cuprizone-treated mice, a possible model of schizophrenia, highlighting the simultaneous abnormalities of GABA, serine and glycine in hippocampus.
Topics: Animals; Cuprizone; Disease Models, Animal; gamma-Aminobutyric Acid; Glycine; Hippocampus; Male; Met | 2019 |
Effects of pregabalin on behavioral alterations induced by ketamine in rats.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, | 2012 |
Exposure to the cytokine EGF leads to abnormal hyperactivity of pallidal GABA neurons: implications for schizophrenia and its modeling.
Topics: Action Potentials; Animals; Animals, Newborn; Antipsychotic Agents; Disease Models, Animal; Electroe | 2013 |
GABA predicts inhibition of frequency-specific oscillations in schizophrenia.
Topics: Acoustic Stimulation; Adult; Brain; Brain Mapping; Electroencephalography; Female; gamma-Aminobutyri | 2013 |
Development of antipsychotic medications with novel mechanisms of action based on computational modeling of hippocampal neuropathology.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Antipsychotic Agents; Computer Simulation; | 2013 |
Reduced binding potential of GABA-A/benzodiazepine receptors in individuals at ultra-high risk for psychosis: an [18F]-fluoroflumazenil positron emission tomography study.
Topics: Adolescent; Brain; Case-Control Studies; Caudate Nucleus; Female; Flumazenil; gamma-Aminobutyric Aci | 2014 |
Time-dependent effects of haloperidol on glutamine and GABA homeostasis and astrocyte activity in the rat brain.
Topics: Animals; Antipsychotic Agents; Astrocytes; Chromatography, High Pressure Liquid; gamma-Aminobutyric | 2013 |
In vivo neurometabolic profiling to characterize the effects of social isolation and ketamine-induced NMDA antagonism: a rodent study at 7.0 T.
Topics: Animals; Disease Models, Animal; gamma-Aminobutyric Acid; Glutamic Acid; Glutamine; Gyrus Cinguli; K | 2014 |
Perceptual and cognitive effects of antipsychotics in first-episode schizophrenia: the potential impact of GABA concentration in the visual cortex.
Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Cognition Disorders; Contrast Sensiti | 2013 |
Deficient GABAergic gliotransmission may cause broader sensory tuning in schizophrenia.
Topics: gamma-Aminobutyric Acid; Humans; Interneurons; Neural Networks, Computer; Neuroglia; Schizophrenia; | 2013 |
Altered cortical expression of GABA-related genes in schizophrenia: illness progression vs developmental disturbance.
Topics: Adult; Animals; Calbindin 2; Case-Control Studies; Disease Progression; Female; GABA Plasma Membrane | 2015 |
Mutations in the BLOC-1 subunits dysbindin and muted generate divergent and dosage-dependent phenotypes.
Topics: Animals; Carrier Proteins; Dysbindin; Dystrophin-Associated Proteins; gamma-Aminobutyric Acid; Hippo | 2014 |
GABA level, gamma oscillation, and working memory performance in schizophrenia.
Topics: Adult; Brain; Electroencephalography; Executive Function; Female; Gamma Rhythm; gamma-Aminobutyric A | 2014 |
Prefrontal cortical GABA transmission modulates discrimination and latent inhibition of conditioned fear: relevance for schizophrenia.
Topics: Animals; Bicuculline; Conditioning, Psychological; Discrimination, Psychological; Electroshock; Fear | 2014 |
Lower expression of glutamic acid decarboxylase 67 in the prefrontal cortex in schizophrenia: contribution of altered regulation by Zif268.
Topics: Adult; Animals; Antipsychotic Agents; Autopsy; Cognition Disorders; Confounding Factors, Epidemiolog | 2014 |
Identifying pathways leading to prefrontal GABA-ergic interneuron dysfunction in schizophrenia.
Topics: Animals; Antipsychotic Agents; Cognition Disorders; Female; gamma-Aminobutyric Acid; Glutamate Decar | 2014 |
Tiagabine improves hippocampal long-term depression in rat pups subjected to prenatal inflammation.
Topics: Animals; Child Development Disorders, Pervasive; Female; GABAergic Neurons; gamma-Aminobutyric Acid; | 2014 |
Neuroinflammation versus decreased Zif268 mRNA expression as causal mediators of decreased GAD67 mRNA expression within dorsolateral prefrontal cortex in schizophrenia.
Topics: Animals; Antipsychotic Agents; Cognition Disorders; Female; gamma-Aminobutyric Acid; Glutamate Decar | 2014 |
Response to Pearlman and Najjar.
Topics: Animals; Antipsychotic Agents; Cognition Disorders; Female; gamma-Aminobutyric Acid; Glutamate Decar | 2014 |
Possible drug-drug interaction between pregabalin and clozapine in patients with schizophrenia: clinical perspectives.
Topics: Adult; Analgesics; Antipsychotic Agents; Anxiety; Clozapine; Drug Interactions; gamma-Aminobutyric A | 2015 |
Transcriptional dysregulation of γ-aminobutyric acid transporter in parvalbumin-containing inhibitory neurons in the prefrontal cortex in schizophrenia.
Topics: Adult; Aged; Aged, 80 and over; Female; GABA Plasma Membrane Transport Proteins; gamma-Aminobutyric | 2014 |
GABA and glutamate in schizophrenia: a 7 T ¹H-MRS study.
Topics: Adult; Aspartic Acid; Brain Chemistry; Choline; Creatine; Female; gamma-Aminobutyric Acid; Glutamic | 2014 |
α₄β₂ Nicotinic receptor stimulation of the GABAergic system within the orbitofrontal cortex ameliorates the severe crossmodal object recognition impairment in ketamine-treated rats: implications for cognitive dysfunction in schizophrenia.
Topics: Animals; Disease Models, Animal; gamma-Aminobutyric Acid; Glutamic Acid; Ketamine; Male; Neuropsycho | 2015 |
Chemokine receptors and cortical interneuron dysfunction in schizophrenia.
Topics: Adult; Analysis of Variance; Female; gamma-Aminobutyric Acid; Glutamate Decarboxylase; Humans; Inter | 2015 |
DNA-methyltransferase1 (DNMT1) binding to CpG rich GABAergic and BDNF promoters is increased in the brain of schizophrenia and bipolar disorder patients.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Bipolar Disorder; Brain; Brain-Derived Neurotrophic F | 2015 |
Ketamine Administration During the Second Postnatal Week Alters Synaptic Properties of Fast-Spiking Interneurons in the Medial Prefrontal Cortex of Adult Mice.
Topics: Action Potentials; Animals; Animals, Newborn; Disease Models, Animal; Excitatory Postsynaptic Potent | 2016 |
GABA circuitry, cells and molecular regulation in schizophrenia: life in the graveyard.
Topics: Animals; Brain; GABAergic Neurons; gamma-Aminobutyric Acid; Humans; Schizophrenia | 2015 |
Proteomic pathway analysis of the hippocampus in schizophrenia and bipolar affective disorder implicates 14-3-3 signaling, aryl hydrocarbon receptor signaling, and glucose metabolism: potential roles in GABAergic interneuron pathology.
Topics: 14-3-3 Proteins; Adult; Bipolar Disorder; Female; gamma-Aminobutyric Acid; Glucose; Hippocampus; Hum | 2015 |
Circuit- and Diagnosis-Specific DNA Methylation Changes at γ-Aminobutyric Acid-Related Genes in Postmortem Human Hippocampus in Schizophrenia and Bipolar Disorder.
Topics: Adaptor Proteins, Signal Transducing; Bipolar Disorder; Case-Control Studies; Co-Repressor Proteins; | 2015 |
Early-life lead exposure recapitulates the selective loss of parvalbumin-positive GABAergic interneurons and subcortical dopamine system hyperactivity present in schizophrenia.
Topics: Animals; Blotting, Western; Brain; Chromatography, High Pressure Liquid; Dopamine; Female; gamma-Ami | 2015 |
Medial frontal GABA is lower in older schizophrenia: a MEGA-PRESS with macromolecule suppression study.
Topics: Adult; Age Factors; Case-Control Studies; Cognition Disorders; Female; Frontal Lobe; gamma-Aminobuty | 2016 |
Clozapine potentiation of GABA mediated cortical inhibition in treatment resistant schizophrenia.
Topics: Adult; Analysis of Variance; Clozapine; Cortical Spreading Depression; Dose-Response Relationship, D | 2015 |
Early Adolescent Emergence of Reversal Learning Impairments in Isolation-Reared Rats.
Topics: Age Factors; Animals; Behavior, Animal; Cognition Disorders; Disease Models, Animal; Female; gamma-A | 2015 |
Altered Markers of Cortical γ-Aminobutyric Acid Neuronal Activity in Schizophrenia: Role of the NARP Gene.
Topics: Biomarkers; Bipolar Disorder; C-Reactive Protein; Case-Control Studies; Cytoskeletal Proteins; Depre | 2015 |
In vivo measurement of GABA transmission in healthy subjects and schizophrenia patients.
Topics: Adult; Carbon Radioisotopes; Case-Control Studies; Cerebral Cortex; Female; Flumazenil; GABA Modulat | 2015 |
The GABA system in schizophrenia: cells, molecules and microcircuitry.
Topics: Brain; gamma-Aminobutyric Acid; Humans; Nerve Net; Schizophrenia | 2015 |
[Augmented antipsychotic therapy with pantogam active in patients with schizophrenia].
Topics: Adult; Antipsychotic Agents; Cognition; Female; GABA Agents; gamma-Aminobutyric Acid; Humans; Male; | 2015 |
Abnormal GABAergic function and face processing in schizophrenia: A pharmacologic-fMRI study.
Topics: Adult; Brain; Face; Female; gamma-Aminobutyric Acid; Humans; Hypnotics and Sedatives; Image Processi | 2015 |
Cortico-Striatal GABAergic and Glutamatergic Dysregulations in Subjects at Ultra-High Risk for Psychosis Investigated with Proton Magnetic Resonance Spectroscopy.
Topics: Corpus Striatum; Female; gamma-Aminobutyric Acid; Genetic Predisposition to Disease; Glutamic Acid; | 2015 |
Markedly Lower Glutamic Acid Decarboxylase 67 Protein Levels in a Subset of Boutons in Schizophrenia.
Topics: Adult; Autopsy; Female; GABAergic Neurons; gamma-Aminobutyric Acid; Glutamate Decarboxylase; Humans; | 2016 |
Imaging the "GABA shift" in schizophrenia.
Topics: Female; gamma-Aminobutyric Acid; Humans; Male; Radionuclide Imaging; Schizophrenia; Schizophrenic Ps | 2015 |
Frontal Glutamate and γ-Aminobutyric Acid Levels and Their Associations With Mismatch Negativity and Digit Sequencing Task Performance in Schizophrenia.
Topics: Adult; Auditory Cortex; Auditory Perception; Electroencephalography; Evoked Potentials; Female; Fron | 2016 |
Age-related changes in anterior cingulate cortex glutamate in schizophrenia: A (1)H MRS Study at 7 Tesla.
Topics: Adult; Aging; Antipsychotic Agents; Aspartic Acid; Choline; Creatine; Dipeptides; Female; gamma-Amin | 2016 |
Cortical Gene Expression After a Conditional Knockout of 67 kDa Glutamic Acid Decarboxylase in Parvalbumin Neurons.
Topics: Animals; Behavior, Animal; Cerebral Cortex; Disease Models, Animal; Female; GABAergic Neurons; gamma | 2016 |
A heuristic model for working memory deficit in schizophrenia.
Topics: Brain; Computer Simulation; gamma-Aminobutyric Acid; Glutamic Acid; Heuristics; Humans; Ketamine; Me | 2016 |
Gabapentin prevents behavioral changes on the amphetamine-induced animal model of schizophrenia.
Topics: Amines; Amphetamine; Animals; Behavior, Animal; Calcium Channel Blockers; Cyclohexanecarboxylic Acid | 2016 |
7T Proton Magnetic Resonance Spectroscopy of Gamma-Aminobutyric Acid, Glutamate, and Glutamine Reveals Altered Concentrations in Patients With Schizophrenia and Healthy Siblings.
Topics: Adult; Brain; Female; gamma-Aminobutyric Acid; Genetic Predisposition to Disease; Glutamic Acid; Glu | 2017 |
Cortical GABA markers identify a molecular subtype of psychotic and bipolar disorders.
Topics: Adult; Biomarkers; Bipolar Disorder; Female; GABAergic Neurons; gamma-Aminobutyric Acid; Glutamate D | 2016 |
Potential Regional Differences in GABA Levels in Patients With Psychosis Compared With Control Subjects.
Topics: gamma-Aminobutyric Acid; Humans; Psychotic Disorders; Schizophrenia | 2016 |
(1)H-MRS and MEGA-PRESS pulse sequence in the study of balance of inhibitory and excitatory neurotransmitters in the human brain of ultra-high risk of schizophrenia patients.
Topics: Adolescent; Adult; Creatine; Frontal Lobe; Functional Laterality; gamma-Aminobutyric Acid; Glutamic | 2016 |
DNA methylation regulates gabrb2 mRNA expression: developmental variations and disruptions in l-methionine-induced zebrafish with schizophrenia-like symptoms.
Topics: Animals; Disease Models, Animal; DNA Methylation; gamma-Aminobutyric Acid; Gene Expression Regulatio | 2016 |
Risperidone increases the cortical silent period in drug-naive patients with first-episode schizophrenia: A transcranial magnetic stimulation study.
Topics: Adult; Antipsychotic Agents; Cerebral Cortex; gamma-Aminobutyric Acid; Humans; Neural Inhibition; Ps | 2017 |
Altered brain arginine metabolism in schizophrenia.
Topics: Agmatine; Arginase; Arginine; Autopsy; Blotting, Western; Brain; Case-Control Studies; Chromatograph | 2016 |
Protein Markers of Neurotransmitter Synthesis and Release in Postmortem Schizophrenia Substantia Nigra.
Topics: Dopamine; Female; gamma-Aminobutyric Acid; Glutamate Decarboxylase; Glutamic Acid; Humans; Male; Mid | 2017 |
Cytosolic Accumulation of L-Proline Disrupts GABA-Ergic Transmission through GAD Blockade.
Topics: Animals; Central Nervous System; Cytosol; Disease Models, Animal; Gamma Rhythm; gamma-Aminobutyric A | 2016 |
Altered cortical processing of motor inhibition in schizophrenia.
Topics: Adult; Antipsychotic Agents; Brain Mapping; Electromyography; Evoked Potentials, Motor; Female; gamm | 2016 |
l-Proline, GABA Synthesis and Gamma Oscillations in Schizophrenia.
Topics: GABAergic Neurons; gamma-Aminobutyric Acid; Parvalbumins; Prefrontal Cortex; Proline; Schizophrenia | 2016 |
Perisylvian GABA levels in schizophrenia and bipolar disorder.
Topics: Adult; Antipsychotic Agents; Auditory Cortex; Bipolar Disorder; Female; gamma-Aminobutyric Acid; Hum | 2017 |
A Novel Multisensory Integration Task Reveals Robust Deficits in Rodent Models of Schizophrenia: Converging Evidence for Remediation via Nicotinic Receptor Stimulation of Inhibitory Transmission in the Prefrontal Cortex.
Topics: Animals; gamma-Aminobutyric Acid; In Vitro Techniques; Isoxazoles; Ketamine; Male; Mice; Mice, Inbre | 2016 |
Electrophysiological evidence for defective fast-spiking GABAergic neurones in a schizophrenia model.
Topics: Action Potentials; Electrophysiological Phenomena; GABAergic Neurons; gamma-Aminobutyric Acid; Human | 2017 |
Reduced
Topics: Adolescent; Adult; Female; gamma-Aminobutyric Acid; Glutamic Acid; Glutamine; Humans; Magnetic Reson | 2016 |
Comprehensive association analysis of 27 genes from the GABAergic system in Japanese individuals affected with schizophrenia.
Topics: Adult; Aged; Asian People; Carrier Proteins; Female; gamma-Aminobutyric Acid; Gene Frequency; Geneti | 2017 |
Morphological, structural, and functional alterations of the prefrontal cortex and the basolateral amygdala after early lesion of the rat mediodorsal thalamus.
Topics: Animals; Animals, Newborn; Anxiety; Basolateral Nuclear Complex; Behavior, Animal; Cognition; Dendri | 2017 |
GABA and schizophrenia: Where we stand and where we need to go.
Topics: Animals; Brain; gamma-Aminobutyric Acid; Humans; Schizophrenia | 2017 |
CSF GABA is reduced in first-episode psychosis and associates to symptom severity.
Topics: Adult; Antipsychotic Agents; Brain; Case-Control Studies; Chromatography, High Pressure Liquid; Fema | 2018 |
Chandelier cartridges in the prefrontal cortex are reduced in isolation reared rats.
Topics: Animals; Axons; Behavior, Animal; Cell Differentiation; Disease Models, Animal; Environment, Control | 2008 |
Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia.
Topics: Adult; Aged; Female; gamma-Aminobutyric Acid; Gene Expression; Humans; Male; Middle Aged; Prefrontal | 2008 |
Reduced cortical inhibition in first-episode schizophrenia.
Topics: Adult; Antipsychotic Agents; Cerebral Cortex; Control Groups; Evoked Potentials, Motor; Female; Func | 2008 |
Mice lacking the schizophrenia-associated protein FEZ1 manifest hyperactivity and enhanced responsiveness to psychostimulants.
Topics: Animals; Base Sequence; Brain; Central Nervous System Stimulants; Disease Models, Animal; Dizocilpin | 2008 |
Prenatal immune activation leads to multiple changes in basal neurotransmitter levels in the adult brain: implications for brain disorders of neurodevelopmental origin such as schizophrenia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemistry; Brain Diseases; Chromatography, High Press | 2009 |
BL-1020: a novel antipsychotic drug with GABAergic activity and low catalepsy, is efficacious in a rat model of schizophrenia.
Topics: Acetylcholine; Amphetamine; Animals; Antipsychotic Agents; Biological Availability; Brain; Catalepsy | 2009 |
Serotonin 1A receptors in human and monkey prefrontal cortex are mainly expressed in pyramidal neurons and in a GABAergic interneuron subpopulation: implications for schizophrenia and its treatment.
Topics: Aged; Animals; Autoradiography; Calbindins; gamma-Aminobutyric Acid; Glutamate Decarboxylase; Humans | 2008 |
Altered expression of genes involved in GABAergic transmission and neuromodulation of granule cell activity in the cerebellum of schizophrenia patients.
Topics: Adult; Aged; Cerebellum; gamma-Aminobutyric Acid; Gene Expression; Glutamate Decarboxylase; Granuloc | 2008 |
A neonatal ventral hippocampal lesion causes functional deficits in adult prefrontal cortical interneurons.
Topics: Aging; Animals; Animals, Newborn; Biomarkers; Denervation; Dopamine Agonists; gamma-Aminobutyric Aci | 2008 |
Interleukin-6 mediates the increase in NADPH-oxidase in the ketamine model of schizophrenia.
Topics: Animals; Antibodies; Cells, Cultured; Disease Models, Animal; Enzyme Activation; gamma-Aminobutyric | 2008 |
Interleukin-6 mediates the increase in NADPH-oxidase in the ketamine model of schizophrenia.
Topics: Animals; Antibodies; Cells, Cultured; Disease Models, Animal; Enzyme Activation; gamma-Aminobutyric | 2008 |
Interleukin-6 mediates the increase in NADPH-oxidase in the ketamine model of schizophrenia.
Topics: Animals; Antibodies; Cells, Cultured; Disease Models, Animal; Enzyme Activation; gamma-Aminobutyric | 2008 |
Interleukin-6 mediates the increase in NADPH-oxidase in the ketamine model of schizophrenia.
Topics: Animals; Antibodies; Cells, Cultured; Disease Models, Animal; Enzyme Activation; gamma-Aminobutyric | 2008 |
Interleukin-6 mediates the increase in NADPH-oxidase in the ketamine model of schizophrenia.
Topics: Animals; Antibodies; Cells, Cultured; Disease Models, Animal; Enzyme Activation; gamma-Aminobutyric | 2008 |
Interleukin-6 mediates the increase in NADPH-oxidase in the ketamine model of schizophrenia.
Topics: Animals; Antibodies; Cells, Cultured; Disease Models, Animal; Enzyme Activation; gamma-Aminobutyric | 2008 |
Interleukin-6 mediates the increase in NADPH-oxidase in the ketamine model of schizophrenia.
Topics: Animals; Antibodies; Cells, Cultured; Disease Models, Animal; Enzyme Activation; gamma-Aminobutyric | 2008 |
Interleukin-6 mediates the increase in NADPH-oxidase in the ketamine model of schizophrenia.
Topics: Animals; Antibodies; Cells, Cultured; Disease Models, Animal; Enzyme Activation; gamma-Aminobutyric | 2008 |
Interleukin-6 mediates the increase in NADPH-oxidase in the ketamine model of schizophrenia.
Topics: Animals; Antibodies; Cells, Cultured; Disease Models, Animal; Enzyme Activation; gamma-Aminobutyric | 2008 |
Circuitry-based gene expression profiles in GABA cells of the trisynaptic pathway in schizophrenics versus bipolars.
Topics: Bipolar Disorder; Female; gamma-Aminobutyric Acid; Gene Expression Profiling; Gene Expression Regula | 2008 |
Characterization of the action of antipsychotic subtypes on valproate-induced chromatin remodeling.
Topics: Animals; Antipsychotic Agents; Cell Adhesion Molecules, Neuronal; Chromatin Assembly and Disassembly | 2009 |
Molecular determinants of dysregulated GABAergic gene expression in the prefrontal cortex of subjects with schizophrenia.
Topics: Adult; Aged; Aged, 80 and over; Animals; Brain-Derived Neurotrophic Factor; Case-Control Studies; Ch | 2009 |
Neural basis of psychosis-related behaviour in the infection model of schizophrenia.
Topics: Animals; Avoidance Learning; Brain; Disease Models, Animal; Dopamine; Female; gamma-Aminobutyric Aci | 2009 |
The role of epigenetics in altered gene expression involved in GABAergic transmission in the cerebellum of schizophrenia patients.
Topics: Autistic Disorder; Cerebellum; Epigenesis, Genetic; gamma-Aminobutyric Acid; Gene Expression; Glutam | 2009 |
An upregulation of DNA-methyltransferase 1 and 3a expressed in telencephalic GABAergic neurons of schizophrenia patients is also detected in peripheral blood lymphocytes.
Topics: Adult; Aged; Cohort Studies; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransfer | 2009 |
Pregabalin in the treatment of schizophrenic anxiety.
Topics: Adult; Anticonvulsants; Anxiety Disorders; gamma-Aminobutyric Acid; Humans; Male; Pregabalin; Schizo | 2009 |
Reduction of brain gamma-aminobutyric acid (GABA) concentrations in early-stage schizophrenia patients: 3T Proton MRS study.
Topics: Adult; Brain; Creatine; Female; gamma-Aminobutyric Acid; Humans; Magnetic Resonance Spectroscopy; Ma | 2009 |
Neural circuitry models of schizophrenia: is it dopamine, GABA, glutamate, or something else?
Topics: Brain; Dopamine; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Neural Pathways; Neurons; Schizophr | 2009 |
A rodent model of schizophrenia derived from postmortem studies.
Topics: Amygdala; Animals; Disease Models, Animal; Electrophysiology; GABA Antagonists; gamma-Aminobutyric A | 2009 |
Site-specific regulation of cell cycle and DNA repair in post-mitotic GABA cells in schizophrenic versus bipolars.
Topics: Bipolar Disorder; Cell Cycle; DNA Repair; Endodeoxyribonucleases; gamma-Aminobutyric Acid; Gene Expr | 2009 |
Schizophrenia-like GABAergic gene expression deficits in cerebellar Golgi cells from rats chronically exposed to low-dose phencyclidine.
Topics: Action Potentials; Animals; Cerebellum; Disease Models, Animal; Dose-Response Relationship, Drug; Dr | 2009 |
GABA and homovanillic acid in the plasma of Schizophrenic and bipolar I patients.
Topics: Adolescent; Adult; Biomarkers; Bipolar Disorder; Dopamine; Female; gamma-Aminobutyric Acid; Homovani | 2010 |
Postnatal exposure to MK801 induces selective changes in GAD67 or parvalbumin.
Topics: Aging; Animals; Animals, Newborn; Cell Count; Cell Differentiation; Disease Models, Animal; Dizocilp | 2010 |
Role of GABAA receptors in cognition.
Topics: Animals; Anxiety; Brain; Cognition; Electroencephalography; gamma-Aminobutyric Acid; Humans; Interne | 2009 |
Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes.
Topics: Action Potentials; Analysis of Variance; Animals; Animals, Newborn; Cerebral Cortex; Disease Models, | 2010 |
Associations between plasma levels of 3-methoxy-4-hydroxyphenylglycol (MHPG) and negative symptoms or cognitive impairments in early-stage schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Brain-Derived Neurotrophic Factor; Cognition Disorders; Fem | 2009 |
GABA concentration in schizophrenia patients and the effects of antipsychotic medication: a proton magnetic resonance spectroscopy study.
Topics: Adult; Antipsychotic Agents; Brain; Chronic Disease; Female; gamma-Aminobutyric Acid; Humans; Magnet | 2010 |
Schizophrenia-related endophenotypes in heterozygous neuregulin-1 'knockout' mice.
Topics: Animals; Aspartic Acid; Behavior, Animal; Brain; Dizocilpine Maleate; Excitatory Amino Acid Antagoni | 2010 |
Relationship of GAD(67) regulation to cell cycle and DNA repair in GABA neurons in the adult hippocampus: bipolar disorder versus schizophrenia.
Topics: Bipolar Disorder; Cell Cycle; DNA Repair; gamma-Aminobutyric Acid; Gene Expression Regulation; Gluta | 2010 |
Model-based parametric study of frontostriatal abnormalities in schizophrenia patients.
Topics: Algorithms; Antipsychotic Agents; Computational Biology; Corpus Striatum; Dopamine; Dopamine Antagon | 2010 |
Effect of amphetamine on extracellular concentrations of amino acids in striatum in neurotensin subtype 1 and 2 receptor null mice: a possible interaction between neurotensin receptors and amino acid systems for study of schizophrenia.
Topics: Amino Acids; Amphetamine; Animals; Central Nervous System Stimulants; Corpus Striatum; Extracellular | 2010 |
GABA concentration is reduced in visual cortex in schizophrenia and correlates with orientation-specific surround suppression.
Topics: Adolescent; Adult; Female; gamma-Aminobutyric Acid; Humans; Male; Orientation; Photic Stimulation; S | 2010 |
Control of cortical GABA circuitry development by Nrg1 and ErbB4 signalling.
Topics: Animals; Cell Differentiation; Cerebral Cortex; Dendrites; Embryo, Mammalian; ErbB Receptors; Excita | 2010 |
Augmentation with pregabalin in schizophrenia.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Anxiety Disorders; Drug Therapy, Combination; Female; | 2010 |
Elevated gamma-aminobutyric acid levels in chronic schizophrenia.
Topics: Adult; Analysis of Variance; Aspartic Acid; Case-Control Studies; Chronic Disease; Creatine; Female; | 2010 |
Editorial: Etiological hypotheses of mental disorders at the molecular level.
Topics: Bipolar Disorder; Circadian Rhythm; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Mental Disorders | 2010 |
Regulation of intermittent oscillatory activity of pyramidal cell neurons by GABA inhibitory interneurons is impaired in schizophrenia: rationale for pharmacotherapeutic GABAergic interventions.
Topics: Animals; Axons; Biological Clocks; Carisoprodol; Dendrites; Dendritic Spines; Frontal Lobe; GABA Ago | 2010 |
No alterations of brain GABA after 6 months of treatment with atypical antipsychotic drugs in early-stage first-episode schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Brain; Drug Administration Schedule; Early Diagnosis; Femal | 2010 |
D2 and D4 dopamine receptor mRNA distribution in pyramidal neurons and GABAergic subpopulations in monkey prefrontal cortex: implications for schizophrenia treatment.
Topics: Animals; Calbindins; gamma-Aminobutyric Acid; Glutamate Decarboxylase; Glutamic Acid; In Situ Hybrid | 2010 |
Late prenatal immune activation in mice leads to behavioral and neurochemical abnormalities relevant to the negative symptoms of schizophrenia.
Topics: Animals; Behavior, Animal; Central Nervous System Viral Diseases; Disease Models, Animal; Dopamine; | 2010 |
Schizophrenia: The making of a troubled mind.
Topics: Adolescent; Algorithms; Animals; Brain; Child; Cognition; gamma-Aminobutyric Acid; Health; Humans; M | 2010 |
Failure of NMDA receptor hypofunction to induce a pathological reduction in PV-positive GABAergic cell markers.
Topics: Animals; Blotting, Western; Brain; Disease Models, Animal; Excitatory Amino Acid Antagonists; gamma- | 2011 |
Reducing prefrontal gamma-aminobutyric acid activity induces cognitive, behavioral, and dopaminergic abnormalities that resemble schizophrenia.
Topics: Amphetamine; Animals; Behavior, Animal; Bicuculline; Cognition; Cues; Discrimination Learning; Dopam | 2011 |
Region-specific alteration of GABAergic markers in the brain of heterozygous reeler mice.
Topics: Animals; Biomarkers; Brain; Cell Adhesion Molecules, Neuronal; Extracellular Matrix Proteins; Female | 2011 |
Developmental GABAergic deficit enhances methamphetamine-induced apoptosis.
Topics: Animals; Apoptosis; Central Nervous System Stimulants; Disease Models, Animal; Dizocilpine Maleate; | 2011 |
Cortical deficits of glutamic acid decarboxylase 67 expression in schizophrenia: clinical, protein, and cell type-specific features.
Topics: Adult; Blotting, Western; Cognition Disorders; Cohort Studies; Female; gamma-Aminobutyric Acid; Glut | 2011 |
Expression of GABA signaling molecules KCC2, NKCC1, and GAD1 in cortical development and schizophrenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antipsychotic Agents; Cerebral Cortex; Child; C | 2011 |
Molecular etiologies of schizophrenia: are we almost there yet?
Topics: Cognition Disorders; Endophenotypes; Female; gamma-Aminobutyric Acid; Genetic Association Studies; G | 2011 |
Concentration change of DA, DOPAC, Glu and GABA in brain tissues in schizophrenia developmental model rats induced by MK-801.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Animals, Newborn; Brain; Dizocilpine Maleate; Dopamine; gam | 2011 |
Schizophrenia and the epigenetic hypothesis.
Topics: DNA Methylation; Epigenesis, Genetic; gamma-Aminobutyric Acid; Glutamate Decarboxylase; Glutamic Aci | 2010 |
Elevated prefrontal cortex γ-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy.
Topics: Adult; Case-Control Studies; Female; gamma-Aminobutyric Acid; Glutamic Acid; Glutamine; Humans; Magn | 2012 |
Pregabalin-associated increase of clozapine serum levels.
Topics: Antimanic Agents; Antipsychotic Agents; Anxiety Disorders; Clozapine; Female; gamma-Aminobutyric Aci | 2012 |
Differences in the circuitry-based association of copy numbers and gene expression between the hippocampi of patients with schizophrenia and the hippocampi of patients with bipolar disorder.
Topics: Bipolar Disorder; gamma-Aminobutyric Acid; Gene Dosage; Gene Expression Regulation; Glutamate Decarb | 2012 |
Alpha7 nicotinic cholinergic neuromodulation may reconcile multiple neurotransmitter hypotheses of schizophrenia.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Antipsychotic Agents; Cholinergic Agonists; Dopami | 2012 |
Interplay between DISC1 and GABA signaling regulates neurogenesis in mice and risk for schizophrenia.
Topics: Animals; Dendrites; Disease Susceptibility; Female; gamma-Aminobutyric Acid; Mice; Mice, Inbred C57B | 2012 |
Modeling interneuron dysfunction in schizophrenia.
Topics: Animals; Cerebral Cortex; Disease Models, Animal; gamma-Aminobutyric Acid; Glutamate Decarboxylase; | 2012 |
Biological perspectives: the role of glutamate in schizophrenia and its treatment.
Topics: Antipsychotic Agents; Dopamine; Excitatory Amino Acid Agonists; gamma-Aminobutyric Acid; Glutamic Ac | 2012 |
Selective overexpression of Comt in prefrontal cortex rescues schizophrenia-like phenotypes in a mouse model of 22q11 deletion syndrome.
Topics: Animals; Benzodiazepinones; Catechol O-Methyltransferase; Chromatography, High Pressure Liquid; DiGe | 2012 |
Selective expression of KCNS3 potassium channel α-subunit in parvalbumin-containing GABA neurons in the human prefrontal cortex.
Topics: Adult; Female; gamma-Aminobutyric Acid; Humans; LIM-Homeodomain Proteins; Male; Middle Aged; Nerve T | 2012 |
In vivo measurements of glutamate, GABA, and NAAG in schizophrenia.
Topics: Adult; Age Factors; Attention; Cerebrum; Dipeptides; Female; gamma-Aminobutyric Acid; Glutamic Acid; | 2013 |
Periadolescent exposure to the NMDA receptor antagonist MK-801 impairs the functional maturation of local GABAergic circuits in the adult prefrontal cortex.
Topics: Animals; Dizocilpine Maleate; Electric Stimulation; Excitatory Amino Acid Antagonists; gamma-Aminobu | 2013 |
Prenatal immune activation induces maturation-dependent alterations in the prefrontal GABAergic transcriptome.
Topics: Age Factors; Animals; Behavior, Animal; Disease Models, Animal; Female; GABAergic Neurons; gamma-Ami | 2014 |
Understanding the neurotransmitter pathology of schizophrenia: selective deficits of subtypes of cortical GABAergic neurons.
Topics: Bipolar Disorder; Calbindin 2; Calbindins; Cerebral Cortex; Depression; gamma-Aminobutyric Acid; Hum | 2002 |
Selective deficits in prefrontal cortical GABAergic neurons in schizophrenia defined by the presence of calcium-binding proteins.
Topics: Adult; Calbindin 2; Calbindins; Calcium-Binding Proteins; Cell Count; Female; gamma-Aminobutyric Aci | 2002 |
Gabapentin-induced paradoxical exacerbation of psychosis in a patient with schizophrenia.
Topics: Acetates; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyri | 2002 |
Inhibitory control of sensory gating in a computer model of the CA3 region of the hippocampus.
Topics: Acoustic Stimulation; Action Potentials; Afferent Pathways; Animals; Cholinergic Fibers; Computer Si | 2003 |
Some possible genetic parallels across alcoholism, bipolar disorder and schizophrenia.
Topics: Alcoholism; Bipolar Disorder; Catecholamines; Chromosome Deletion; Chromosomes, Human, Pair 10; Chro | 2003 |
Limitations of brain imaging in forensic psychiatry.
Topics: Antipsychotic Agents; Brain; Electroencephalography; Forensic Psychiatry; gamma-Aminobutyric Acid; H | 2003 |
Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia.
Topics: Adult; Aged; Animals; Autoradiography; Benztropine; Calbindin 2; Cell Count; Female; gamma-Aminobuty | 2003 |
Gene expression in dopamine and GABA systems in an animal model of schizophrenia: effects of antipsychotic drugs.
Topics: Animals; Animals, Newborn; Antipsychotic Agents; Brain; Clozapine; Dopamine; Enkephalins; gamma-Amin | 2003 |
[IMMEDIATE CLINICAL RESULTS WITH GAMMA AMINOBUTYRIC ACID B6 IN SCHIZOPHRENIAS AND DELIRIUMS].
Topics: Aminobutyrates; Biochemical Phenomena; Biochemistry; Delirium; gamma-Aminobutyric Acid; Mental Disor | 1963 |
Valproate and GABAergic system effects.
Topics: Brain; gamma-Aminobutyric Acid; Humans; Schizophrenia; Valproic Acid | 2003 |
The neonatal ventral hippocampal lesion model of schizophrenia: effects on dopamine and GABA mRNA markers in the rat midbrain.
Topics: Aging; Animals; Animals, Newborn; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane Transpo | 2003 |
DNA-methyltransferase 1 mRNA is selectively overexpressed in telencephalic GABAergic interneurons of schizophrenia brains.
Topics: Adult; Aged; Case-Control Studies; Cell Adhesion Molecules, Neuronal; DNA (Cytosine-5-)-Methyltransf | 2004 |
Neurons expressing calcium-binding proteins in the prefrontal cortex in schizophrenia.
Topics: Adult; Aged; Analysis of Variance; Calcium-Binding Proteins; Case-Control Studies; Cell Count; Cell | 2004 |
Valproic acid induces manifestations of simultaneous dopamine enhancement and reduction in schizophrenia.
Topics: Adult; Benztropine; Dopamine; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Interacti | 2004 |
Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-D-aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder.
Topics: Adult; Aged; Bipolar Disorder; Cell Count; Digoxigenin; Female; gamma-Aminobutyric Acid; Gene Expres | 2004 |
Immunohistochemical and immunoblot study of GABA(A) alpha1 and beta2/3 subunits in the prefrontal cortex of subjects with schizophrenia and bipolar disorder.
Topics: Adult; Aged; Aged, 80 and over; Bipolar Disorder; Female; gamma-Aminobutyric Acid; Humans; Image Cyt | 2004 |
GABA transporters GAT-1 and GAT-3 in the human dorsolateral prefrontal cortex in schizophrenia.
Topics: Adult; Autopsy; beta-Alanine; Case-Control Studies; Female; GABA Plasma Membrane Transport Proteins; | 2004 |
No evidence for selective GABAergic interneuron deficits in the anterior thalamic complex of patients with schizophrenia.
Topics: Adult; Analysis of Variance; Anterior Thalamic Nuclei; Cell Count; gamma-Aminobutyric Acid; Glutamat | 2004 |
GABA neurons in the human prefrontal cortex.
Topics: Calbindin 2; Cognition Disorders; gamma-Aminobutyric Acid; Gene Expression; Humans; In Situ Hybridiz | 2004 |
Relationship of brain-derived neurotrophic factor and its receptor TrkB to altered inhibitory prefrontal circuitry in schizophrenia.
Topics: Adult; Aged; Animals; Anti-Dyskinesia Agents; Antipsychotic Agents; Benztropine; Brain-Derived Neuro | 2005 |
Serum glutamic acid decarboxylase 65 antibody levels in people with schizophrenia and their families.
Topics: Antibodies; Central Nervous System; Coxsackievirus Infections; Diabetes Mellitus, Type 1; Female; Fe | 2005 |
Neurotensin activates GABAergic interneurons in the prefrontal cortex.
Topics: Animals; Axons; Dopamine; Dopamine Agonists; gamma-Aminobutyric Acid; Interneurons; Male; Microdialy | 2005 |
Behavioral and neurochemical repercussions of hippocampal network activity blockade during the neonatal period.
Topics: Animals; Animals, Newborn; Behavior, Animal; Body Weight; Disease Models, Animal; Dopamine; Female; | 2005 |
Changes in hippocampal GABAA receptor subunit composition in bipolar 1 disorder.
Topics: Adult; Aged; Binding, Competitive; Bipolar Disorder; Brain Chemistry; Clonazepam; Female; Flumazenil | 2005 |
Reelin and glutamic acid decarboxylase67 promoter remodeling in an epigenetic methionine-induced mouse model of schizophrenia.
Topics: Animals; Cell Adhesion Molecules, Neuronal; Chromatin Assembly and Disassembly; Chromosomal Proteins | 2005 |
Regulation of synaptic plasticity in a schizophrenia model.
Topics: Animals; Disease Models, Animal; Electrophysiology; gamma-Aminobutyric Acid; Hippocampus; Male; Neur | 2005 |
Disruption of interneuron development.
Topics: Animals; Autistic Disorder; Behavior, Animal; Cell Division; Cell Movement; Cerebral Cortex; Disease | 2005 |
Increased density of GABAA receptors in the superior temporal gyrus in schizophrenia.
Topics: Adaptation, Physiological; Adult; Binding, Competitive; GABA Agonists; gamma-Aminobutyric Acid; Hall | 2006 |
Possible role of potassium channel, big K in etiology of schizophrenia.
Topics: Animals; Brain; Diazoxide; Dopamine; gamma-Aminobutyric Acid; Humans; Large-Conductance Calcium-Acti | 2006 |
Glutathione deficit during development induces anomalies in the rat anterior cingulate GABAergic neurons: Relevance to schizophrenia.
Topics: Animals; Brain Chemistry; Calbindin 2; Calbindins; Disease Models, Animal; Dopamine; Extracellular F | 2006 |
Cortical microcircuits in schizophrenia--the dopamine hypothesis revisited.
Topics: Cerebral Cortex; Dopamine; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Internal-External Control | 2006 |
BDNF Val66Met polymorphism and GAD67 mRNA expression in the prefrontal cortex of subjects with schizophrenia.
Topics: Brain-Derived Neurotrophic Factor; Cohort Studies; Diazepam; Female; gamma-Aminobutyric Acid; Gene E | 2006 |
Increased expression of activity-dependent genes in cerebellar glutamatergic neurons of patients with schizophrenia.
Topics: Adult; Aged; Brain-Derived Neurotrophic Factor; Cerebellar Cortex; Cerebellum; Female; gamma-Aminobu | 2006 |
Selective epigenetic alteration of layer I GABAergic neurons isolated from prefrontal cortex of schizophrenia patients using laser-assisted microdissection.
Topics: Adult; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Epigenesis, Gene | 2007 |
Towards understanding the schizophrenia code: an expanded convergent functional genomics approach.
Topics: Animals; Behavior, Animal; Biomarkers; Clozapine; gamma-Aminobutyric Acid; Gene Expression Regulatio | 2007 |
Epigenetic mechanisms expressed in basal ganglia GABAergic neurons differentiate schizophrenia from bipolar disorder.
Topics: Adult; Aged; Aged, 80 and over; Basal Ganglia; Bipolar Disorder; Caudate Nucleus; Cell Adhesion Mole | 2007 |
No association between the glutamate decarboxylase 67 gene (GAD1) and schizophrenia in the Japanese population.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Asian People; Female; gamma-Aminobutyric Acid; Gene Expr | 2007 |
Sub-chronic psychotomimetic phencyclidine induces deficits in reversal learning and alterations in parvalbumin-immunoreactive expression in the rat.
Topics: Animals; Behavior, Animal; Cognition Disorders; Conditioning, Operant; Dentate Gyrus; Disease Models | 2007 |
Prenatal exposure to an NMDA receptor antagonist, MK-801 reduces density of parvalbumin-immunoreactive GABAergic neurons in the medial prefrontal cortex and enhances phencyclidine-induced hyperlocomotion but not behavioral sensitization to methamphetamine
Topics: Age Factors; Animals; Behavior, Animal; Central Nervous System Stimulants; Disease Models, Animal; D | 2007 |
Clozapine and haloperidol differently suppress the MK-801-increased glutamatergic and serotonergic transmission in the medial prefrontal cortex of the rat.
Topics: Animals; Antipsychotic Agents; Clozapine; Dizocilpine Maleate; Excitatory Amino Acid Antagonists; Ex | 2007 |
The neuronal pathology of schizophrenia: molecules and mechanisms.
Topics: Animals; Aspartic Acid; Brain; Corpus Striatum; Disease Models, Animal; gamma-Aminobutyric Acid; Glu | 2007 |
Alterations in GABA(A) receptor expression in neonatal ventral hippocampal lesioned rats: comparison of prepubertal and postpubertal periods.
Topics: Adaptation, Physiological; Aging; Animals; Animals, Newborn; Binding, Competitive; Bridged Bicyclo C | 2007 |
Systematic study of association of four GABAergic genes: glutamic acid decarboxylase 1 gene, glutamic acid decarboxylase 2 gene, GABA(B) receptor 1 gene and GABA(A) receptor subunit beta2 gene, with schizophrenia using a universal DNA microarray.
Topics: Adult; Asian People; Case-Control Studies; China; Electrophoretic Mobility Shift Assay; Female; gamm | 2007 |
DNA fragmentation is increased in non-GABAergic neurons in bipolar disorder but not in schizophrenia.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Bipolar Disorder; Cell Count; Cohort Studies; DNA Fragmen | 2007 |
Regulation of the GABA cell phenotype in hippocampus of schizophrenics and bipolars.
Topics: Bipolar Disorder; Case-Control Studies; Down-Regulation; Female; gamma-Aminobutyric Acid; Gene Expre | 2007 |
Alterations of hippocampal and prefrontal GABAergic interneurons in an animal model of psychosis induced by NMDA receptor antagonism.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dizocilpine Maleate; gamma-Aminobutyric Acid; | 2007 |
Dopamine modulation of prefrontal cortex interneurons occurs independently of DARPP-32.
Topics: Action Potentials; Animals; Biomarkers; Calbindins; Dopamine; Dopamine and cAMP-Regulated Phosphopro | 2008 |
Prefrontal dysfunction in schizophrenia involves mixed-lineage leukemia 1-regulated histone methylation at GABAergic gene promoters.
Topics: Adult; Animals; Cells, Cultured; Child; DNA Methylation; Female; gamma-Aminobutyric Acid; Glutamate | 2007 |
Adult brain and behavioral pathological markers of prenatal immune challenge during early/middle and late fetal development in mice.
Topics: Acoustic Stimulation; Age Factors; Amphetamines; Animals; Autistic Disorder; Brain; Cell Adhesion Mo | 2008 |
Changes in density of calcium-binding-protein-immunoreactive GABAergic neurons in prefrontal cortex in schizophrenia and bipolar disorder.
Topics: Bipolar Disorder; Calcium-Binding Proteins; Female; gamma-Aminobutyric Acid; Humans; Image Processin | 2008 |
Increased truncated TrkB receptor expression and decreased BDNF/TrkB signaling in the frontal cortex of reeler mouse model of schizophrenia.
Topics: Animals; Blotting, Western; Brain-Derived Neurotrophic Factor; Cell Adhesion Molecules, Neuronal; Di | 2008 |
Gabapentin for ultra resistant schizophrenia with aggressive behavior.
Topics: Adult; Aggression; Amines; Anticonvulsants; Antipsychotic Agents; Cyclohexanecarboxylic Acids; Drug | 2008 |
Conserved regional patterns of GABA-related transcript expression in the neocortex of subjects with schizophrenia.
Topics: Adult; Aged; Cause of Death; Female; gamma-Aminobutyric Acid; Gene Expression Profiling; Glutamate D | 2008 |
Modeling GABA alterations in schizophrenia: a link between impaired inhibition and altered gamma and beta range auditory entrainment.
Topics: Acoustic Stimulation; Adolescent; Adult; Algorithms; Auditory Cortex; Auditory Perception; Beta Rhyt | 2008 |
Dysfunctional GABAergic inhibition in the prefrontal cortex leading to "psychotic" hyperactivation.
Topics: Algorithms; Animals; Computer Simulation; Dopamine; Down-Regulation; gamma-Aminobutyric Acid; Humans | 2008 |
Tardive dyskinesia: clinical, biological, and pharmacological perspectives.
Topics: Acetylcholine; Animals; Antipsychotic Agents; Choline; Corpus Striatum; Diagnosis, Differential; Dop | 1980 |
Neurotransmitter receptors in brain in schizophrenia.
Topics: Brain; gamma-Aminobutyric Acid; Humans; Ligands; Membranes; Neurotransmitter Agents; Quinuclidinyl B | 1981 |
Effects of chronic amphetamine treatment on the glutamate concentration in cerebrospinal fluid and brain: implications for a theory of schizophrenia.
Topics: Animals; Brain; Cerebral Cortex; Corpus Striatum; Dextroamphetamine; gamma-Aminobutyric Acid; Glutam | 1981 |
[Quantitative analysis of gamma-aminobutyric acid and glutamic acid in the cerebrospinal fluid of schizophrenics].
Topics: Adolescent; Adult; Age Factors; Female; gamma-Aminobutyric Acid; Glutamates; Glutamic Acid; Humans; | 1982 |
Neurotransmitters and CNS disease. Schizophrenia.
Topics: Antipsychotic Agents; Atrophy; Brain; Cerebral Ventricles; Chronic Disease; Dopamine; Endorphins; GA | 1982 |
[Old and new thought concepts on the biochemical principles of psychopharmcotherapy].
Topics: Acetylcholine; Brain; Depressive Disorder; Dopamine; gamma-Aminobutyric Acid; Humans; Mental Disorde | 1982 |
Effects of a GABA-mimetic drug (sodium valproate) on visually evoked potentials in chronic schizophrenics.
Topics: Adult; Brain; Brief Psychiatric Rating Scale; Chronic Disease; Clozapine; Dibenzazepines; Drug Thera | 1984 |
[A biochemical theory of schizophrenia].
Topics: Animals; Antipsychotic Agents; Brain; Dopamine; gamma-Aminobutyric Acid; Glutamates; Glutamic Acid; | 1984 |
CSF neurochemistry in depressed, manic, and schizophrenic patients compared with that of normal controls.
Topics: Adolescent; Adult; Age Factors; Aged; Bipolar Disorder; Calcium; Choline; Depressive Disorder; Femal | 1984 |
Plasma GABA levels in psychiatric illness.
Topics: Alcoholism; Bipolar Disorder; Depressive Disorder; Dexamethasone; gamma-Aminobutyric Acid; Humans; L | 1984 |
Short- and long-term effects of GABA and dopamine neurons during treatment with sulpiride.
Topics: Cyclic AMP; Cyclic GMP; Dopamine; gamma-Aminobutyric Acid; Homovanillic Acid; Humans; Neurons; Prola | 1980 |
Biological studies of schizoaffective disorders.
Topics: Blood Platelets; Catechol O-Methyltransferase; Dexamethasone; Dopamine; Dopamine beta-Hydroxylase; g | 1984 |
Distribution of GABA in post-mortem brain tissue from control, psychotic and Huntington's chorea subjects.
Topics: Brain; Female; gamma-Aminobutyric Acid; Glutamate Decarboxylase; Humans; Huntington Disease; Male; S | 1980 |
Plasma GABA in affective illness. A preliminary investigation.
Topics: Bipolar Disorder; Depressive Disorder; Female; gamma-Aminobutyric Acid; Humans; Male; Schizophrenia | 1981 |
Chronic haloperidol administration enhances the gamma-aminobutyric acid level in the rat striatum without altering the glutamate level.
Topics: Animals; Corpus Striatum; Dopamine; gamma-Aminobutyric Acid; Glutamates; Haloperidol; Humans; Male; | 1984 |
CSF levels of gamma-aminobutyric acid in schizophrenia. Low values in recently ill patients.
Topics: Adult; Double-Blind Method; Female; gamma-Aminobutyric Acid; Humans; Male; Pimozide; Psychotic Disor | 1982 |
Possible drug differentiation of the psychoses.
Topics: Affective Disorders, Psychotic; Bipolar Disorder; Diagnosis, Differential; gamma-Aminobutyric Acid; | 1982 |
[Use of haloperidol in high doses in schizophrenia. Clinical, biochemical and pharmacokinetic study].
Topics: Adult; Dose-Response Relationship, Drug; Female; gamma-Aminobutyric Acid; Haloperidol; Homovanillic | 1982 |
Preliminary studies on CSF gamma-aminobutyric acid levels in psychiatric patients before and during treatment with different psychotropic drugs.
Topics: Adult; Depression; Female; gamma-Aminobutyric Acid; Humans; Male; Mental Disorders; Middle Aged; Psy | 1980 |
CSF GABA in normal subjects and patients with depression, schizophrenia, mania, and anorexia nervosa.
Topics: Adolescent; Adult; Affective Disorders, Psychotic; Aged; Anorexia Nervosa; Bipolar Disorder; Depress | 1981 |
gamma-Aminobutyric acid concentration in cerebrospinal fluid in schizophrenia.
Topics: Acute Disease; Adult; Chronic Disease; Female; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; R | 1981 |
GABA levels in CSF of patients with psychiatric disorders.
Topics: Adult; Aged; Bipolar Disorder; Depression; Female; gamma-Aminobutyric Acid; Humans; Male; Middle Age | 1980 |
[Current views in biological research on schizophrenia].
Topics: Brain; Dopamine; Endorphins; gamma-Aminobutyric Acid; Humans; Research; Schizophrenia | 1980 |
Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics.
Topics: Adult; Age of Onset; Aged; Autoradiography; Cell Count; Cell Death; Densitometry; Down-Regulation; F | 1995 |
Antagonistic interaction between adenosine A2A receptors and dopamine D2 receptors in the ventral striopallidal system. Implications for the treatment of schizophrenia.
Topics: Adenosine; Animals; Antihypertensive Agents; Antipsychotic Agents; Autoradiography; Binding, Competi | 1994 |
Hippocampal benzodiazepine receptors in schizophrenia.
Topics: Aged; Female; Flunitrazepam; gamma-Aminobutyric Acid; Hippocampus; Humans; In Vitro Techniques; Kine | 1993 |
A familial/genetic study of plasma serine and glycine concentrations.
Topics: Dopamine; Female; gamma-Aminobutyric Acid; Glucose; Glutamates; Glycine; Humans; Internal-External C | 1993 |
The macrophage-T-lymphocyte theory of schizophrenia: additional evidence.
Topics: Acetylcholine; Animals; Cytokines; Evoked Potentials, Auditory; gamma-Aminobutyric Acid; Glutamic Ac | 1995 |
Startle and sensorimotor correlates of ventral thalamic dopamine and GABA in rodents.
Topics: Analysis of Variance; Animals; Apomorphine; Behavior, Animal; Dopamine; gamma-Aminobutyric Acid; Mus | 1995 |
Development of the glutamate, GABA, and dopamine systems in relation to NRH-induced neurotoxicity.
Topics: Age Factors; Animals; Cerebral Cortex; Disease Models, Animal; Dopamine; gamma-Aminobutyric Acid; Gl | 1995 |
Local circuit neurons of the prefrontal cortex in schizophrenia: selective increase in the density of calbindin-immunoreactive neurons.
Topics: Adult; Aged; Brain Mapping; Calbindin 2; Calbindins; Dominance, Cerebral; Female; gamma-Aminobutyric | 1995 |
Correlation between reduced in vivo benzodiazepine receptor binding and severity of psychotic symptoms in schizophrenia.
Topics: Adolescent; Adult; Cerebral Cortex; Female; Flumazenil; Frontal Lobe; gamma-Aminobutyric Acid; Human | 1997 |
Glycyldodecylamide, a phencyclidine behavioral antagonist, blocks cortical glycine uptake: implications for schizophrenia and substance abuse.
Topics: Animals; Cerebral Cortex; Dizocilpine Maleate; Excitatory Amino Acid Antagonists; gamma-Aminobutyric | 1997 |
Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics.
Topics: Aged; Female; gamma-Aminobutyric Acid; Humans; Immunohistochemistry; Interneurons; Male; Matched-Pai | 1997 |
Schizophrenia and the parvalbumin-containing class of cortical local circuit neurons.
Topics: Cell Count; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; Neurons; Parvalbumins; Prefrontal Co | 1997 |
In vitro 1H-magnetic resonance spectroscopy of postmortem brains with schizophrenia.
Topics: Adult; Aged; Aged, 80 and over; Amino Acids; Aspartic Acid; Brain Chemistry; Cerebellum; Cerebral Co | 1997 |
Altered distribution of parvalbumin-immunoreactive local circuit neurons in the anterior cingulate cortex of schizophrenic patients.
Topics: Adult; Aged; Aged, 80 and over; Brain Mapping; Female; gamma-Aminobutyric Acid; Gyrus Cinguli; Human | 1997 |
Benzodiazepine receptor binding and schizophrenia.
Topics: Flumazenil; Frontal Lobe; gamma-Aminobutyric Acid; Humans; Magnetic Resonance Imaging; Prefrontal Co | 1997 |
Cellular and molecular neuropathology of schizophrenia: new directions from developmental neurobiology.
Topics: Biomarkers; Brain; Dopamine; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Nerve Growth Factors; N | 1997 |
A subclass of prefrontal gamma-aminobutyric acid axon terminals are selectively altered in schizophrenia.
Topics: Autopsy; Axons; Carrier Proteins; Female; GABA Plasma Membrane Transport Proteins; gamma-Aminobutyri | 1998 |
GABA and brain abnormalities in schizophrenia.
Topics: Adult; Analysis of Variance; Atrophy; Brain; Cerebral Ventricles; Chromatography, High Pressure Liqu | 1998 |
Chandelier cells: shedding light on altered cortical circuitry in schizophrenia.
Topics: Animals; Axons; gamma-Aminobutyric Acid; Humans; Models, Neurological; Prefrontal Cortex; Pyramidal | 1998 |
Measurement of GABAergic parameters in the prefrontal cortex in schizophrenia: focus on GABA content, GABA(A) receptor alpha-1 subunit messenger RNA and human GABA transporter-1 (HGAT-1) messenger RNA expression.
Topics: Aged; Carrier Proteins; Chromatography, High Pressure Liquid; DNA Probes; Female; GABA Plasma Membra | 1999 |
Gabapentin prophylaxis of clozapine-induced seizures.
Topics: Acetates; Adolescent; Adult; Amines; Anticonvulsants; Antipsychotic Agents; Clozapine; Cyclohexaneca | 2000 |
Decreased glutamic acid decarboxylase67 messenger RNA expression in a subset of prefrontal cortical gamma-aminobutyric acid neurons in subjects with schizophrenia.
Topics: Adult; Animals; Female; gamma-Aminobutyric Acid; Gene Expression; Glutamate Decarboxylase; Humans; I | 2000 |
GABAergic local circuit neurons and prefrontal cortical dysfunction in schizophrenia.
Topics: gamma-Aminobutyric Acid; Humans; Neural Pathways; Neurons; Prefrontal Cortex; Schizophrenia | 2000 |
Bilateral blockade of NMDA receptors in anterior thalamus by dizocilpine (MK-801) injures pyramidal neurons in rat retrosplenial cortex.
Topics: Animals; Anterior Thalamic Nuclei; Baclofen; Dizocilpine Maleate; Excitatory Amino Acid Antagonists; | 2000 |
Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998.
Topics: Acetates; Adult; Amines; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Carbamazepine; Cyc | 2000 |
Hippocampal pathology in schizophrenia: magnetic resonance imaging and spectroscopy studies.
Topics: Adult; Aspartic Acid; Case-Control Studies; Dominance, Cerebral; gamma-Aminobutyric Acid; Glutamic A | 2000 |
Differential expression of GABA(A) receptor subunit mRNAs and ligand binding sites in rat brain following phencyclidine administration.
Topics: Animals; Behavior, Animal; Binding Sites; Brain; gamma-Aminobutyric Acid; Gene Expression Regulation | 2000 |
Neuronal nicotinic receptors in synaptic functions in humans and rats: physiological and clinical relevance.
Topics: Alzheimer Disease; Animals; Brain; Brain Mapping; Cerebral Cortex; Culture Techniques; gamma-Aminobu | 2000 |
Viral infection of developing GABAergic neurons in a model of hippocampal disinhibition.
Topics: Animals; Central Nervous System Viral Diseases; Dentate Gyrus; Disease Models, Animal; Epilepsy, Tem | 2000 |
GABA transporter-1 mRNA in the prefrontal cortex in schizophrenia: decreased expression in a subset of neurons.
Topics: Adult; Animals; Carrier Proteins; Cell Count; Female; GABA Plasma Membrane Transport Proteins; gamma | 2001 |
Amygdalar activation alters the hippocampal GABA system: "partial" modelling for postmortem changes in schizophrenia.
Topics: Amygdala; Animals; Dentate Gyrus; Disease Models, Animal; GABA Antagonists; gamma-Aminobutyric Acid; | 2001 |
Glutamate decarboxylase(65)-immunoreactive terminals in cingulate and prefrontal cortices of schizophrenic and bipolar brain.
Topics: Adult; Aged; Antibodies; Bipolar Disorder; Female; gamma-Aminobutyric Acid; Glutamate Decarboxylase; | 2000 |
GABAergic neuronal subtypes in the human frontal cortex--development and deficits in schizophrenia.
Topics: Aged; Aging; Calbindin 2; Calbindins; Female; Frontal Lobe; gamma-Aminobutyric Acid; Humans; Immunoh | 2001 |
Functional neuroanatomy of the ventral striopallidal GABA pathway. New sites of intervention in the treatment of schizophrenia.
Topics: Animals; Cholecystokinin; Dopamine; Dopamine D2 Receptor Antagonists; Extracellular Space; gamma-Ami | 2001 |
Studies on dopaminergic and GABAergic markers in striatum reveals a decrease in the dopamine transporter in schizophrenia.
Topics: Adult; Corpus Striatum; Dopamine; Dopamine Plasma Membrane Transport Proteins; Female; gamma-Aminobu | 2001 |
GluR5,6,7 subunit immunoreactivity on apical pyramidal cell dendrites in hippocampus of schizophrenics and manic depressives.
Topics: Adult; Aged; Aged, 80 and over; Bipolar Disorder; Dendrites; gamma-Aminobutyric Acid; GluK2 Kainate | 2001 |
Increased [(3)H]tiagabine binding to GAT-1 in the cingulate cortex in schizophrenia.
Topics: Aged; Aged, 80 and over; Brain; Carrier Proteins; Case-Control Studies; Caudate Nucleus; Chronic Dis | 2002 |
The density and spatial distribution of GABAergic neurons, labelled using calcium binding proteins, in the anterior cingulate cortex in major depressive disorder, bipolar disorder, and schizophrenia.
Topics: Adult; Bipolar Disorder; Calcium-Binding Proteins; Cell Count; Depressive Disorder, Major; Female; g | 2002 |
Is NMDA receptor hypofunction in schizophrenia associated with a primary hyperglutamatergic state?
Topics: Excitatory Amino Acid Antagonists; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Ketamine; Lamotri | 2002 |
Implications for altered glutamate and GABA metabolism in the dorsolateral prefrontal cortex of aged schizophrenic patients.
Topics: Age Factors; Aged; Citrate (si)-Synthase; Female; Functional Laterality; gamma-Aminobutyric Acid; Gl | 2002 |
[The contribution of drug research to the understanding of schizophrenia].
Topics: Adult; Amphetamines; Animals; Antipsychotic Agents; Baclofen; Chlorpromazine; Corpus Striatum; Dopam | 1975 |
[Findings of biochemical research on schizophrenia (author's transl)].
Topics: 5-Methoxytryptamine; Antipsychotic Agents; Brain; Dopamine; gamma-Aminobutyric Acid; Humans; Lysergi | 1978 |
Improvement in tardive dyskinesia after muscimol therapy.
Topics: Adult; Aged; Antipsychotic Agents; Dopamine; Drug Evaluation; Dyskinesia, Drug-Induced; Extrapyramid | 1979 |
Neurotransmitter receptors in frontal cortex of schizophrenics.
Topics: Adolescent; Adult; Aged; Alprenolol; Antipsychotic Agents; Child; Female; Frontal Lobe; gamma-Aminob | 1979 |
The dopamine hypothesis of schizophrenia revisited.
Topics: Antipsychotic Agents; Cerebral Cortex; Corpus Striatum; Dopamine; Dopamine beta-Hydroxylase; gamma-A | 1979 |
[The metabolically disordered neuron].
Topics: Adenosine Triphosphate; Antidepressive Agents; Biogenic Amines; Brain; Depression; Energy Metabolism | 1979 |
Letter: Baclofen in the treatment of schizophrenia.
Topics: Aminobutyrates; Chlorobenzenes; Chlorpromazine; Drug Therapy, Combination; Fluphenazine; gamma-Amino | 1975 |
gamma-Aminobutyric-acid deficiency in schizophrenia.
Topics: Aminobutyrates; gamma-Aminobutyric Acid; Humans; Schizophrenia; Valerates; Valproic Acid | 1976 |
Gabergic compounds and schizophrenia.
Topics: Baclofen; gamma-Aminobutyric Acid; Humans; Schizophrenia; Valproic Acid | 1976 |
Gamma-aminobutyric-acid deficiency in brain of schizophrenic patients.
Topics: Brain Chemistry; gamma-Aminobutyric Acid; Humans; Huntington Disease; Middle Aged; Nucleus Accumbens | 1979 |
Gamma-aminobutyric acid in the brain in schizophrenia.
Topics: gamma-Aminobutyric Acid; Humans; Nucleus Accumbens; Schizophrenia; Septal Nuclei; Thalamus | 1979 |
[GABA system in the brain. Possible clinical and pharmacological aspects].
Topics: Brain; Epilepsy; gamma-Aminobutyric Acid; Humans; Huntington Disease; Schizophrenia | 1978 |
Mass spectrometric identification and selected ion monitoring quantitation of gamma-amino-butyric acid (GABA) in human lumbar cerebrospinal fluid.
Topics: Bipolar Disorder; Chromatography, Gas; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Humans; Hu | 1978 |
GABA in Huntington's chorea, Parkinsonism and schizophrenia.
Topics: Animals; Body Temperature; Brain; Carboxy-Lyases; Death, Sudden; gamma-Aminobutyric Acid; Glutamate | 1979 |
Stimulation of prolactin and growth hormone secretion by muscimol, a gamma-aminobutyric acid agonist.
Topics: Adult; Aged; Chronic Disease; Female; gamma-Aminobutyric Acid; Growth Hormone; Humans; Huntington Di | 1978 |
Letter: Gamma-aminobutyric acid in CSF in schizophrenia.
Topics: Aminobutyrates; Animals; Brain Chemistry; Cats; gamma-Aminobutyric Acid; Humans; Microwaves; Rats; S | 1975 |
[New treatment of schizophrenia?].
Topics: Aminobutyrates; gamma-Aminobutyric Acid; Humans; Schizophrenia | 1975 |
[Baclofen in schizophrenia therapy--preliminary note].
Topics: Adult; Aminobutyrates; Autistic Disorder; Blood-Brain Barrier; Female; gamma-Aminobutyric Acid; Huma | 1975 |
[Certain principles for differential utilization of metabolic treatment preparations in the complex therapy of mental disorders].
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Brain Injuries; gamma-Aminobutyric Acid; Humans; Infectio | 1979 |
[Pathogenesis of stereotyped behavior].
Topics: Animals; Behavior; Caudate Nucleus; Diazepam; Disease Models, Animal; gamma-Aminobutyric Acid; Halop | 1979 |
Gamma-aminobutyric acid (GABA) in the CSF of schizophrenic patients before and after neuroleptic treatment.
Topics: Adult; Aminobutyrates; Female; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; Schizophrenia; Tr | 1978 |
gamma-Aminobutyric acid (Gaba) and the dopamine hypothesis of schizophrenia.
Topics: Aminobutyrates; Aminooxyacetic Acid; Blood-Brain Barrier; Brain; Cycloserine; Dopamine; GABA Antagon | 1977 |
GHB and GABA.
Topics: Aminobutyrates; Brain; gamma-Aminobutyric Acid; Humans; Hydroxybutyrates; Schizophrenia; Sodium Oxyb | 1977 |
Meeting report: Biochemical aspects of schizophrenia. Alabama, April 1975.
Topics: Acute Disease; Blood Platelets; Chronic Disease; Dopamine; Folic Acid; gamma-Aminobutyric Acid; Hall | 1975 |
Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons.
Topics: Acetylcholine; Animals; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Electric Stimul | 1975 |
The dopamine hypothesis of schizophrenia. A critical analysis.
Topics: Acetylcholine; Amphetamine; Apomorphine; Cocaine; Dopamine; Electroconvulsive Therapy; gamma-Aminobu | 1975 |
Gaba blockade, dopamine and schizophrenia: experimental activation of the mesolimbic system.
Topics: Aminobutyrates; Animals; Cats; Disease Models, Animal; Dopamine; gamma-Aminobutyric Acid; Humans; Li | 1975 |
Regionally selective deficits in uptake sites for glutamate and gamma-aminobutyric acid in the basal ganglia in schizophrenia.
Topics: Aspartic Acid; Brain; Caudate Nucleus; Dominance, Cerebral; gamma-Aminobutyric Acid; Globus Pallidus | 1992 |
Initial studies of embryonic transplants of human hippocampus and cerebral cortex derived from schizophrenic women.
Topics: Adult; Animals; Brain Tissue Transplantation; Brain-Derived Neurotrophic Factor; Cerebral Cortex; Fe | 1992 |
Evidence of glutamatergic deficiency in schizophrenia.
Topics: Aged; Aspartic Acid; Brain Chemistry; Cerebral Cortex; Female; gamma-Aminobutyric Acid; Glutamate De | 1991 |
Deficient NMDA-mediated glutamate release from synaptosomes of schizophrenics.
Topics: Brain; Culture Techniques; gamma-Aminobutyric Acid; Glutamates; Glutamic Acid; Humans; Male; Recepto | 1991 |
Exploring the role of an endogenous caffeine-like substance in the pathogenesis of schizophrenia.
Topics: Brain; Caffeine; Female; gamma-Aminobutyric Acid; Humans; Pregnancy; Pregnancy Complications; Recept | 1991 |
Neuroleptic-induced "painful legs and moving toes" syndrome: successful treatment with clonazepam and baclofen.
Topics: Baclofen; Causalgia; Clonazepam; Dyskinesia, Drug-Induced; Female; gamma-Aminobutyric Acid; Humans; | 1990 |
Abnormal serine hydroxymethyl transferase activity in the temporal lobes of schizophrenics.
Topics: Adult; Female; Frontal Lobe; gamma-Aminobutyric Acid; Glycine; Glycine Hydroxymethyltransferase; Hum | 1990 |
Deficit and hemispheric asymmetry of GABA uptake sites in the hippocampus in schizophrenia.
Topics: Aged; Aged, 80 and over; Amygdala; Dominance, Cerebral; Dopamine; Female; gamma-Aminobutyric Acid; H | 1990 |
Schizophrenia, tardive dyskinesia, and brain GABA.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Brain; Dyskinesia, Drug-Induced; Female; gamma | 1989 |
Saccadic distractibility in schizophrenic patients with tardive dyskinesia.
Topics: Antipsychotic Agents; Dyskinesia, Drug-Induced; Eye Movements; Fixation, Ocular; gamma-Aminobutyric | 1989 |
Reduced GABA uptake sites in the temporal lobe in schizophrenia.
Topics: Amygdala; Cerebral Cortex; Functional Laterality; gamma-Aminobutyric Acid; Hippocampus; Humans; Midd | 1989 |
Chemical and structural changes in the brain in patients with movement disorder.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcholine; Antipsychotic Agents; Brain; Choline O-Acetyltransfer | 1985 |
[Anxiolytic action of sodium valproate (possible role of gamma-aminobutyric acid in affective disorders)].
Topics: Adult; Animals; Anti-Anxiety Agents; Anxiety; Brain; Cats; Female; gamma-Aminobutyric Acid; Humans; | 1985 |
Neurotransmitter amino acids in post-mortem brains of chronic schizophrenic patients.
Topics: Adult; Aged; Amino Acids; Amygdala; Brain Chemistry; Chronic Disease; Female; gamma-Aminobutyric Aci | 1987 |
Failure of the GABAergic drug, sodium valproate, to reduce basal plasma prolactin secretion in chronic schizophrenia.
Topics: Adult; Chronic Disease; Female; gamma-Aminobutyric Acid; Humans; Hypothalamo-Hypophyseal System; Mid | 1985 |
Diazepam-binding inhibitor. A brain neuropeptide present in human spinal fluid: studies in depression, schizophrenia, and Alzheimer's disease.
Topics: Adult; Age Factors; Aged; Alzheimer Disease; Depressive Disorder; Diazepam Binding Inhibitor; Female | 1986 |